Document:

EX-10.10

 Exhibit 10.10 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed. 
 CONFIDENTIAL 

Execution Version 

COLLABORATIVE RESEARCH AND LICENSE AGREEMENT 

BETWEEN 

BIOGEN MA INC. 

AND 
 C4
THERAPEUTICS, INC. 
 Dated December 28, 2018 

 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 ARTICLE 1
	 	DEFINITIONS	  	 	1	 
			
	 ARTICLE 2
	 	LICENSE GRANTS	  	 	17	 
			
	 2.1
	 	Licenses and Assignment to Biogen	  	 	17	 
	 2.2
	 	Licenses to C4	  	 	18	 
	 2.3
	 	No Implied Licenses	  	 	18	 
			
	 ARTICLE 3
	 	COLLABORATION	  	 	18	 
			
	 3.1
	 	Candidate Development Programs	  	 	18	 
	 3.2
	 	Sandbox Program	  	 	25	 
	 3.3
	 	Records	  	 	28	 
	 3.4
	 	Copies and Inspection of Records	  	 	28	 
	 3.5
	 	Collaboration Term	  	 	28	 
	 3.6
	 	Exclusivity	  	 	29	 
	 3.7
	 	Effect of Acquisition of C4	  	 	29	 
			
	 ARTICLE 4
	 	GOVERNANCE	  	 	30	 
			
	 4.1
	 	Alliance Management	  	 	30	 
	 4.2
	 	Joint Steering Committee	  	 	30	 
	 4.3
	 	Disbandment of the JSC	  	 	33	 
			
	 ARTICLE 5
	 	DEVELOPMENT, REGULATORY MATTERS, AND COMMERCIALIZATION	  	 	33	 
			
	 5.1
	 	Technology Transfer	  	 	33	 
	 5.2
	 	Development and Medical Affairs	  	 	33	 
	 5.3
	 	Regulatory Activities	  	 	34	 
	 5.4
	 	Commercialization	  	 	34	 
	 5.5
	 	Diligence Obligations	  	 	34	 
	 5.6
	 	C4 Support	  	 	34	 
			
	 ARTICLE 6
	 	MANUFACTURING	  	 	35	 
			
	 6.1
	 	General Responsibilities	  	 	35	 
	 6.2
	 	Observation by Biogen	  	 	35	 
	 6.3
	 	Manufacturing Technology Transfer	  	 	35	 
	 6.4
	 	C4 Manufacturing Support	  	 	35	 
			
	 ARTICLE 7
	 	PAYMENTS AND ROYALTIES	  	 	36	 
			
	 7.1
	 	One-Time R&D Prepayments	  	 	36	 
	 7.2
	 	Hit Fee	  	 	36	 
	 7.3
	 	Lead Fee	  	 	36	 
	 7.4
	 	IND-Enabling Study Commencement Fee	  	 	36	 
	 7.5
	 	Milestone Payments	  	 	37	 
	 7.6
	 	Royalties	  	 	39	 
	 7.7
	 	Payment Method	  	 	41	 
	 7.8
	 	Currency Exchange	  	 	41	 
	 7.9
	 	Late Payments	  	 	41	 
	 7.10
	 	Taxes	  	 	42	 
	 7.11
	 	Financial Audits	  	 	42	 

  
 i 

							
	 ARTICLE 8
	 	REPRESENTATIONS, WARRANTIES, AND COVENANTS	  	 	43	 
			
	 8.1
	 	Mutual Representations and Warranties of the Parties	  	 	43	 
	 8.2
	 	Additional Representations and Warranties of C4	  	 	44	 
	 8.3
	 	Covenants of C4	  	 	46	 
	 8.4
	 	DISCLAIMER OF WARRANTIES	  	 	46	 
	 8.5
	 	LIMITATION OF LIABILITY	  	 	46	 
			
	 ARTICLE 9
	 	CONFIDENTIALITY	  	 	47	 
			
	 9.1
	 	Confidential Information	  	 	47	 
	 9.2
	 	Non-Disclosure and Non-Use Obligation	  	 	47	 
	 9.3
	 	Return of Confidential Information	  	 	47	 
	 9.4
	 	Exemptions	  	 	47	 
	 9.5
	 	Permitted Disclosures	  	 	48	 
	 9.6
	 	Confidential Treatment	  	 	49	 
	 9.7
	 	Use of Name and Logo	  	 	49	 
	 9.8
	 	Residual Knowledge	  	 	49	 
	 9.9
	 	Publications	  	 	49	 
			
	 ARTICLE 10
	 	INTELLECTUAL PROPERTY	  	 	50	 
			
	 10.1
	 	Ownership	  	 	50	 
	 10.2
	 	Assignments	  	 	51	 
	 10.3
	 	Joint Technology	  	 	53	 
	 10.4
	 	Patent Prosecution and Maintenance	  	 	53	 
	 10.5
	 	Patent Enforcement	  	 	55	 
	 10.6
	 	Defense of Claims	  	 	56	 
	 10.8
	 	Patent Term Extensions	  	 	57	 
	 10.9
	 	Summary of Activities	  	 	57	 
			
	 ARTICLE 11
	 	INDEMNIFICATION	  	 	57	 
			
	 11.1
	 	Indemnification by C4	  	 	57	 
	 11.2
	 	Indemnification by Biogen	  	 	57	 
	 11.3
	 	Procedure	  	 	57	 
			
	 ARTICLE 12
	 	TERM AND TERMINATION	  	 	58	 
			
	 12.1
	 	Term	  	 	58	 
	 12.2
	 	Termination for Cause	  	 	58	 
	 12.3
	 	Termination for Insolvency	  	 	59	 
	 12.4
	 	Termination for Convenience	  	 	60	 
	 12.5
	 	Effects of Termination	  	 	60	 
	 12.6
	 	Alternative Remedy in Lieu of Termination	  	 	61	 
	 12.7
	 	Rights Accruing Prior to Expiration or Termination	  	 	61	 
	 12.8
	 	Survival	  	 	61	 
			
	 ARTICLE 13
	 	MISCELLANEOUS	  	 	61	 
			
	 13.1
	 	Assignment	  	 	61	 
	 13.2
	 	Entire Agreement; Amendments	  	 	62	 
	 13.3
	 	Force Majeure	  	 	62	 
	 13.4
	 	Waiver	  	 	62	 
	 13.5
	 	Severability	  	 	62	 
	 13.6
	 	Notices	  	 	62	 
	 13.7
	 	Governing Law	  	 	63	 

  
 ii 

							
	 13.8
	 	Dispute Resolution	  	 	63	 
	 13.9
	 	Jurisdiction; Venue	  	 	63	 
	 13.10
	 	Relationship of the Parties	  	 	64	 
	 13.11
	 	Performance by Affiliates	  	 	64	 
	 13.12
	 	Interpretation	  	 	64	 
	 13.13
	 	Further Assurances	  	 	65	 
	 13.14
	 	Counterparts	  	 	65	 

 Schedules: 
 Schedule
1.37: C4 Hit Criteria 
 Schedule 1.42: C4 Licensed Patent Rights 

Schedule 3.1.3(a): Candidate Development Plan for [***] 

Schedule 3.1.3(b): Candidate Development Plan for [***] 

Schedule 3.1.3(c): Candidate Development Plan for [***] 

Schedule 3.1.9: Form of Candidate Development Financial Report 

Schedule 4.1.1: Contact List 
 Schedule 9.9.2: Press Release 

  
 iii 

 COLLABORATIVE RESEARCH AND
LICENSE AGREEMENT 
 This COLLABORATIVE RESEARCH AND
LICENSE AGREEMENT (this “Agreement”) is entered into as of December 28, 2018 (the “Effective Date”) by and among Biogen MA Inc., a corporation organized and existing under the laws
of Massachusetts and having a principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”) and C4 Therapeutics, Inc., a corporation organized and existing under the laws of Delaware with a principle place of
business at 490 Arsenal Way, Watertown, MA 02472 (“C4”). Biogen and C4 are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 
 WHEREAS,
Biogen is engaged in, among other things, Development, Manufacturing, and Commercialization of biopharmaceutical products; 

WHEREAS, C4 has certain expertise and proprietary protein degradation technology that uses Degronimid compounds to activate the
ubiquitin proteasome system in target proteins; 
 WHEREAS, the Parties are interested in entering into a collaboration to utilize
Biogen’s and C4’s expertise and C4 Degrader Platform to perform research services and other activities, including (a) Candidate Development Activities, with the goal of identifying Development Candidates directed to each Collaboration
Target, and (b) Sandbox Activities to, among other things, inform the selection of the Additional Targets and identification of potentially useful ligands, each in accordance with the terms and conditions set forth in this Agreement; 

WHEREAS, Biogen is making upfront payments to C4 as prepayment of the costs and expenses to be incurred by C4 in the performance of
research services under this Agreement; and 
 WHEREAS, C4 desires to (a) grant to Biogen, and Biogen desires to receive from
C4, an exclusive, worldwide license under the C4 Licensed Technology to exploit Development Candidates and Products in the Field in the Territory, and (b) assign to Biogen, and Biogen desires to accept such assignment from C4, all of C4’s
rights, title, and interests in and to the Target-Specific Technology and Product-Specific Technology. 
 NOW, THEREFORE, the Parties
hereto agree as follows: 
 ARTICLE 1 DEFINITIONS 
  

	1.1	 [***] 

  

	1.2	 “Acquiror” has the meaning set forth in Section 3.7 (Effect of Acquisition of C4).

  

	1.3	 “Acquisition Party” has the meaning set forth in Section 3.7 (Effect of Acquisition of
C4). 

  

	1.4	 “Additional Cure Period” has the meaning set forth in Section 12.2.3 (Disputes Regarding
Material Breach). 

  

	1.5	 “Additional Target” means any target that will be the subject of a Candidate Development
Program, which targets will be selected in accordance with Section 3.1.1(b)(i) (Selection of Additional Targets) and any alternative splice variants, mutants, polymorphisms, and fragments thereof. 

  
 1 

	1.6	 “Additional Target Notice” has the meaning set forth in Section 3.1.1(b)(i) (Selection of
Additional Targets). 

  

	1.7	 “Additional Target Selection Period” has the meaning set forth in Section 3.1.1(b)(i)
(Selection of Additional Targets). 

  

	1.8	 “Affiliates” of a Person means any other Person that (directly or indirectly) is controlled
by, controls or is under common control with such Person. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used
with respect to a Person, will mean the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities, by contract or otherwise,
and “control” will be presumed to exist if either of the following conditions is met: (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least 50% of the votes in the election
of directors or (b) in the case of a non-corporate entity, direct or indirect ownership of at least 50% of the equity interests with the power to direct the management and policies of such entity.

  

	1.9	 “Alliance Manager” has the meaning set forth in Section 4.1.1 (Alliance Managers).

  

	1.10	 “Applicable Law” means applicable laws, statutes, rules, regulations, and other pronouncements
having the effect of law of any Governmental Authority that may be in effect from time to time, including for clarity any applicable rules, regulations, guidances, and other requirements of any Regulatory Authority that may be in effect from time to
time. 

  

	1.11	 “Assigned Platform Know-How” means any Collaboration
Platform Know-How that is developed or invented during the Collaboration Term by Biogen or its Affiliates’, licensees’, Sublicensees’, or Subcontractors’ employees, agents, or independent
contractors, or any Person contractually required to assign or license such Know-How (or Patent Rights Covering such Know-How) to Biogen or any Affiliate of Biogen,
whether solely or jointly with others, in the course of performance of Collaboration Activities undertaken pursuant to this Agreement. Notwithstanding any provision of this Agreement to the contrary, Assigned Platform
Know-How expressly excludes any Product-Specific Know-How or Target-Specific Know-How. 

 

	1.12	 “Assigned Platform Patent Rights” means any Collaboration Platform Patent Rights that Cover
Assigned Platform Know-How. Notwithstanding any provision of this Agreement to the contrary, Assigned Platform Patent Rights expressly excludes any Product-Specific Patent Rights or Target-Specific Patent
Rights. 

  

	1.13	 “Assigned Platform Technology” means Assigned Platform Patent Rights and Assigned Platform Know-How. 

  

	1.14	 “Audited Party” has the meaning set forth in Section 7.11 (Financial Audits).

  

	1.15	 “Auditing Party” has the meaning set forth in Section 7.11 (Financial Audits).

  

	1.16	 “Biogen Candidate Development Activities” has the meaning set forth in Section 3.1.2(b)
(Biogen Candidate Development Activities). 

  
 2 

	1.17	 “Biogen Collaboration Know-How” means Collaboration Know-How, other than Assigned Platform Know-How, developed or invented solely by Biogen’s or its Affiliates’, licensees’, Sublicensees’, or
Subcontractors’ employees, agents, or independent contractors, or any Persons contractually required to assign or license such Collaboration Know-How to Biogen or any Affiliate of Biogen, in each case, in
the performance of Collaboration Activities under this Agreement during the Term. 

  

	1.18	 “Biogen Collaboration Patent Rights” means all Collaboration Patent Rights that Cover Biogen
Collaboration Know-How. 

  

	1.19	 “Biogen First Right Patent Rights” has the meaning set forth in Section 10.4.1(a)
(Biogen’s Rights). 

  

	1.20	 “Biogen Grantback Claim” means any claim (a) of a Collaboration Patent Right
solely owned by Biogen (including those assigned to Biogen pursuant to this Agreement) that solely and specifically Covers a discovery, improvement, modification, enhancement, or creation to (i) an E3 Ligase Binding Moiety, (ii) a Linker,
or (iii) a combination of (i) and (ii), in each case ((i) – (iii)), to the extent that such E3 Ligase Binding Moiety or Linker is delivered by C4 to Biogen pursuant to a Candidate Development Plan, or (b) included in a C4
Licensed Patent Right that exists as of the Effective Date. Notwithstanding anything to the contrary set forth in this Agreement, “Biogen Grantback Claims” does not include any claim of a Product-Specific Patent Right or Target-Specific
Patent Right. 

  

	1.21	 “Biogen Identified Rights” has the meaning set forth in Section 7.6.5 (C4 Third Party
Agreements). 

  

	1.22	 “Biogen Indemnified Party” has the meaning set forth in Section 11.1 (Indemnification by
C4). 

  

	1.23	 “Biogen Know-How” means any Know-How Controlled by Biogen or any of its Affiliates, whether or not developed or acquired by Biogen or any of its Affiliates before or after the Effective Date, including all Biogen Collaboration Know-How, Product-Specific Know-How, and Target-Specific Know-How. 

 

	1.24	 “Biogen Licensed Know-How” means any Biogen Know-How that is (a) necessary or useful for C4 to conduct any C4 Candidate Development Activities under any Candidate Development Plan or the Sandbox Activities allocated to C4 under the Sandbox Plan and
(b) actually provided by Biogen to C4 for use in such C4 Candidate Development Activities or Sandbox Activities. 

  

	1.25	 “Biogen Licensed Patent Rights” means any Patent Rights Controlled by Biogen or any of its
Affiliates that Cover any Biogen Licensed Know-How, including all Biogen Collaboration Patent Rights, Product-Specific Patent Rights, and Target-Specific Patent Rights. 

 

	1.26	 “Biogen Licensed Technology” means Biogen Licensed Know-How and Biogen Licensed Patent Rights. 

  

	1.27	 “Biogen Patent Rights” means any Patent Rights Controlled by Biogen or any of its Affiliates
that Cover Biogen Know-How. 

  

	1.28	 “Biogen-Prosecuted Patent Rights” has the meaning set forth in Section 10.4.1(a)
(Biogen’s Rights). 

  

	1.29	 “Biogen Records” has the meaning set forth in Section 7.11 (Financial Audits).

  
 3 

	1.30	 “Biogen Technology” means Biogen Know-How and
Biogen Patent Rights. 

  

	1.31	 “Business Day” means any day other than a Saturday, Sunday, or bank or other public holiday in
Boston, Massachusetts. 

  

	1.32	 “C4 Candidate Development Activities” has the meaning set forth in Section 3.1.2(a) (C4
Candidate Development Activities). 

  

	1.33	 “C4 Collaboration Know-How” means Collaboration Know-How, other than Target-Specific Know-How and Product-Specific Know-How, developed or invented solely by C4’s or its
Affiliates’, licensees’, Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any Persons contractually required to assign or license such Collaboration
Know-How to C4 or any Affiliate of C4, in each case, in the performance of Collaboration Activities under this Agreement during the Term. 

 

	1.34	 “C4 Collaboration Patent Rights” means all Collaboration Patent Rights that Cover C4
Collaboration Know-How, but expressly excluding Target-Specific Patent Rights and Product-Specific Patent Rights. 

  

	1.35	 “C4 Degrader Platform” means the C4 degradation platform comprised of its proprietary Degrader
Components and assays relevant to the discovery or development of Degraders. 

  

	1.36	 “C4 First Right Patent Rights” has the meaning set forth in Section 10.4.1(b) (C4’s
Rights). 

  

	1.37	 “C4 Hit Criteria” means, with respect to a target that Biogen proposes to select as an
Additional Target, C4’s success criteria for degraders directed to such target set forth on Schedule 1.37 (C4 Hit Criteria), which success criteria are intended to identify such degraders and associated ligands as capable of binding to or
having activity with respect to such target, including appropriate screening assays and parameters, binding potency, and cross-assays to confirm selectivity for such target. 

 

	1.38	 “C4 Indemnified Party” has the meaning set forth in Section 11.2 (Indemnification by
Biogen). 

  

	1.39	 “C4 Internal Program” means, with respect to a target that Biogen proposes to select as an
Additional Target, a bona fide Development or Commercialization program (a) with a detailed written plan and an associated budget with respect to which C4 is performing such Development and Commercialization, and (b) under which C4
or its Affiliates have synthesized at least one degrader directed to such proposed target that meets the C4 Hit Criteria for such proposed target. 

  

	1.40	 “C4 Know-How” means any
Know-How Controlled by C4 or any of its Affiliates, including all C4 Collaboration Know-How and Assigned Platform Know-How,
whether or not developed or acquired by C4 or any of its Affiliates before or after the Effective Date. 

  

	1.41	 “C4 Licensed Know-How” means any and all C4 Know-How, other than any Joint Know-How, that is necessary or useful to (a) perform any Candidate Development Activities or the Sandbox Activities, or (b) Exploit
any Degrader or Product, in each case, including all Assigned Platform Know-How and C4 Collaboration Know-How. 

 

	1.42	 “C4 Licensed Patent Rights” means any and all C4 Patent Rights, other than any Joint
Patent Rights, that are necessary or useful to (a) perform any Candidate Development Activities or the Sandbox Activities, or (b) Exploit any Degrader or Product, including all Assigned Platform Patent Rights and C4 Collaboration Patent
Rights. The C4 Licensed Patent Rights existing as of the Effective Date are set forth on Schedule 1.42 (C4 Licensed Patent Rights). 

  
 4 

	1.43	 “C4 Licensed Technology” means all C4 Licensed
Know-How and C4 Licensed Patent Rights and C4’s interest in the Joint Technology. 

  

	1.44	 “C4 Patent Rights” means any Patent Rights Controlled by C4 or any of its Affiliates that
Cover C4 Know-How. 

  

	1.45	 “C4-Prosecuted Patent Rights” has the meaning set
forth in Section 10.4.1(b) (C4’s Rights). 

  

	1.46	 “C4 Records” has the meaning set forth in Section 7.11 (Financial Audits).

  

	1.47	 “C4 Technology” means C4 Know-How and C4 Patent
Rights. 

  

	1.48	 “C4’s Knowledge” means the actual knowledge, after reasonable investigation
(including consultation with C4’s outside intellectual property counsel), of the following: [***] 

  

	1.49	 “Calendar Quarter” means the respective periods of three consecutive calendar months ending on
March 31st, June 30th, September 30th, or December 31st in any Calendar Year. 

  

	1.50	 “Calendar Year” means any calendar year beginning on January 1st and ending on December 31st.

  

	1.51	 “Candidate Development Activities” has the meaning set forth in Section 3.1.2(b) (Biogen
Candidate Development Activities). 

  

	1.52	 “Candidate Development Budget” has the meaning set forth in Section 3.1.3 (Candidate
Development Plans and Candidate Development Budgets). 

  

	1.53	 “Candidate Development Plan” has the meaning set forth in Section 3.1.3 (Candidate
Development Plans and Candidate Development Budgets). 

  

	1.54	 “Candidate Development Program” means, on a Collaboration Target-by-Collaboration Target basis, the program of Candidate Development Activities undertaken for a Collaboration Target as set forth in Section 3.1 (Candidate Development Programs) and under the
applicable Candidate Development Plan for such Collaboration Target. 

  

	1.55	 “Change of Control” means, with respect to a Party, that: (a) any Third Party acquires
directly or indirectly the beneficial ownership of any voting security of such Party, or if the percentage ownership of such Third Party in the voting securities of such Party is increased through stock redemption, cancellation, or other
recapitalization, and immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing at least 50% of the total voting power of all of the then outstanding voting
securities of such Party; (b) a merger, consolidation, recapitalization, or reorganization of such Party is consummated that would result in shareholders or equity holders of such Party immediately prior to such transaction, owning at least 50%
of the outstanding voting securities of the surviving entity (or its parent entity) immediately following such transaction; or (c) there is a sale or transfer to a Third Party of all or substantially all of such Party’s consolidated assets
taken as a whole, through one or more related transactions. 

  
 5 

	1.56	 “Clinical Trial” means any clinical trial in humans that is designed to generate data in
support or maintenance of an IND or MAA, or other similar marketing application, including any Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, or any post-approval clinical trial in humans. 

 

	1.57	 “CMO” has the meaning set forth in Section 6.2 (Observation by Biogen).

  

	1.58	 “Collaboration Activities” means (a) the Candidate Development Activities for each
Collaboration Target and (b) the Sandbox Activities. 

  

	1.59	 “Collaboration Know-How” means any Know-How developed or invented during the Term by a Party’s or its Affiliates’, licensees’, Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any persons
contractually required to assign or license such Know-How to a Party or any Affiliate of a Party, either alone or jointly with the other Party’s or its Affiliates’, licensees’,
Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any persons contractually required to assign or license such Know-How to the other Party or any Affiliate of the
other Party, in each case, in the performance of Collaboration Activities under this Agreement. 

  

	1.60	 “Collaboration Patent Rights” means any Patent Rights that (a) have a priority date after
the Effective Date and (b) Cover any Collaboration Know-How. 

  

	1.61	 “Collaboration Platform Know-How” means any
Collaboration Know-How that constitutes a discovery, improvement, modification, enhancement, or creation of an E3 Ligase Binding Moiety, or the combination of an E3 Ligase Binding Moiety and a Linker wherein
the E3 Ligase Binding Moiety and the Linker are covalently connected. For clarity, Collaboration Platform Know-How does not include Know-How that does not specifically
relate to an E3 Ligase Binding Moiety, or the combination of an E3 Ligase Binding Moiety and a Linker wherein the E3 Ligase Binding Moiety and the Linker are covalently connected. 

 

	1.62	 “Collaboration Platform Patent Rights” means any Collaboration Patent Rights that Cover
any Collaboration Platform Know-How. Notwithstanding any provision of this Agreement to the contrary, (a) any Patent Rights that Cover both Collaboration Platform
Know-How and Target-Specific Know-How will be Target-Specific Patent Rights for the purposes of this Agreement, and (b) any Patent Rights that Cover both
Collaboration Platform Know-How and Product-Specific Know-How will be Product-Specific Patent Rights for the purposes of this Agreement. 

 

	1.63	 “Collaboration Targets” means the Initial Targets and the Additional Targets (including the
Initial Term Targets and the Extended Term Targets). 

  

	1.64	 “Collaboration Term” has the meaning set forth in Section 3.5.2 (Extension of
Collaboration Term). 

  

	1.65	 “Combination Product” means a Product that is (a) sold in the form of a combination that
contains or comprises a Development Candidate together with one or more other therapeutically active pharmaceutical agents (whether coformulated or copackaged or otherwise sold for a single price), (b) sold for a single invoice price together with
any (i) delivery device or component therefor, (ii) companion diagnostic related to any Product, process, service, or therapy, or (iii) product, process, service, or therapy other than the Product (such additional therapeutically
active pharmaceutical agent and each of (i) – (iii), an “Other Component”); or (c) defined as a “combination product” by the FDA pursuant to 21 C.F.R. §3.2(e) or its foreign equivalent.

  
 6 

	1.66	 “Commercialization,” “Commercializing,” or “Commercialize”
means any and all activities directed to the marketing, promotion, distribution, offering for sale, sale, having sold, importing, having imported, exporting, having exported or other commercialization of a pharmaceutical or biologic product, but
excluding activities directed to Manufacturing, Development, or Medical Affairs. “Commercialize,” “Commercializing,” and “Commercialized” will be construed accordingly. 

 

	1.67	 “Commercially Reasonable Efforts” means, [***]. 

 

	1.68	 “Competing Infringement” has the meaning set forth in Section 10.5.2 (Infringement
Actions). 

  

	1.69	 “Competitive Product” has the meaning set forth in Section 3.6 (Exclusivity).

  

	1.70	 “Confidential Information” means, with respect to each Party, all Know-How or other information, including proprietary information and materials (whether or not patentable) regarding or embodying such Party’s technology, products, business information or objectives, that is
communicated by or on behalf of the Disclosing Party to the Receiving Party or its permitted recipients, including information disclosed prior to the Effective Date pursuant to the Confidentiality Agreement. 

 

	1.71	 “Confidentiality Agreement” means that certain Mutual
Non-Disclosure Agreement dated December 11, 2017 by and between the Parties. 

  

	1.72	 “Control” or “Controlled” means the possession by a Party (whether by
ownership, license, or otherwise other than pursuant to this Agreement) of, (a) with respect to any tangible Know-How, the legal authority or right to physical possession of such tangible Know-How, with the right to provide such tangible Know-How to the other Party on the terms set forth herein, or (b) with respect to Patent Rights, Regulatory Approvals,
Regulatory Submissions, intangible Know-How, or other Intellectual Property, the legal authority or right to grant a license, sublicense, access, or right to use (as applicable) to the other Party under such
Patent Rights, Regulatory Approvals, Regulatory Submissions, intangible Know-How, or other Intellectual Property on the terms set forth herein, in each case ((a) and (b)), without breaching or otherwise
violating the terms of any arrangement or agreement with a Third Party in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such access, right to use, licenses, or sublicense.

  

	1.73	 “Cover,” “Covering” or “Covered” means, with respect to a
product, technology, process, method, or mode of administration that, in the absence of ownership of or a license granted under a particular Valid Claim, the manufacture, use, offer for sale, sale, or importation of such product or the practice of
such technology, process, method, or mode of administration would infringe such Valid Claim or, in the case of a claim that has not yet issued, would infringe such claim if it were to issue and become a Valid Claim. 

 

	1.74	 “CPI” means the Consumer Price Index for the US City Average (all times).

  

	1.75	 “Debarred” means, with respect to an individual or entity, that such individual or entity has
been debarred or suspended under 21 U.S.C. §335(a) or (b), the subject of a conviction described in Section 306 of the FD&C Act, excluded from a federal or governmental health care program, debarred from federal contracting, convicted
of or pled nolo contendere to any felony, or to any federal or state legal violation (including misdemeanors) relating to prescription drug products or fraud, the subject to OFAC sanctions or on the OFAC list of specially designated
nationals, or the subject of any similar sanction of any Governmental Authority in the Territory. 

  
 7 

	1.76	 “Defaulting Party” has the meaning set forth in Section 12.2.3 (Disputes regarding
Material Breach). 

  

	1.77	 “Degrader” means with respect to a Collaboration Target, a compound comprising (a) a
Target Binding Moiety, (b) optionally, a Linker, and (c) an E3 Ligase Binding Moiety that degrades such Collaboration Target. 

  

	1.78	 “Degrader Component” means any Target Binding Moiety, Linker, or E3 Ligase Binding Moiety.

  

	1.79	 “Deliverables” means any and all deliverables to be generated or provided by C4 in connection
with the performance of (i) C4 Candidate Development Activities with respect to each Collaboration Target, as specified in the applicable Candidate Development Plan, or (ii) Sandbox Activities, as specified in the applicable Sandbox
Workstream or under the Sandbox Plan. 

  

	1.80	 “Develop” or “Development” means all internal and external research,
development, and regulatory activities related to pharmaceutical or biologic products, including (a) research, non-clinical testing, toxicology, testing and studies,
non-clinical and preclinical activities, and Clinical Trials, and (b) preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to
obtain authorization to conduct Clinical Trials and to obtain, support, or maintain Regulatory Approval of a pharmaceutical or biologic product and interacting with Regulatory Authorities following receipt of Regulatory Approval in the applicable
country or region for such pharmaceutical or biologic product regarding the foregoing, but excluding activities directed to Manufacturing, Medical Affairs, or Commercialization. Development will include development and regulatory activities for
additional forms, formulations, or indications for a pharmaceutical or biologic product after receipt of Regulatory Approval of such product (including label expansion), including Clinical Trials initiated following receipt of Regulatory Approval or
any Clinical Trial to be conducted after receipt of Regulatory Approval that was mandated by the applicable Regulatory Authority as a condition of such Regulatory Approval with respect to an approved formulation or indication (such as post-marketing
studies, observational studies, implementation and management of registries and analysis thereof, in each case, if required by any Regulatory Authority in any region in the Territory to support or maintain Regulatory Approval for a pharmaceutical or
biologic product in such region). “Develop,” “Developing,” and “Developed” will be construed accordingly. 

  

	1.81	 “Development Candidate” means on a Collaboration Target-by-Collaboration Target basis, each Degrader directed to a Collaboration Target that (a) is suitable for the commencement of IND-Enabling Studies and
otherwise meets the Development Candidate Criteria set forth in the Candidate Development Plan for such Collaboration Target, or (b) with respect to which Biogen otherwise elects to commence IND-Enabling
Studies (regardless of whether or not such Degrader meets the applicable Development Candidate Criteria). 

  

	1.82	 “Development Candidate Criteria” means, with respect to a Collaboration Target, (a) the
criteria for Degraders directed to such Collaboration Target set forth in the Candidate Development Plan as “Development Candidate Criteria” for such Collaboration Target, which criteria are intended to indicate that such Degraders are
suitable for testing in IND-Enabling Studies, and (b) the IP Criteria for Degraders directed to such Collaboration Target (to the extent not set forth in the Candidate Development Plan).

  

	1.83	 “Development Candidate Report” has the meaning set forth in Section 3.1.8(a) (Delivery of
Development Candidates; Development Candidate Report). 

  
 8 

	1.84	 “Development Milestone Event” has the meaning set forth in Section 7.5.1 (Development
Milestones). 

  

	1.85	 “Development Milestone Payment” has the meaning set forth in Section 7.5.1 (Development
Milestones). 

  

	1.86	 “Directed To” means, with regard to a Degrader, that such Degrader is designed to bind to a
Collaboration Target. 

  

	1.87	 “Disclosing Party” has the meaning set forth in Section 9.1.2 (Confidential Information).

  

	1.88	 “Dollar” means the U.S. dollar, and “$” will be interpreted accordingly.

  

	1.89	 “E3 Ligase Binding Moiety” means a moiety that binds to an E3 ligase that is Controlled by C4
or its Affiliates. 

  

	1.90	 “Effective Date” has the meaning set forth in the preamble. 

 

	1.91	 “Executive Officers” has the meaning set forth in Section 13.8 (Dispute Resolution).

  

	1.92	 “Exploit” means Develop, have Developed, make, have made, use, have used, perform Medical
Affairs, have performed Medical Affairs, offer for sale, have offered for sale, sell, have sold, export, have exported, import, have imported, Manufacture, have Manufactured, Commercialize, have Commercialized or otherwise exploit.
“Exploitation” and “Exploiting” will be construed accordingly. 

  

	1.93	 “Extended Term Targets” means those targets selected pursuant to Section 3.1.1(b)
(Additional Targets) and Section 3.5.3 (Effect of Extension of Initial Collaboration Term) as a result of Biogen’s extension of the Collaboration Term pursuant to Section 3.5.2 (Extension of Collaboration Term). 

 

	1.94	 “FD&C Act” means the Federal Food, Drug and Cosmetic Act, as the same may be amended or
supplemented from time to time. 

  

	1.95	 “FDA” means the U.S. Food and Drug Administration, or any successor agency thereto.

  

	1.96	 “Field” means any and all uses. 

 

	1.97	 “First Commercial Sale” means, with respect to any Product in any country or region, the first
sale of such Product to a Third Party (other than a Sublicensee) for distribution, use, or consumption in such country or region after receipt of Regulatory Approval for such Product in such country or region. First Commercial Sale excludes any
transfers of Product to Third Parties for Clinical Trial purposes, any expanded access program, any compassionate sales or use program (including named patient program or single patient program), or any indigent program. 

 

	1.98	 “FTE” means a qualified full time person, or more than one person working the equivalent of a
full-time person, where “full time” is based upon a total of [***]working hours per Calendar Year of scientific or technical work carried out by one or more duly qualified employees of C4. Overtime, and work on weekends, holidays,
and the like will not be counted with any multiplier (e.g. time-and-a-half or double time) toward the number of hours that
are used to calculate the FTE contribution. 

  
 9 

	1.99	 “FTE Rate” means $[***] per FTE for the Calendar Years 2018 and 2019, subject to annual
increases beginning on January 1, 2020 to reflect any year to year percentage increase in the CPI for 2019 and each subsequent Calendar Year. 

  

	1.100	 “GAAP” means United States generally accepted accounting principles, which principles are
currently used at the relevant time and consistently applied by the applicable Party. 

  

	1.101	 “Generic Product” means with respect to a given Product in a given country in the Territory, a
product that (a) (i) contains the same active pharmaceutical ingredient as such Product and is approved in reliance, in whole or in part, on a prior Regulatory Approval of such Product or (ii) is otherwise approved in reliance, in whole or
in part, on a prior Regulatory Approval of such Product, and (b) is sold or marketed for sale in such country by a Third Party that has not obtained the rights to market or sell such product as a Sublicensee, Subcontractor, or Third Party
Distributor of Biogen or any of its Affiliates, Sublicensees, or Subcontractors with respect to such Product. 

  

	1.102	 “GLP” means all applicable good laboratory practice standards, including, as applicable, as
set forth in the then-current good laboratory practice standards promulgated or endorsed by the U.S. Food and Drug Administration, as defined in 21 C.F.R. Part 58, and the equivalent Applicable Law in the region in the Territory, each as may be
amended and applicable from time to time. 

  

	1.103	 “Governmental Authority” means any court, tribunal, arbitrator, agency, commission,
department, ministry, official, authority or other instrumentality of any national, state, county, city or other political subdivision. 

  

	1.104	 “Grandfathered Products” has the meaning set forth in Section 3.7 (Effect of Acquisition
of C4). 

  

	1.105	 “Hit Criteria” means, with respect to a Collaboration Target, the success criteria for
Degraders directed to such Collaboration Target set forth in the Candidate Development Plan as “Hit Criteria” for such Collaboration Target, which success criteria are intended to identify such Degraders and associated ligands as capable
of binding to or having activity with respect to such Collaboration Target, including appropriate screening assays and parameters, binding potency, and cross-assays to confirm selectivity for such Collaboration Target. 

 

	1.106	 “Hit Fee” has the meaning set forth in Section 7.2 (Hit Fee). 

 

	1.107	 [***] 

  

	1.108	 “IND” means an Investigational New Drug application required pursuant to 21 C.F.R. Part 312 or
any comparable filings outside of the United States required to commence human clinical trials in such country or region, and all supplements or amendments that may be filed with respect to the foregoing. 

 

	1.109	 “IND-Enabling Study” means a toxicology study
(a) that is conducted using applicable GLP, (b) that is conducted in a species that satisfies applicable regulatory requirements, and (c) the data and results from which are intended to meet the standard necessary for submission
thereof as part of an IND with the applicable Regulatory Authority. 

  

	1.110	 “IND-Enabling Study Commencement Fee” has the meaning
set forth in Section 7.4 (IND-Enabling Study Commencement Fee). 

  

	1.111	 “Indemnified Party” has the meaning set forth in Section 11.3 (Procedure).

  
 10 

	1.112	 “Indemnifying Party” has the meaning set forth in Section 11.3 (Procedure).

  

	1.113	 “Infringement” has the meaning set forth in Section 10.5.2 (Infringement Actions).

  

	1.114	 “Infringement Action” has the meaning set forth in Section 10.5.2(a)(i) (Infringement
Actions for Competing Infringements). 

  

	1.115	 “Initial Collaboration Term” has the meaning set forth in Section 3.5.1 (Initial Term).

  

	1.116	 “Initial Targets” has the meaning set forth in Section 3.1.1(a) (Initial Targets).

  

	1.117	 “Initial Term Targets” means the Initial Targets and the [***] Additional Targets
selected pursuant to Section 3.1.1(b)(i) (Selection of Additional Targets) (excluding, for clarity, any Extended Term Targets). 

  

	1.118	 “Initiating Party” has the meaning set forth in Section 10.5.2(c) (Procedures).

  

	1.119	 “Initiation” means the fifth dosing of a human subject in a Clinical Trial.

  

	1.120	 “Intellectual Property” means all Patent Rights, rights to Inventions, copyrights, design
rights, trademarks, trade secrets, Know-How, and all other intellectual property rights (whether registered or unregistered) and all applications and rights to apply for any of the foregoing, anywhere in the
world. 

  

	1.121	 “Invention” means any process, method, utility, formulation, composition of matter, Article of
manufacture, material, creation, discovery or finding, or any improvement thereof, that is made, conceived, discovered, or otherwise generated, whether patentable or not. 

 

	1.122	 “IP Counsels” has the meaning set forth in Section 7.6.6 (Biogen Identified Rights
Dispute). 

  

	1.123	 “IP Criteria” means, with respect to a Collaboration Target, the criteria for Degraders
directed to such Collaboration Target that are agreed to by the Parties, which criteria are intended to reflect any intellectual property considerations in determining whether such Degraders are suitable for testing in
IND-Enabling Studies. 

  

	1.124	 “Joint Collaboration Know-How” means any Collaboration
Know-How developed or invented jointly by a Party’s or its Affiliates’, licensees’, Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any Persons
contractually required to assign or license such Collaboration Know-How to such Party or any Affiliate of such Party, on the one hand, and the other Party’s or its Affiliates’, licensees’,
Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any Persons contractually required to assign or license such Collaboration Know-How to such Party or any Affiliate
of such Party, on the other hand, in the performance of Collaboration Activities under this Agreement during the Term, but excluding any Assigned Platform Know-How, Target-Specific Know-How, or Product-Specific Know-How. 

  

	1.125	 “Joint Collaboration Patent Rights” means those Collaboration Patent Rights that Cover Joint
Collaboration Know-How. 

  

	1.126	 “Joint Know-How” means all Joint Collaboration Know-How and Sandbox Know-How. 

  

	1.127	 “Joint Patent Rights” means all Joint Collaboration Patent Rights and Sandbox Patent Rights.

  
 11 

	1.128	 “Joint Technology” means all Joint Know-How and Joint
Patent Rights. 

  

	1.129	 “JSC” has the meaning set forth in Section 4.2.1 (Joint Steering Committee).

  

	1.130	 “Know-How” means any (a) proprietary information
or materials, including records, improvements, modifications, techniques, assays, chemical or biological materials, designs, protocols, formulas, data (including physical data, chemical data, toxicology data, animal data, raw data, clinical data,
and analytical and quality control data), dosage regimens, control assays, product specifications, marketing, pricing and distribution costs, Inventions, algorithms, technology, forecasts, profiles, strategies, plans, results in any form whatsoever,
know-how, and trade secrets (in each case, whether or not patentable, copyrightable, or otherwise protectable), and (b) any physical embodiments of any of the foregoing. 

 

	1.131	 “Lead Criteria” means, with respect to a Collaboration Target, the success criteria for
Degraders directed to such Collaboration Target set forth in the Candidate Development Plan as “Lead Criteria” for such Collaboration Target, which success criteria are intended to indicate that such Degraders are suitable for further
optimization as a potential Development Candidate directed to such Collaboration Target. 

  

	1.132	 “Lead Fee” has the meaning set forth in Section 7.3 (Lead Fee). 

 

	1.133	 “Liability” has the meaning set forth in Section 11.2 (Indemnification by Biogen).

  

	1.134	 “Linker” means a moiety that is Controlled by C4 or its Affiliates and connects the Target
Binding Moiety and the E3 Ligase Binding Moiety. 

  

	1.135	 “MAA” means any new drug application, biologics license application, or other marketing
authorization application, in each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, which application is required to commercially market or sell a pharmaceutical or biologic product in such country
or jurisdiction (and any amendments thereto), including all New Drug Applications submitted to the FDA in the United States in accordance with the FD&C Act with respect to a biologic or pharmaceutical product or any analogous application or
submission with any Regulatory Authority outside of the United States. 

  

	1.136	 “Major European Market” means any of France, Germany, Italy, Spain, or the United Kingdom.

  

	1.137	 “Manufacture” means activities directed to manufacturing, processing, packaging, labeling,
filling, finishing, assembly, quality assurance, quality control, testing, and release, shipping, or storage of any pharmaceutical or biologic product (or any components or process steps involving any product or any companion diagnostic), placebo,
or comparator agent, as the case may be, including process development, qualification, and validation, scale-up, pre-clinical, clinical, and commercial manufacture and
analytic development, product characterization, and stability testing, but excluding activities directed to Development, Commercialization, or Medical Affairs. “Manufacturing” will be construed accordingly. 

 

	1.138	 “Medical Affairs” means activities conducted by a Party’s medical affairs departments
(or, if a Party does not have a medical affairs department, the equivalent function thereof), including communications with key opinion leaders, medical education, symposia, advisory boards (to the extent related to medical affairs or clinical
guidance), activities performed in connection with patient registries, and other medical programs and communications, including educational grants, research grants (including conducting investigator-initiated studies), and charitable donations to
the extent related to medical affairs and not to other activities that do not involve the promotion, marketing, sale, or other Commercialization of the Products and are not conducted by a Party’s medical affairs (or equivalent) departments.

  
 12 

	1.139	 “Milestone Payments” has the meaning set forth in Section 7.5.2 (Sales Milestones).

  

	1.140	 “Net Sales” means [***]. 

 

	1.141	 “Non-Defaulting Party” has the meaning set forth in
Section 12.2.3 (Disputes Regarding Material Breach). 

  

	1.142	 “Occupied Target” has the meaning set forth in Section 3.1.1(b)(iv) (Occupied Targets).

  

	1.143	 “One-Time R&D Prepayment” means each of the
payments to C4 described in Section 7.1.1 (Initial Collaboration Term) and Section 7.1.2 (Extended Collaboration Term). 

  

	1.144	 “Other Component(s)” has the meaning set forth in Section 1.140 (Net Sales).

  

	1.145	 “Patent Rights” means any and all (a) patents, (b) patent applications, including all
provisional and non-provisional applications, patent cooperation treaty (PCT) applications, substitutions, continuations,
continuations-in-part, divisions and renewals, and all patent rights granted thereon, (c) all
patents-of-addition, reissues, re-examinations and extensions or restorations by existing or future extension or restoration
mechanisms, including supplementary protection certificates and equivalents thereof, (d) inventor’s certificates, letters patent, or (e) any other substantially equivalent form of government issued right substantially similar to any
of the foregoing described in subsections (a) through (e) above, anywhere in the world. 

  

	1.146	 “Patent Term Extension” has the meaning set forth in Section 10.8 (Patent Term
Extensions). 

  

	1.147	 “Per Product Annual Net Sales” has the meaning set forth in Section 7.6 (Royalties).

  

	1.148	 “Person” means any individual, firm, corporation, partnership, limited liability company,
trust, business trust, joint venture, Governmental Authority, association or other entity. 

  

	1.149	 “Phase I Clinical Trial” means a clinical trial in humans that generally provides for the
first introduction into humans of a pharmaceutical or biologic product with the primary purpose of determining safety, metabolism, and pharmacokinetic properties and clinical pharmacology of such product, in a manner that meets the requirements of
21 C.F.R. § 312.21(a), as amended (or its successor regulation), or, with respect to any other country or region, the equivalent of such a clinical trial in such other country or region. 

 

	1.150	 “Phase II Clinical Trial” mean a clinical trial in humans that is intended to explore the
feasibility, safety, dose ranging, or efficacy of a pharmaceutical or biologic product that is prospectively designed to generate sufficient data (if successful) to commence a Phase III Clinical Trial for such product, in a manner that meets the
requirements of 21 C.F.R. § 312.21(b), as amended (or its successor regulation), or, with respect to any other country or region, the equivalent of such a clinical trial in such other country or region. 

  
 13 

	1.151	 “Phase III Clinical Trial” means a clinical trial in humans of a pharmaceutical or biologic
product that the FDA permits to be conducted under an open IND and that is performed to gain evidence with statistical significance of the efficacy of such product in a target population, and to obtain expanded evidence of safety for such product
that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an MAA by a Regulatory Authority and to provide an adequate basis for physician labeling, in a manner that meets the requirements of
21 C.F.R. § 312.21(c), as amended (or its successor regulation), or, with respect to any other country or region, the equivalent of such a clinical trial in such other country or region. Notwithstanding anything to the contrary set forth in
this Agreement, treatment of patients as part of an expanded access program, compassionate sales or use program (including named patient program or single patient program), or an indigent program, in each case, will not be included in
determining whether or not a clinical trial is a Phase III Clinical Trial or whether a patient has been dosed thereunder. 

  

	1.152	 “Pre-Existing Restriction” has the meaning set forth
in Section 3.1.1(b)(iv) (Occupied Targets). 

  

	1.153	 “Product” means any product incorporating a Development Candidate (or derivative thereof).

  

	1.154	 “Product-Specific Know-How” any (a) Collaboration
Know-How that is developed or invented during the Collaboration Term by C4 or its Affiliates’, licensees’, Sublicensees’, or Subcontractors’ employees, agents, or independent contractors,
or any Person contractually required to assign or license such Know-How (or Patent Rights Covering such Know-How) to C4 or any Affiliate of C4, whether solely or jointly
with others, in the course of performance of Collaboration Activities undertaken pursuant to this Agreement, or (b) C4 Licensed Know-How or Sandbox Know-How, in
each case, ((a) and (b)), related to (i) any Degrader or any Product incorporating or derived from any such Degrader, (ii) any use or a method of using any such Degrader or Product incorporating or derived from any such Degrader, or
(iii) any method for Manufacturing any such Degrader or Product incorporating or derived from any such Degrader. 

  

	1.155	 “Product-Specific Patent Rights” means any C4 Licensed Patent Rights or Collaboration Patent
Rights that Cover any Product-Specific Know-How. Notwithstanding any provision of this Agreement to the contrary, any Patent Rights that Cover both Assigned Platform
Know-How and Product-Specific Know-How will be Product-Specific Patent Rights for the purposes of this Agreement. 

 

	1.156	 “Product-Specific Technology” means Product-Specific
Know-How and Product-Specific Patent Rights. 

  

	1.157	 “Prosecuting Party” means, with respect to any Patent Right, the Party that is responsible for
the preparation, filing, prosecution, and maintenance of such Patent Right pursuant to Section 10.4.1 (Right to Prosecute) or Section 10.4.2 (Step-In Right), as applicable. 

 

	1.158	 “Receiving Party” has the meaning set forth in Section 9.1 (Confidential Information).

  

	1.159	 “Regulatory Approval” means, with respect to a particular country or other regulatory
jurisdiction, any approval of an MAA or other approval, product, or establishment license, registration, or authorization of any Regulatory Authority necessary for the commercial marketing or sale of a pharmaceutical or biologic product in such
country or other regulatory jurisdiction, including, in each case, Reimbursement Approval in those countries and jurisdictions where required. 

  

	1.160	 “Regulatory Authority” means any applicable Governmental Authority with jurisdiction or
authority over the Development, Manufacture, Commercialization, or other Exploitation (including Regulatory Approval or Reimbursement Approval) of pharmaceutical or biologic products in a particular country or other regulatory jurisdiction, and any
corresponding national or regional regulatory authorities. 

  
 14 

	1.161	 “Regulatory Submissions” means any filing, application, or submission with any Regulatory
Authority in support of the Development, Manufacture, Commercialization, or other Exploitation of a pharmaceutical or biologic product (including to obtain, support, or maintain Regulatory Approval from that Regulatory Authority), and all
correspondence or communication with or from the relevant Regulatory Authority, as well as minutes of any material meetings, telephone conferences, or discussions with the relevant Regulatory Authority. Regulatory Submissions include all INDs, MAAs,
and other applications for Regulatory Approval and their equivalents. 

  

	1.162	 “Reimbursement Approval” means an approval, agreement, determination, or other decision by the
applicable Governmental Authority that establishes prices charged to end-users for pharmaceutical or biologic products at which a particular pharmaceutical or biologic product will be reimbursed by the
Regulatory Authorities or other applicable Governmental Authorities in the Territory. 

  

	1.163	 “Replacement Target Notice” has the meaning set forth in Section 3.1.1(b)(ii)
(Replacement Target Notice). 

  

	1.164	 “Results” means any and all (a) results, information, data, presentations, summaries, and
analyses that are generated pursuant to or prepared as a result of, or in connection with the performance of (i) the Candidate Development Activities under the Candidate Development Plan with respect to each Collaboration Target or
(ii) the Sandbox Activities under any Sandbox Workstream or under the Sandbox Plan, including, in each case, information related to the composition, production, and purification of Development Candidates, and (b) Intellectual Property that
claims or otherwise covers any of the foregoing. 

  

	1.165	 “Royalty Term” has the meaning set forth in Section 7.6.2 (Royalty Term).

  

	1.166	 “Sales Milestone Event” has the meaning set forth in Section 7.5.2 (Sales Milestones).

  

	1.167	 “Sales Milestone Payment” has the meaning set forth in Section 7.5.2 (Sales Milestones).

  

	1.168	 “Sandbox Activities” has the meaning set forth in Section 3.2.1 (Sandbox Activities).

  

	1.169	 “Sandbox Budget” has the meaning set forth in Section 3.2.2 (Sandbox Plan).

  

	1.170	 “Sandbox High Interest Target” has the meaning set forth in Section 3.2.7 (Sandbox High
Interest Targets). 

  

	1.171	 “Sandbox High Interest Target List” has the meaning set forth in Section 3.2.7 (Sandbox
High Interest Targets). 

  

	1.172	 “Sandbox Know-How” means any Know-How developed or invented during the Term by a Party’s or its Affiliates’, licensees’, Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any persons
contractually required to assign or license such Know-How to a Party or any Affiliate of a Party, either alone or jointly with the other Party’s or its Affiliates’, licensees’,
Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any persons contractually required to assign or license such Know-How to the other Party or any Affiliate of the
other Party, in each case, in the performance of Sandbox Activities. For clarity, Sandbox Know-How does not include Patent Rights or Know-How owned or Controlled by a
Party prior to the Effective Date, or that are developed or invented by a Party outside of this Agreement. 

  
 15 

	1.173	 “Sandbox Patent Rights” means any Patent Rights that (a) have a priority date after the
Effective Date, and (b) Cover any Sandbox Know-How. 

  

	1.174	 “Sandbox Plan” has the meaning set forth in Section 3.2.2 (Sandbox Plan).

  

	1.175	 “Sandbox Program” means the program of Sandbox Activities undertaken as set forth in
Section 3.2 (Sandbox Program) and under the applicable Sandbox Workstream and the Sandbox Plan. 

  

	1.176	 “Sandbox Target” means a target that is identified, discovered, or otherwise the subject of
any Sandbox Activities set forth in the Sandbox Plan, including under any Sandbox Workstream. 

  

	1.177	 “Sandbox Technology” means Sandbox Patent Rights and Sandbox
Know-How. 

  

	1.178	 “Sandbox Workstream” has the meaning set forth in Section 3.2.1 (Sandbox
Activities). 

  

	1.179	 “Selling Party” has the meaning set forth in Section 1.140 (Net Sales).

  

	1.180	 “Subcontractor” means a Third Party contractor engaged by a Party to perform certain
obligations or exercise certain rights of such Party under this Agreement on a fee-for-service basis (including contract research organizations or contract manufacturing
organizations), excluding all Sublicensees and Third Party Distributors. 

  

	1.181	 “Sublicensees” means any Third Party to whom a Party or any of its Affiliates grants a
sublicense of its rights hereunder to Exploit Products, excluding all Subcontractors and Third Party Distributors. 

  

	1.182	 “Target Binding Moiety” means a moiety that is directed to and binds to a particular
Collaboration Target that is Controlled by C4 or its Affiliates. 

  

	1.183	 “Target Selection Period” has the meaning set forth in Section 3.1.1(b)(v) (Expiration of
Pre-Existing Restrictions). 

  

	1.184	 “Target-Specific Know-How” means any
(a) Collaboration Know-How that is developed or invented during the Collaboration Term by C4 or its Affiliates’, licensees’, Sublicensees’, or Subcontractors’ employees, agents, or
independent contractors, or any Person contractually required to assign or license such Know-How (or Patent Rights Covering such Know-How) to C4 or any Affiliate of C4,
whether solely or jointly with others, in the course of performance of Collaboration Activities undertaken pursuant to this Agreement, or (b) C4 Licensed Know-How or Sandbox
Know-How, in each case, ((a) and (b)), that constitutes a discovery, improvement, modification, enhancement, or creation to any Target Binding Moiety(ies) or Collaboration Target. 

 

	1.185	 “Target-Specific Patent Rights” means any C4 Licensed Patent Rights or Collaboration Patent
Rights that Cover Target-Specific Know-How. Notwithstanding any provision of this Agreement to the contrary, any Patent Rights that Cover both Assigned Platform Know-How
and Target-Specific Know-How will be Target-Specific Patent Rights for the purposes of this Agreement. 

  
 16 

	1.186	 “Target-Specific Technology” means Target-Specific
Know-How and Target-Specific Patent Rights. 

  

	1.187	 [***] 

  

	1.188	 “Term” has the meaning set forth in Section 12.1 (Term). 

 

	1.189	 “Territory” means all of the countries of the world, and their territories and possessions.

  

	1.190	 “Third Party” means any Person other than Biogen or C4 or their respective Affiliates.

  

	1.191	 “Third Party Distributor” means, with respect to a country, any Third Party that purchases its
requirements for Products in such country from Biogen or its Affiliates or Sublicensees and is appointed as a distributor to distribute, market, and resell such Product in such country, even if such Third Party is granted ancillary rights to
Develop, package, or obtain Regulatory Approval of such Product in order to distribute, market, or sell such Product in such country. 

  

	1.192	 “Valid Claim” means a claim of (a) an issued, unexpired, and in-force patent, which claim has not been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be or has been taken and has not been held or admitted
to be invalid or unenforceable through re-examination, inter partes review, post grant review or disclaimer, opposition procedure, nullity suit, or otherwise, or (b) a pending patent
application that has not been finally abandoned, finally rejected, or expired; provided, however, that if a claim of a pending patent application will not have issued within [***] after the earliest filing date from which such claim
takes priority, then such claim will not constitute a Valid Claim for the purposes of this Agreement unless and until a patent issues with such claim. 

ARTICLE 2 LICENSE GRANTS 
  

	2.1	 Licenses and Assignment to Biogen. 

 

	 	2.1.1	 Collaboration License. C4 hereby grants to Biogen and its Affiliates, during the Collaboration Term, a
royalty-free, worldwide, exclusive (even as to C4, except to the extent necessary for C4 to perform any Collaboration Activities under any Candidate Development Plan or expressly allocated to C4 under the Sandbox Plan) license, with the right to
sublicense through multiple tiers (subject to the provisions of Section 2.1.4 (Sublicensing by Biogen)), under the C4 Licensed Technology solely for the purpose of performing (or having performed) Candidate Development Activities (except to the
extent required for C4 to perform the Candidate Development Activities assigned to C4 under the Candidate Development Plans) under each Candidate Development Plan and Sandbox Activities under the Sandbox Plan. 

 

	 	2.1.2	 Commercial License. C4 hereby grants to Biogen and its Affiliates a worldwide, royalty-bearing,
exclusive (even as to C4, except to the extent necessary for C4 to perform any Collaboration Activities under any Candidate Development Plan or expressly allocated to C4 under the Sandbox Plan) license, with the right to sublicense through multiple
tiers (subject to the provisions of Section 2.1.4 (Sublicensing by Biogen)), under the C4 Licensed Technology to Exploit all Degraders and Products in the Field in the Territory. 

  
 17 

	 	2.1.3	 C4 Collaboration Technology License. C4 hereby grants to Biogen and its Affiliates a worldwide,
royalty-free, irrevocable, perpetual, non-exclusive license, with the right to sublicense through multiple tiers, under all C4 Collaboration Patent Rights and C4 Collaboration
Know-How, to modify, improve, and enhance Degraders or Products (including any Degrader Component included therein). 

  

	 	2.1.4	 Sublicensing by Biogen. Biogen and its Affiliates may grant sublicenses under Section 2.1.1
(Collaboration License) and Section 2.1.2 (Commercial License) to any Affiliate or Third Party. Any such sublicense will be consistent with the terms of this Agreement and will include confidentiality,
non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in this Agreement. 

 

	2.2	 Licenses to C4. 

 

	 	2.2.1	 Collaboration License. Biogen hereby grants to C4, during the Collaboration Term, a royalty-free, non-exclusive, worldwide license, with the right to sublicense through multiple tiers (subject to the provisions of Section 2.2.3 (Sublicensing by C4)), under the Biogen Licensed Technology solely for the
purpose of performing the C4 Candidate Development Activities under the applicable Candidate Development Plan, and to the extent allocated to C4 under the Sandbox Plan, the Sandbox Activities. 

 

	 	2.2.2	 Grantback License. Biogen hereby grants to C4 an irrevocable, royalty-free, fully-paid, non-exclusive, perpetual, worldwide license, with the right to sublicense through multiple tiers, under any Biogen Grantback Claims to practice any method and to make, use, sell, offer for sale or import any product
other than (a) Degraders or Products or (b) any compounds or products Directed To any Collaboration Target. 

  

	 	2.2.3	 Sublicensing by C4. C4 may not grant any sublicense to use the Biogen Licensed Technology under
Section 2.2.1 (Collaboration License), except with the prior written consent of Biogen. Any such sublicense will be consistent with the terms of this Agreement and will include confidentiality,
non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in this Agreement. 

 

	2.3	 No Implied Licenses. Except as expressly provided in this Agreement, neither Party will be deemed to
have granted the other Party any license or other right with respect to any Intellectual Property of such Party. 

ARTICLE 3 COLLABORATION 
  

	3.1	 Candidate Development Programs. 

 

	 	3.1.1	 Collaboration Targets. 

 

	 	(a)	 Initial Targets. As of the Effective Date, the initial targets that will be the subject of Candidate
Development Programs are [***] (such targets, the “Initial Targets”). 

  

	 	(b)	 Additional Targets. 

 

	 	(i)	 Selection of Additional Targets. During the period commencing on the Effective Date and ending on the
date that is [***] thereafter (the “Additional Target Selection Period”), Biogen may select [***] additional targets (that are not Initial Targets) as Additional Targets

  
 18 

	 	
hereunder (which such Additional Targets so selected pursuant to this sentence will be Initial Term Targets hereunder). In addition, if Biogen elects to extend the Collaboration Term for an
additional [***] pursuant to Section 3.5.2 (Extension of Collaboration Term), then (A) upon such election, Biogen may select [***] additional targets as Additional Targets hereunder, and (B) during the period commencing
on the date of such election and ending on the date that is [***] thereafter, Biogen may select [***] additional targets as Additional Targets hereunder (all of which such Additional Targets so selected pursuant to the foregoing
clauses ((A) and (B)), will be Extended Term Targets hereunder), as described further in Section 3.5.3 (Effect of Extension of Initial Collaboration Term). Biogen may select each such Additional Target by sending a written notice to C4 during
the Collaboration Term, which notice will identify the applicable proposed target (each, an “Additional Target Notice”). 

  

	 	(ii)	 Replacement Target Notice. On an Initial
Target-by-Initial Target basis, if the JSC determines that the Candidate Development Program for an Initial Target has failed to deliver at least [***] in a
particular series directed to such Initial Target that meet the Hit Criteria set forth in the applicable Candidate Development Plan, then, subject to Section 3.1.1(b)(iv) (Occupied Targets), Biogen may select a replacement target as a
Collaboration Target by sending a written notice to C4 during the Collaboration Term, which notice will identify the applicable proposed target (each, a “Replacement Target Notice”). During the Collaboration Term, Biogen may send no
more than [***] Replacement Target Notice for each Initial Target. 

  

	 	(iii)	 Effects of Notice. Effective immediately upon C4’s receipt of an Additional Target Notice or
Replacement Target Notice (as applicable), subject to Section 3.1.1(b)(iv) (Occupied Targets), the applicable target that is specified in such notice will become an Additional Target for purposes of this Agreement and, following the
Parties’ agreement on a Candidate Development Plan with respect to such Additional Target in accordance with Section 3.1.4 (Additional Candidate Development Plans), C4 will promptly initiate Candidate Development Activities with respect to
such Additional Target in accordance with this Section 3.1 (Candidate Development Programs). 

  

	 	(iv)	 Occupied Targets. If, at the time of C4’s receipt of an Additional Target Notice or
Replacement Target Notice for a proposed target, [***] then Biogen may select another proposed target (and another if such other proposed target is an Occupied Target and so on) until such time that Biogen selects a target that is not an
Occupied Target, at which point such proposed target will be added as an Additional Target under this Agreement. 

  

	 	(v)	 Expiration of Pre-Existing Restrictions. If at any time during
the period in which Biogen is eligible to send C4 an Additional Target Notice under Section 3.1.1(b)(i) (Selection of Additional Targets) or Replacement Target Notice under Section 3.1.1(b)(ii) (Replacement Target Notice) (such period, the
“Target Selection Period”), any Pre-Existing 

  
 19 

	 	
Restriction that precluded Biogen from selecting a proposed target as an Additional Target that Biogen previously proposed to C4 under Section 3.1.1(b)(iv) (Occupied Targets) later expires,
terminates, or is otherwise modified such that such proposed target would no longer be an Occupied Target, then C4 will promptly notify Biogen of such expiration, termination, or modification. 

 

	 	3.1.2	 Candidate Development Activities. 

 

	 	(a)	 C4 Candidate Development Activities. For each Candidate Development Program with respect to a
Collaboration Target, C4 will be responsible for (i) performing all activities assigned to it under the applicable Candidate Development Plan, (ii) applying its C4 Degrader Platform to the discovery and initial optimization of at least
[***] directed to each Collaboration Target that satisfy the applicable Hit Criteria for such Collaboration Target, and (iii) preparing and delivering all Deliverables and Results related to such Collaboration Target in accordance with
this Agreement and the applicable Candidate Development Plan, including the preparation of all reports in accordance with Section 3.1.9 (Reports of Candidate Development Activities) and the Development Candidate Report for each Development
Candidate in accordance with Section 3.1.8(a) (Delivery of Development Candidates; Development Candidate Report) (collectively, together with any other activity expressly set forth under this Agreement to be performed by or on behalf of C4
during the Collaboration Term (other than the Sandbox Activities), the “C4 Candidate Development Activities”). C4 will perform, or have performed, all C4 Candidate Development Activities in accordance with the applicable Candidate
Development Plan and the applicable Candidate Development Budget for such Collaboration Target and otherwise in accordance with this Agreement. C4 will not perform any activities with respect to a Collaboration Target (including the Exploitation of
any Degrader directed to such Collaboration Target) that are not set forth in the applicable Candidate Development Plan for such Collaboration Target (other than the Sandbox Activities, which activities C4 will perform in accordance with
Section 3.2 (Sandbox Program)). 

  

	 	(b)	 Biogen Candidate Development Activities. Biogen (i) will perform all activities assigned to it
under the applicable Candidate Development Plan, and (ii) may elect to lead other neurosciences-related activities with respect to each Collaboration Target, including cellular testing of Degraders, development of target binding assays and
primary and secondary screening assays and testing and validation of the binding of ligands, and Degraders, in each case, to such Collaboration Target using such assays, cellular mechanism of action studies, pharmacokinetic studies, efficacy and
pharmacodynamic models, translational efforts, further optimizing Degraders that satisfy the applicable Hit Criteria and Lead Criteria for such Collaboration Target for potency, selectivity, brain penetrance, and ADME/PK properties to demonstrate
in vivo proof of principle, and other pilot toxicology (together ((i) and (ii)), with any other activities to be performed by or on behalf of Biogen with respect to each Collaboration Target during the Collaboration Term, collectively, the
“Biogen Candidate Development Activities,” and, together with the C4 Candidate Development Activities, the “Candidate Development Activities”). 

  
 20 

	 	3.1.3	 Candidate Development Plans and Candidate Development Budgets. For each Collaboration Target, C4
will perform the C4 Candidate Development Activities for such Collaboration Target and Biogen will perform the Biogen Candidate Development Activities for such Collaboration Target in accordance with a written development plan that sets forth:
(a) the C4 Candidate Development Activities to be performed by or on behalf of C4 during the Collaboration Term, (b) the Biogen Candidate Development Activities to be performed by or on behalf of Biogen during the Collaboration Term,
(c) the Hit Criteria for Degraders directed to the applicable Collaboration Target, (d) the Lead Criteria for Degraders directed to the applicable Collaboration Target, (e) the Development Candidate Criteria for Degraders directed to
the applicable Collaboration Target, (f) the timelines upon which C4 will work to deliver to Biogen Degraders that meet each of the Hit Criteria, Lead Criteria, and Development Candidate Criteria for such Collaboration Target and their
respective satisfaction of the applicable criteria, (g) the Deliverables and other Results required for the JSC to determine whether Degraders directed to such Collaboration Target have satisfied the Hit Criteria, Lead Criteria, and Development
Candidate Criteria for such Collaboration Target, and other Deliverables and Results to be provided by C4 to Biogen with respect to the C4 Candidate Development Activities, (h) a timeline for completion of other C4 Candidate Development
Activities, and (i) the dedicated and planned resources to be provided by C4 in furtherance of performing the C4 Candidate Development Activities (each such plan, a “Candidate Development Plan”). In addition, for each
Collaboration Target, the Candidate Development Plan will include a written budget pursuant to which C4 or its authorized Third Party designees will perform the C4 Candidate Development Activities allocated to C4 under such Candidate Development
Plan, which budget will include a good-faith estimate of (i) the number of FTEs to be dedicated by C4 under such Candidate Development Plan, and (ii) any direct
out-of-pocket expenses expected to be incurred (each such budget, the “Candidate Development Budget”). All internal personnel and resources of C4 under
each Candidate Development Budget will be expressed in terms of FTEs plus any direct out-of-pocket costs to be incurred (e.g., from the use of contract research
organizations) in connection with the performance of Candidate Development Activities as outlined in the applicable Candidate Development Plan and such budgeted cost will be calculated using the relevant FTE Rates. The initial Candidate Development
Plan agreed to by the Parties for each of the Initial Targets is attached hereto as Schedule 3.1.3(a) (Candidate Development Plan for [***]), Schedule 3.1.3(b) (Candidate Development Plan for [***]), and Schedule 3.1.3(c) (Candidate
Development Plan for [***]), respectively. 

  

	 	3.1.4	 Additional Candidate Development Plans and Budgets. No later than [***] after
Biogen’s delivery of an Additional Target Notice for an Additional Target, subject to Section 3.1.1(b)(iv) (Occupied Targets), the Parties will develop, through the JSC, a Candidate Development Plan for such Additional Target and an
associated Candidate Development Budget included in such Candidate Development Plan for the costs and expenses associated with the performance of the Candidate Development Activities set forth under such Candidate Development Plan, in each case, in
accordance with this Section 3.1.4 (Additional Candidate Development Plans and Budgets). The content of the Candidate Development Plan for each Additional Target will be consistent in scale and scope to that set forth in the Candidate
Development Plans for the Initial Targets, including (a) Hit Criteria, Lead Criteria, and Development Candidate for Degraders directed to such Additional Target that are substantially similar to the corresponding criteria set forth under the
Candidate Development Plans for such Initial Targets, and (b) C4 Candidate Development Activities that are consistent in scale and scope with the corresponding activities under the Candidate Development Plans for such Initial Targets and Biogen

  
 21 

	 	
Candidate Development Activities that are at least equivalent in scale and scope as the corresponding activities under the Candidate Development Plans for such Initial Targets. The Candidate
Development Budget for each Additional Target will be substantially similar to the Candidate Development Budgets for the Initial Targets. 

  

	 	3.1.5	 Updates to Candidate Development Plans. The Parties may update and amend each Candidate Development Plan
and the corresponding Candidate Development Budget included in such Candidate Development Plan from time to time through the JSC, each of which updated plan and budget the JSC will have the right to determine whether to approve, subject to
Section 4.2.4 (Decision Making Authority). 

  

	 	3.1.6	 Satisfaction of Hit Criteria. On a Collaboration Target-by-Collaboration Target basis, C4 will use diligent efforts to deliver to Biogen at least [***] directed to each Collaboration Target that meet the Hit Criteria set forth in the applicable
Candidate Development Plan in accordance with the timeframes for such delivery set forth in such Candidate Development Plan. On a Collaboration Target-by-Collaboration
Target basis, C4 will provide written notice to the JSC upon the development of each Degrader directed to each Collaboration Target that satisfies the Hit Criteria for such Collaboration Target, together with all Deliverables to be provided with
respect to Degraders that satisfy such Hit Criteria (as set forth in the applicable Candidate Development Plan) and applicable Deliverables and supporting Results. The JSC will review, discuss, and determine whether each such Degrader satisfies the
applicable Hit Criteria for the applicable Collaboration Target. Upon the JSC’s confirmation that at least [***] directed to a Collaboration Target satisfy the Hit Criteria for such Collaboration Target, Biogen will pay the Hit Fee with
respect to such Collaboration Target in accordance with Section 7.2 (Hit Fee). Biogen will only be obligated to pay the Hit Fee one time with respect to each Collaboration Target, and after Biogen pays the Hit Fee for a Collaboration Target,
without limiting C4’s obligations under this Agreement, Biogen will not be obligated to pay any additional Hit Fee for any additional Degraders directed to such Collaboration Target that satisfy the Hit Criteria. 

 

	 	3.1.7	 Satisfaction of Lead Criteria. On a Collaboration Target-by-Collaboration Target basis, C4 will use diligent efforts to deliver to Biogen at least [***] directed to each Collaboration Target that meet the Lead Criteria set forth in the applicable
Candidate Development Plan in accordance with the timeframes for such delivery set forth in such Candidate Development Plan. On a Collaboration Target-by-Collaboration
Target basis, C4 will provide written notice to the JSC upon the development of each Degrader directed to each Collaboration Target that satisfies the Lead Criteria for such Collaboration Target, together with all Deliverables to be provided with
respect to Degraders that satisfy such Lead Criteria (as set forth in the applicable Candidate Development Plan) and applicable Deliverables and supporting Results. The JSC will review, discuss, and determine whether each such Degrader satisfies the
applicable Lead Criteria for the applicable Collaboration Target. Upon the JSC’s confirmation that at least [***] directed to a Collaboration Target satisfy the Lead Criteria for such Collaboration Target, Biogen will pay the Lead Fee
with respect to such Collaboration Target in accordance with Section 7.3 (Lead Fee). Biogen will only be obligated to pay the Lead Fee one time with respect to each Collaboration Target, and after Biogen pays the Lead Fee for a Collaboration
Target, without limiting C4’s obligations under this Agreement, Biogen will not be obligated to pay any additional Lead Fee for any additional Degraders directed to such Collaboration Target that satisfy the Lead Criteria for such Collaboration
Target. 

  
 22 

	 	3.1.8	 Satisfaction of Development Candidate Criteria. 

 

	 	(a)	 Delivery of Development Candidates; Development Candidate Report. On a Collaboration Target-by-Collaboration Target basis, C4 will use diligent efforts to deliver to Biogen at least [***] directed to each Collaboration Target that meets the Development
Candidate Criteria set forth in the applicable Candidate Development Plan in accordance with the timeframes for such delivery set forth in such Candidate Development Plan. In addition, no later than [***] after completion by C4 of all C4
Candidate Development Activities set forth under the applicable Candidate Development Plan with respect to each Degrader, C4 will deliver to Biogen a report summarizing all Results for each Degrader as a result of the performance by or on behalf of
C4 of the C4 Candidate Development Activities set forth under the applicable Candidate Development Plan with respect to such Degrader (for each Degrader, a “Development Candidate Report”). On a Degrader-by-Degrader basis, following C4’s completion of the C4 Candidate Development Activities set forth under the applicable Candidate Development Plan with respect to such Degrader, Biogen will have
sole control over, will bear all costs and expenses of, and will have sole discretion and decision-making authority with respect to, the performance of further activities with respect to such Degrader and all Products that incorporate such Degrader,
in each case, during the Collaboration Term. 

  

	 	(b)	 IND-Enabling Study Commencement Fee. On a Collaboration Target-by-Collaboration Target basis, with respect to the first Degrader directed to each Collaboration Target for which Biogen commences
IND-Enabling Studies, Biogen will pay to C4 the IND-Enabling Study Commencement Fee for such Collaboration Target pursuant to Section 7.4 (IND-Enabling Study Commencement Fee). Biogen will only be obligated to pay the IND-Enabling Study Commencement Fee one time with respect to each Collaboration Target, and
after Biogen pays the IND-Enabling Study Commencement Fee for the first Degrader directed to a particular Collaboration Target, Biogen may commence IND-Enabling Studies
for any other Degrader directed to such Collaboration Target without paying any additional IND-Enabling Study Commencement Fee. For clarity, Biogen may, at its sole discretion, determine to conduct IND-Enabling Studies (or further Development or Commercialization thereafter) with respect to any Degrader, regardless of whether such Degrader meets the Hit Criteria, Development Candidate Criteria, or Lead
Criteria set forth in the applicable Candidate Development Plan. 

  

	 	3.1.9	 Reports of Candidate Development Activities. Notwithstanding anything to the contrary in this Agreement,
C4 will keep Biogen reasonably informed, through the JSC, regarding the status and progress of C4’s activities with respect to Collaboration Targets and Degraders, including the status of all C4 Candidate Development Activities. Biogen will
keep C4 reasonably informed, through the JSC, regarding the status and progress of Biogen’s activities with respect to Collaboration Targets and Degraders by providing C4 a high-level summary of the status of Biogen Candidate Development
Activities at each meeting of the JSC. During the Collaboration Term on a quarterly basis, C4 will prepare written reports for each Collaboration Target for which C4 is performing (or has performed) any C4 Candidate Development Activities to update
Biogen on the status of all such C4 Candidate Development Activities for such Collaboration Target performed by or on behalf of C4 during the applicable Calendar Quarter. Such reports must be sufficient in

  
 23 

	 	
content to allow Biogen to evaluate the progress of the C4 Candidate Development Activities against the objectives, One-Time R&D Prepayment and
timelines included therefor in the applicable Candidate Development Plan. In addition, for each Calendar Quarter, C4 shall provide to Biogen a summary report in the form attached hereto as Schedule 3.1.9 (Form of Candidate Development Financial
Report). In addition, C4 will include in such reports such other Deliverables, Results, or other information as may be required under any Candidate Development Plan or otherwise required for the performance of the Biogen Candidate Development
Activities with respect to a particular Collaboration Target (or as may be reasonably requested by Biogen). The JSC will review the quarterly update reports for each such Collaboration Target and (i) confer regarding the progress towards
developing Degraders directed to such Collaboration Target that satisfy the Hit Criteria, Lead Criteria, and Development Candidate Criteria (including determining whether or not Degraders directed to each Collaboration Target satisfy the Hit
Criteria, Lead Criteria, and Development Candidate Criteria, in each case, for such Collaboration Target), (ii) review relevant Deliverables provided and Results generated in the performance of such C4 Candidate Development Activities,
(iii) consider and advise on any technical issues that may arise, and (iv) discuss the Biogen Candidate Development Activities performed by or on behalf of Biogen with respect to such Collaboration Target during the same period;
provided that Biogen will not be obligated to discuss the Biogen Candidate Development Activities with the JSC or C4 in the event of a Change of Control of C4 involving a Third Party that is, at such time, Exploiting any Competitive Product.

  

	 	3.1.10	 Costs of Candidate Development Activities. The payments to be made pursuant to Section 7.1 (One-Time R&D Prepayments) will compensate C4 for, and are being made to C4 as a prepayment of costs and expenses to be incurred by or on behalf of C4 in connection with the performance of all C4 Candidate
Development Activities to be performed by or on behalf of C4 under each Candidate Development Plan. C4 will be responsible for all costs and expenses incurred by or on behalf of C4 in the performance of all C4 Candidate Development Activities and
any other activities undertaken by C4 with respect to each Candidate Development Program during the Collaboration Term (including any additional resources that may be required for C4 to perform the C4 Candidate Development Activities under any
Candidate Development Plan in accordance with this Agreement). Biogen will be responsible for all costs and expenses incurred by or on behalf of Biogen in the performance of all Biogen Candidate Development Activities and any other activities
undertaken by Biogen with respect to each Candidate Development Program during the Collaboration Term. 

  

 

	 	3.1.11	 Performance of C4 Candidate Development Activities. C4 will (a) provide all resources necessary for
it to perform all C4 Candidate Development Activities and (b) perform all C4 Candidate Development Activities with reasonable care and skill in accordance with all Applicable Laws and the terms of this Agreement. On a Collaboration Target-by-Collaboration Target basis, as set forth under this Agreement, C4 will use diligent efforts to complete all C4 Candidate Development Activities set forth under each
Candidate Development Plan in accordance with the performance timelines set forth in the applicable Candidate Development Plan, deliver to Biogen [***] that satisfy each of the Hit Criteria, Lead Criteria, and [***] that satisfies the
Development Candidate Criteria set forth under the applicable Candidate Development Plan in accordance with the timeframes set forth in each such Candidate Development Plan, and provide to Biogen all Deliverables and Results set forth in the
applicable Candidate Development Plan within the timeframes included therefor. During the Collaboration Term, C4 will devote the efforts of suitably qualified and trained employees and research assistants capable of carrying out the C4 Candidate
Development Activities set forth under each Candidate Development Plan to a professional workmanlike standard and will provide all necessary materials and facilities therefor. 

  
 24 

	3.2	 Sandbox Program. 

 

	 	3.2.1	 Sandbox Activities. During the Collaboration Term, the Parties will undertake a series of research and
activities to (a) better understand the C4 Degrader Platform and inform Biogen’s selection of the Additional Targets, including understanding the chemical approaches to targeted protein degradation through the modulation of the ubiquitin-
proteasome pathway for the purpose of identifying and discovering ligands and targets (other than the Initial Targets) to be added as Additional Targets hereunder, and (b) with respect to C4, prepare and deliver all Deliverables and Results
related to such activities in accordance with this Agreement, including all reports to be prepared in accordance with Section 3.2.4 (Reports of Sandbox Activities) (the “Sandbox Activities”). For clarity, no target that is an
Occupied Target shall be eligible for any Sandbox Activities. The Parties agree that the Additional Targets derived from the Sandbox Activities shall be intended to address indications in the field of neurology. 

 

	 	3.2.2	 Sandbox Plan and Sandbox Workstreams. 

 

	 	(a)	 Sandbox Plan. Each Party will perform (or have performed) the Sandbox Activities allocated to it in
accordance with a written plan that sets forth: (a) those activities to be performed in order to validate targets that may be selected as Additional Targets and to identify novel ligands, (b) a detailed timeline for the identification of
such targets and ligands and the completion by C4 of all other Sandbox Activities allocated to C4 under such plan, (c) the Deliverables and Results to be provided to Biogen by C4 with respect to the Sandbox Activities to be performed by or on
behalf of C4 under such plan (which Deliverables and Results will be sufficient for Biogen to determine whether or not it wishes to select any such target as an Additional Target), and (d) the FTEs to be dedicated by C4 in furtherance of
performing the activities and achieving the objectives set forth in the foregoing clauses (a) – (d) (the “Sandbox Plan”). Either Party may propose to perform (or have performed, subject to the terms of this Agreement) under the
Sandbox Plan specific Sandbox Activities with respect to a particular Sandbox Target (each, a “Sandbox Workstream”), each of which Sandbox Workstreams will be attached as a separate appendix to the Sandbox Plan and will set
forth in writing (i) those activities to be performed in order to validate a Sandbox Target, (ii) a detailed timeline for the performance of such validation activities and the completion by C4 of all other Sandbox Activities allocated to
C4 under such Sandbox Workstream, (iii) the Deliverables and Results to be provided to Biogen by C4 with respect to the Sandbox Activities to be performed by or on behalf of C4 under such Sandbox Workstream (which Deliverables and Results will
be sufficient for Biogen to determine whether or not it wishes to select any Sandbox Target as an Additional Target), and (iv) the FTEs to be dedicated by C4 in furtherance of performing the activities and achieving the objectives set forth in
the foregoing clauses (i) – (iii). No later than [***] after the Effective Date, the Parties will develop, through the JSC, the Sandbox Plan that sets forth the initial Sandbox Activities (including an individual Sandbox Workstream for
each Sandbox Target that will be the subject of Sandbox Activities as of the date of such initial Sandbox Plan) and the associated detailed, written budget for the costs and expenses of the Sandbox Activities allocated to C4 under the Sandbox Plan

  
 25 

	 	
(including under each such initial Sandbox Workstream), which costs will be based on the number of FTEs to be dedicated by C4 under the Sandbox Plan, charged at the FTE Rate, as well as any
direct out-of-pocket costs incurred by C4 in the course of conducting such Sandbox Activities (for each Sandbox Workstream, a “Sandbox Budget”).

  

	 	(b)	 Additional Sandbox Workstreams. Thereafter, at any point until the earlier of:
(i) the [***] anniversary of the Effective Date, or (ii) the date on which the total costs and expenses incurred by or on behalf of C4 in the performance of all Sandbox Activities under the Sandbox Plan in accordance with the
applicable Sandbox Budget equals [***], either Party may propose a Sandbox Workstream for an additional target to the JSC with respect to which Sandbox Activities are to be conducted under the Sandbox Plan and the associated proposed Sandbox
Budget for the conduct of Sandbox Activities under such Sandbox Workstream. Following the JSC’s approval of each Sandbox Workstream and associated Sandbox Budget with respect to a target, such Sandbox Workstream and Sandbox Budget will be
attached as an appendix to, incorporated into, and made part of the Sandbox Plan. 

  

	 	3.2.3	 Performance of Sandbox Activities. C4 will dedicate the number of FTEs set forth under the Sandbox Plan
(including under each Sandbox Workstream) to perform the Sandbox Activities allocated to C4 under the Sandbox Plan (or applicable Sandbox Workstream) and C4 or its authorized Third Party designees will perform such Sandbox Activities in accordance
with the Sandbox Plan (including as set forth in the applicable Sandbox Workstream) and applicable Sandbox Budget, and otherwise in accordance with this Agreement. The Parties may update and amend the Sandbox Plan or any Sandbox Workstream and
associated Sandbox Budget from time to time through the JSC, each of which updated plan and budget the JSC will have the right to determine whether to approve, subject to Section 4.2.4 (Decision Making Authority); provided that, unless
otherwise agreed to by the Parties (not the JSC) in writing, the total costs and expenses to be incurred by or on behalf of C4 under the Sandbox Budgets in the performance of all Sandbox Activities under the Sandbox Plan (including all Sandbox
Workstreams) may not exceed $[***] in the aggregate. 

  

	 	3.2.4	 Reports of Sandbox Activities. Notwithstanding anything to the contrary set forth in this Agreement,
each Party will keep the other Party reasonably informed, through the JSC, regarding the status and progress of the Sandbox Activities performed by or on behalf of such Party. During the Collaboration Term on a [***] basis, C4 will prepare
written reports to update Biogen on the status of such Sandbox Activities performed by or on behalf of C4 during the applicable [***]. Such reports must be sufficient in content to allow the receiving Party to evaluate the progress of the
Sandbox Activities being performed by or on behalf of the other Party against the objectives, Sandbox Budget and timelines included therefor in each Sandbox Plan. In addition, Biogen will prepare a high-level summary to update C4 on the status of
the Sandbox Activities performed by or on behalf of Biogen during the applicable [***]. C4 will (a) record and account the FTE efforts and direct
out-of-pocket expenses (along with reasonable documentation), in each case, incurred by or on behalf of C4 during the applicable [***] in the performance of the
Sandbox Activities by or on behalf of C4 during the applicable [***] under the Sandbox Plan, and (b) provide a reasonable estimate of the FTEs and direct
out-of-pocket expenses, in each case, to be incurred on a [***] basis by or on behalf of C4 in order to complete the Sandbox Activities as set forth under the
then-current Sandbox Plan in accordance with the applicable Sandbox Budget. In addition, each Party will provide to the other Party such other information as 

  
 26 

	 	
may be reasonably required under the Sandbox Plan or otherwise for the performance of the Sandbox Program or reasonably requested by the other Party. The JSC will review the quarterly update
reports of such Sandbox Activities and (i) confer regarding the progress towards identifying and discovering ligands and targets that Biogen may select as Additional Targets, (ii) review relevant Deliverables provided and Results generated
in the performance of such Sandbox Activities, and (iii) consider and advise on any technical issues that may arise. 

  

	 	3.2.5	 Costs of Sandbox Activities. For each applicable Calendar Quarter, Biogen will reimburse C4 for
(a) the FTE hours actually spent by C4 employees at the applicable FTE Rate in the performance of Sandbox Activities under the Sandbox Plan, and (b) the direct
out-of-pocket expenses (provided with reasonable supporting documentation) incurred by or on behalf of C4 in performing such Sandbox Activities, in each case ((a) and
(b)), in accordance with the Sandbox Plan and applicable Sandbox Budget. In each such Calendar Quarter, C4 will invoice Biogen, and Biogen will pay C4 all undisputed amounts due under this Section 3.2.5 (Costs of Sandbox Activities) within
[***] following receipt of the applicable invoice. Notwithstanding anything to the contrary set forth in this Agreement, unless otherwise agreed to in writing by the Parties (not the JSC), the total amount payable by Biogen to C4 pursuant to
this Section 3.2.5 (Costs of Sandbox Activities) or otherwise with respect to the performance of any Sandbox Activities will not exceed $[***]. In addition, Biogen will be responsible for all costs and expenses incurred by or on behalf
of Biogen in the performance of the Sandbox Activities allocated to Biogen in the applicable Sandbox Plan. 

  

	 	3.2.6	 Performance of Sandbox Activities. C4 will dedicate the number of FTEs set forth in the Sandbox Plan to
perform the Sandbox Activities allocated to C4 thereunder and such FTEs will perform such Sandbox Activities with reasonable care and skill in accordance with all Applicable Laws and the terms of this Agreement. In addition, as set forth in this
Agreement, C4 will use diligent efforts to (a) complete all Sandbox Activities allocated to C4 under the Sandbox Plan in accordance with the applicable Sandbox Budget, and (b) deliver to Biogen, through the JSC all Deliverables and Results
set forth in the Sandbox Plan within the timeframes included therefor. During the Collaboration Term, the FTEs of C4 dedicated to performing the Sandbox Activities under the Sandbox Plan will be suitably qualified and trained employees and research
assistants capable of carrying out such Sandbox Activities to a professional workmanlike standard and will provide all necessary materials and facilities therefor. 

 

	 	3.2.7	 Sandbox High Interest Targets. Within [***] following the Additional Target Selection Period,
Biogen will provide C4 with a prioritized list of up to [***] Sandbox Targets that may be potentially selected as a Replacement Target in accordance with Section 3.1.1(b)(i) (Selection of Additional Targets) or as an Extended Term Target
in accordance with Section 3.1.1(b)(ii) (Replacement Target Notice) (each such Sandbox Target, a “Sandbox High Interest Target” and such list, the “Sandbox High Interest Target List”). Biogen may add or remove
a Sandbox Target to or from the Sandbox High Interest Target List (as applicable) at any time during the Term upon written notice to C4, provided, however, that (a) at no time will the Sandbox High Interest Target List include more than
[***] Sandbox High Interest Targets and (b) if Biogen designates a Sandbox High Interest Target as a Replacement Target in accordance with Section 3.1.1(b)(i) (Selection of Additional Targets) or as an Extended Term Target in
accordance with Section 3.1.1(b)(ii) (Replacement Target Notice), then, in each case, such Sandbox High Interest Target will be automatically removed from the Sandbox High Interest Target List and such Sandbox

  
 27 

	 	
High Interest Target will no longer be deemed a Sandbox High Interest Target for the purposes of this Agreement. During the Collaboration Term, each Sandbox High Interest Target will be subject
to the restrictions set forth in Section 3.6 (Exclusivity) and C4 will, and will cause its Affiliates to, comply with such restrictions with respect thereto. 

 

	3.3	 Records. During the Collaboration Term and for [***] thereafter, C4 will maintain records of all
Collaboration Activities in sufficient detail and in good scientific manner, appropriate for scientific, patent, and regulatory purposes, which records will be complete and properly reflect all work done and results achieved in the performance of
Collaboration Activities by or on behalf of C4. In addition, C4 will calculate and maintain records of FTE effort and direct out-of-pocket expenses, in each case,
incurred by it in the same manner as used for other products developed by C4. 

  

	3.4	 Copies and Inspection of Records. [***], during normal business hours and upon reasonable notice
not less than [***], Biogen will have the right to inspect all records of C4 or its authorized Third Party designees that relate to the performance of Collaboration Activities by or on behalf of C4. Notwithstanding anything to the contrary
set forth in this Agreement, Biogen will have the right to inspect such records more than [***] if it in good faith believes performance of Collaboration Activities by or on behalf of C4 are not in compliance with the terms and conditions of
this Agreement. Biogen will have the right to arrange for its employees or independent consultants and (sub)contractors involved in the performance of activities under this Agreement to (a) visit the offices and laboratories of C4 [***]
during normal business hours and upon reasonable notice not less than [***], and (b) discuss with C4’s technical personnel and consultants the performance and progress of the Collaboration Activities and applicable Deliverables and
associated Results in detail. After preparing or receiving the report for such visit or inspection, Biogen will provide C4 with a written summary of Biogen’s findings of any deficiencies or other areas of remediation that Biogen identifies
during any such visit or inspection. C4 will use diligent efforts to remediate any such deficiencies within [***] after C4’s receipt of such report, at C4’s cost and expense. 

 

	3.5	 Collaboration Term. 

 

	 	3.5.1	 Initial Term. The Collaboration Activities will be performed by or on behalf of the Parties during the
period commencing on the Effective Date and expiring on the date that is [***] thereafter unless (a) extended by Biogen pursuant to Section 3.5.2 (Extension of Collaboration Term), or (b) earlier terminated as provided in
Article 12 (Term and Termination) (the “Initial Collaboration Term”). 

  

	 	3.5.2	 Extension of Collaboration Term. Biogen may elect to extend the Initial Collaboration Term for an
additional [***] (for a total period of [***] after the Effective Date) by delivering to C4 written notice of its desire to so extend the Initial Collaboration Term no later than the fourth anniversary of the Effective Date (the
Initial Collaboration Term, together with such additional [***] period if Biogen so delivers such notice pursuant to this Section 3.5.2 (Extension of Collaboration Term), unless this Agreement is earlier terminated as provided in Article
12 (Term and Termination), collectively, the “Collaboration Term”). Notwithstanding anything to the contrary set forth in this Agreement, each Party will use commercially reasonable efforts to complete within [***] following
the end of the Collaboration Term (whether the Initial Collaboration Term or as extended for an additional [***] period pursuant to this Section 3.5.2 (Extension of Collaboration Term)), all Candidate Development Activities assigned to
such Party under, and in accordance with, each Candidate Development Plan that are ongoing or incomplete at the end of the Collaboration Term (unless technically or scientifically infeasible, as determined by the JSC). 

  
 28 

	 	3.5.3	 Effect of Extension of Initial Collaboration Term. If Biogen elects to extend the Initial Collaboration
Term pursuant to Section 3.5.2 (Extension of Collaboration Term), then: (a) Biogen will have the right to select five more Additional Targets with respect to which the Parties will perform Candidate Development Activities in accordance
with this Agreement, which targets will be selected in accordance with Section 3.1.1(b)(i) (Selection of Additional Targets), and upon selection thereof, such Additional Targets will be Extended Term Targets for purposes of this Agreement and
(b) Biogen will pay to C4 the payment to so extend the Initial Collaboration Term in accordance with Section 7.1.2 (Extended Collaboration Term). 

  

	3.6	 Exclusivity. On a Candidate Development
Program-by-Candidate Development Program and Sandbox Program-by-Sandbox Program Basis,
other than in the performance of activities under this Agreement and subject to Section 3.7 (Exception for Acquisition of C4), C4 will not (and will not permit its Affiliates to), either alone or directly or indirectly with any Third Party,
Exploit : (a) solely with respect to C4 and its Affiliates (other than any Acquiror or any Affiliate of such Acquiror prior to the consummation of the applicable Change of Control) any protein antibody, small molecule compound, or other biological
molecule, chemical compound, or other molecule, and (b) with respect to any Acquiror (including any Affiliate of such Acquiror prior to the consummation of the applicable Change of Control), any protein degrader, in each case ((a) and (b)),
that is Directed To (i) during the Term, any Collaboration Target, (ii) during the Additional Target Selection Period, any Sandbox Target or (iii) during the Collaboration Term, any Sandbox High Interest Target (any such protein,
antibody, small molecule, compound, or other biological molecule, chemical compound, other molecule, or protein degrader, as applicable. described in the foregoing clauses (a) or (b), a “Competitive Product”). For the avoidance
of doubt, the foregoing obligations of exclusivity shall cease immediately with respect to a Candidate Development Program upon termination of this Agreement with respect to such Candidate Development Program and will cease with respect to a
Collaboration Target upon replacement of such Collaboration Target in accordance with Section 3.1.1(b)(ii) (Replacement Target Notice). 

  

	3.7	 Effect of Acquisition of C4. C4 will not be in breach of the restrictions set forth in Section 3.6
(Exclusivity) if C4 undergoes a Change of Control with a Third Party (such Third Party, an “Acquiror,” and, together with its pre-Change of Control Affiliates, the “Acquisition
Party”) that is (either directly or through any Third Party) Exploiting one or more Competitive Products prior to such Change of Control. Competitive Products being Exploited by the Acquisition Party prior to the Change of Control are
referred to herein as “Grandfathered Products.” The Acquisition Party may continue to Exploit such Grandfathered Products following the Change of Control; provided that (a) no C4 Licensed Technology or Biogen Technology is used
by or on behalf of the Acquisition Party or its Affiliates in connection with the Exploitation of such Competitive Products, and (b) C4 and the Acquisition Party institutes commercially reasonable technical and administrative safeguards to
ensure the requirements set forth in the foregoing clause (a) are met, including by creating “firewalls” between the personnel working on such Grandfathered Products and the personnel teams charged with working on any Product or
having access to data from activities performed under this Agreement or Confidential Information of the Parties. 

  
 29 

 ARTICLE 4 GOVERNANCE 

 

	4.1	 Alliance Management. 

 

	 	4.1.1	 Alliance Managers. Each Party will appoint a single individual who possesses sufficient alliance
management experience and is otherwise suitably qualified and that has the requisite decision-making authority, in each case, to act as its alliance manager under this Agreement to support the Collaboration Activities, the Sandbox Program, and the
Candidate Development Programs (the “Alliance Manager”). The initial Alliance Managers will be set forth on Schedule 4.1.1 (Contact List). Each Party may change the person designated as its Alliance Manager upon
written notice (including via email notification) to the other Party, provided that such new Alliance Manager possesses sufficient alliance management experience and otherwise meets the requirements set forth in this Section 4.1.1
(Alliance Managers). 

  

	 	4.1.2	 Roles and Responsibilities. The Alliance Managers will be responsible for (a) facilitating the flow
of information and otherwise promoting communication of the day-to-day work for the Sandbox Program and each Candidate Development Program, (b) coordinating the
Collaboration Activities, (c) providing a single point of communication for seeking consensus both internally within the respective Party’s organization and between the Parties regarding key strategy and planning issues, (d) assisting
the integration of teams across functional areas, (e) preparing and disseminating agendas and presentations for the JSC meetings, (f) conducting the meetings of the JSC, and (g) performing such other functions as requested by the JSC.

  

	4.2	 Joint Steering Committee. 

 

	 	4.2.1	 Formation. As soon as practicable, but no later than [***] after the Effective Date, the Parties
will establish a joint steering committee (the “JSC”) to oversee the Collaboration Activities. The JSC will be comprised of [***] representatives of Biogen and [***] representatives of C4, each of whom will have the
appropriate experience and expertise to perform its responsibilities on the JSC. Each Party will provide notice to the other Party of its initial representatives to the JSC. Either Party may replace its representatives with similarly qualified
individuals at any time upon prior written notice to the other Party. If agreed by the JSC on a case-by-case basis, the JSC may invite other nonmembers to participate in
the discussions and meetings of the JSC, provided that such participants will have no voting authority at the JSC and that any such non-employee participants are bound by written obligations of non-use and confidentiality no less stringent than those set forth in Article 9 (Confidentiality). The Alliance Managers will be responsible, on behalf of the JSC, for setting the agenda for meetings of the JSC with
input from the other members and for conducting the meetings of the JSC. Neither Alliance Manager will be a member of the JSC, but the Alliance Managers or suitable designees will attend all meetings of the JSC. 

 

	 	4.2.2	 Meetings. The JSC will meet in person (alternating between a site designated by each of C4 and Biogen)
or by teleconference at least [***], or with such other frequency as the Parties may agree. Specific meeting dates will be determined by agreement of the Parties. Either Party may also call a special meeting of the JSC (by videoconference or
teleconference) upon at least [***] prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed before the next regularly scheduled JSC meeting, and such Party will provide the JSC
materials reasonably adequate to enable an informed discussion by its members no later than [***] before the special 

  
 30 

	 	
meeting. Biogen will host the first meeting of the JSC at a mutually agreeable time and place no later than [***] after the Effective Date. Each Party will be responsible for its own
expenses relating to attendance at or participation in JSC meetings. The Alliance Managers will prepare and disseminate agendas and presentations no later than [***] in advance of each JSC meeting unless otherwise agreed to by the Parties in
writing. The Alliance Managers will jointly prepare and circulate minutes for each JSC meeting within [***] after each such meeting and will ensure that such minutes are reviewed and approved by their respective companies within [***]
thereafter. 

  

	 	4.2.3	 Responsibilities. The JSC will oversee and monitor the progress of the Collaboration Activities. Within
such scope the JSC will, subject to Section 4.2.4 (Decision Making Authority) and Section 4.2.5 (Limits of JSC Decision Making Authority): 

  

	 	(a)	 discuss and determine whether a Replacement Target Notice is warranted, as described in
Section 3.1.1(b)(ii) (Replacement Target Notice); 

  

	 	(b)	 prepare the Candidate Development Plan (and the Candidate Development Budget included in such Candidate
Development Plan) for each Additional Target, as described in Section 3.1.4 (Additional Candidate Development Plans and Budgets); 

  

	 	(c)	 review and amend each Candidate Development Plan and the corresponding Candidate Development Budget included in
such Candidate Development Plan, as described in Section 3.1.5 (Updates to Candidate Development Plans and Budgets); 

  

	 	(d)	 review and determine whether Degraders directed to a given Collaboration Target satisfy the Hit Criteria set
forth in the applicable Candidate Development Plan for such Collaboration Target, as described in Section 3.1.6 (Satisfaction of Hit Criteria); 

  

	 	(e)	 review and determine whether Degraders directed to a given Collaboration Target satisfy the Lead Criteria set
forth in the applicable Candidate Development Plan for such Collaboration Target, as described in Section 3.1.7 (Satisfaction of Lead Criteria); 

  

	 	(f)	 review C4’s quarterly update reports to Biogen on the status of all C4 Candidate Development Activities
and discuss the C4 Candidate Development Activities performed since the previous JSC meeting, as described in Section 3.1.9 (Reports of Candidate Development Activities); 

 

	 	(g)	 review Biogen’s quarterly high-level summary to C4 on the status of Biogen Candidate Development
Activities and discuss the Biogen Candidate Development Activities performed since the previous JRC meeting, as described in Section 3.1.9 (Reports of Candidate Development Activities); 

 

	 	(h)	 prepare the initial Sandbox Plan and initial Sandbox Workstreams and the associated Sandbox Budgets, and make
amendments thereto, in each case, as described in Section 3.2.2(a) (Sandbox Plan); 

  
 31 

	 	(i)	 review and determine whether to approve each additional Sandbox Workstream and the associated Sandbox Budget,
as described in Section 3.2.2(b) (Additional Sandbox Workstreams); 

  

	 	(j)	 review C4’s quarterly update reports to Biogen on the status of all Sandbox Activities performed by or on
behalf of C4 and discuss the Sandbox Activities performed since the previous JSC meeting, as described in Section 3.2.4 (Reports of Sandbox Activities); 

  

	 	(k)	 review Biogen’s high-level summary to C4 on the status of all Sandbox Activities performed by or on behalf
of Biogen and discuss the Sandbox Activities performed since the previous JSC meeting, as described in Section 3.2.4 (Reports of Sandbox Activities); 

  

	 	(l)	 review, discuss, and determine whether any Candidate Development Activities assigned to a Party that are
ongoing or complete at the end of the Collaboration Term are technically or scientifically infeasible to complete within [***] following the end of the Collaboration Term, as described in Section 3.5.2 (Extension of Collaboration Term);

  

	 	(m)	 consider and advise on any technical issues that arise under the Collaboration Activities;

  

	 	(n)	 discuss, plan, and coordinate the transition of Manufacturing activities and transfer of Know-How from C4 to Biogen that is necessary or useful for the Manufacture of Degraders and Products, such discussion, planning and coordination to begin, on a Candidate Development Program-by- Candidate Development Program basis, prior to the satisfaction of the Lead Criteria with respect to a Candidate Development Program; 

 

	 	(o)	 discuss and coordinate the transfer of (i) all Know-How Controlled
by C4 that is necessary or useful to enable the Manufacture of a Development Candidate and (ii) any materials (as well as any intermediates and impurities of such materials) used by C4 or its Affiliates or Subcontractors in the Manufacture of
such Development Candidate, in each case ((i) and (ii)), in accordance with the applicable technology transfer plan with respect to such Development Candidate, as described in Section 6.3 (Manufacturing Technology Transfer);

  

	 	(p)	 form such other committees as the JSC may deem appropriate, including individual committees to oversee
Collaboration Activities related to particular Collaboration Targets; 

  

	 	(q)	 attempt to resolve any disputes on an informal basis; and 

 

	 	(r)	 perform such other functions as expressly set forth in this Agreement or allocated to the JSC by the written
agreement of the Parties. 

  

	 	4.2.4	 Decision Making Authority. A quorum for a meeting of the JSC will require the presence of at least
[***] from each Party. The JSC will endeavor to reach decisions by consensus, with each Party, through its representative members of the JSC, having [***], provided that a quorum must be present for any decision to be made by
the JSC. Subject to the terms 

  
 32 

	 	
of this Agreement, including Section 4.2.5 (Limits on JSC Decision Making Authority), [***] will have final decision making authority with respect to such decision, including any
Candidate Development Plan or Candidate Development Budget or the Sandbox Plan (including any Sandbox Workstream) or any Sandbox Budget, or any update to any of the foregoing. 

 

	 	4.2.5	 Limits on JSC Decision Making Authority. Notwithstanding anything to the contrary set forth in this
Agreement, without C4’s prior written consent, no decision of the JSC or [***] (in the exercise of its final decision-making authority on any such matters as set forth in Section 4.2.4
(Decision Making Authority)), in each case, may (a) result in a material increase in the scope of activities required to be performed by C4 under this Agreement, including under any Candidate Development Plan or require C4 to dedicate FTEs in
excess of the Sandbox Budget, (b) take or decline to take any action that would be reasonably likely to result in a violation of any Applicable Law, the requirements of any Regulatory Authority, or any agreement between C4 and any Third Party
or that would be reasonably likely to result in the infringement, misappropriation, or other violation of any Intellectual Property of any Third Party, (c) impose any obligation on either Party that would be in violation of such Party’s
written standard operating procedures, written business policies, or written compliance policies or procedures, or (d) conflict with this Agreement. 

  

	4.3	 Disbandment of the JSC. The JSC will terminate upon the earlier of (a) the expiration (or earlier
termination) of the Collaboration Term or (b) the date on which Biogen has, for each Collaboration Target, commenced IND-Enabling Studies for a Development Candidate directed to such Collaboration Target.
Upon the termination of the JSC, the JSC will have a final meeting thereafter to review the results of the all Collaboration Activities and will thereafter have no further authority with respect to the activities hereunder. 

ARTICLE 5 DEVELOPMENT, REGULATORY MATTERS, AND COMMERCIALIZATION 

 

	5.1	 Technology Transfer. C4 will provide to Biogen copies of all C4 Licensed
Know-How that is necessary or useful for the performance of all Biogen Candidate Development Activities no later than [***] after the Effective Date. Thereafter, C4 will provide to Biogen copies of all
C4 Licensed Know-How that is made, conceived, discovered, or otherwise generated following such initial transfer of C4 Licensed Know-How that is (a) necessary or
useful to continue to enable Biogen to perform such Biogen Candidate Development Activities and Sandbox Activities, or (b) necessary or useful to allow Biogen to continue to Exploit any Degrader and Products that incorporate such Degrader, in
each case (a) and (b), as determined by the JSC. In addition to providing copies of the C4 Licensed Know-How in accordance with this Section 5.1 (Technology Transfer), C4 will make its personnel
reasonably available to Biogen so as to enable Biogen to practice under the C4 Licensed Technology in connection with its performance of the Biogen Candidate Development Activities and the Sandbox Activities and the Exploitation of the Degraders and
Products that include such Degraders. 

  

	5.2	 Development and Medical Affairs. On a Development Candidate-by-Development Candidate basis, following completion of the Candidate Development Activities with respect to such Development Candidate, Biogen will have sole control over, will bear all costs and
expenses of, and will have sole discretion and decision-making authority with respect to, the further Development of, and the performance of all Medical Affairs with respect to, such Development Candidate and all Products that incorporate such
Development Candidate. 

  
 33 

	5.3	 Regulatory Activities. Biogen will have sole control over the preparation and submission of all
Regulatory Submissions for all Products at its own cost and expense, including all MAAs and applications for obtaining, supporting, and maintaining Reimbursement Approvals for all Products. Biogen may file all such applications in its own name (or
in the name of its designee) and will own and control all such applications. Without limiting the generality of Section 5.6 (C4 Support), C4 will use commercially reasonable efforts to assist Biogen in its efforts to prepare and submit any
Regulatory Submissions to obtain, support, or maintain Regulatory Approvals for all Products, including by providing to Biogen, upon Biogen’s reasonable request, all data, written reports, and other documentation related to such Product
Controlled by C4 or its Affiliates (which assistance and data generation must be in accordance with Applicable Law and requirements and standards by applicable Regulatory Authorities) as well as any necessary samples and materials. C4 may invoice
Biogen for the internal costs (at the FTE Rate) and documented expenses incurred in connection with providing such assistance and cooperation, and Biogen will pay the undisputed invoiced amounts within [***] after the date of such invoice.

  

	5.4	 Commercialization. Biogen will have sole control over, will bear all costs and expenses of, and will
have sole discretion and decision-making authority with respect to, the Commercialization of all Products. 

  

	5.5	 Diligence Obligations. 

 

	 	5.5.1	 Development Diligence Obligations. If Biogen has commenced an
IND-Enabling Study for a Development Candidate directed to a Collaboration Target in the United States or one Major European Market, then Biogen, itself or through its Affiliates, Sublicensees, or
Subcontractors, will use Commercially Reasonable Efforts to Develop and seek Regulatory Approval for at least [***] directed to such Collaboration Target in the United States or [***] Major European Market. Biogen will have no other
diligence obligations under this Agreement with respect to the Development or Regulatory Approval of any Development Candidates or Products. 

  

	 	5.5.2	 Commercialization Diligence Obligations. Following receipt by or on behalf of Biogen of Regulatory
Approval for a Product in the United States or a Major European Market, Biogen will use Commercially Reasonable Efforts to Commercialize such Product in the United States or such Major European Market (as applicable). Biogen will have no other
diligence obligations under this Agreement with respect to the Commercialization of any Products. 

  

	5.6	 C4 Support. The Parties understand and agree that following completion of the Sandbox Activities and C4
Candidate Development Activities, in addition to the cooperation and assistance to be expressly provided under Section 5.1 (Technology Transfer), Section 5.3 (Regulatory Activities), and Section 6.4 (C4 Manufacturing Support), from
time to time it may be necessary for Biogen to seek assistance and cooperation from C4 in connection with the performance of the Biogen Candidate Development Activities or further Exploitation of Development Candidates and Products. C4 hereby agrees
to use commercially reasonable efforts to provide any such assistance and cooperation reasonably requested by Biogen within [***] following completion of such Sandbox Activities or C4 Candidate Development Activities (as applicable), as a
consultant. C4 may invoice Biogen for the internal costs (at the FTE Rate) and documented expenses incurred in connection with providing such assistance and cooperation, and Biogen will pay the undisputed invoiced amounts within [***] after
the date of such invoice. 

  
 34 

 ARTICLE 6 MANUFACTURING 

 

	6.1	 General Responsibilities. On a Development Candidate-by-Development Candidate basis, following successful manufacturing technology transfer as set forth in Section 6.3 (Manufacturing Technology Transfer) for each Development Candidate and all
Products that incorporate such Development Candidate, Biogen will have sole responsibility for, and sole decision-making authority with respect to, all Manufacturing activities and associated costs and expenses for the Manufacture of such
Development Candidate and all such Products. 

  

	6.2	 Observation by Biogen. Following C4’s delivery to Biogen of a Development Candidate Report for a
Degrader, C4 will provide Biogen with the opportunity, upon Biogen’s reasonable request during normal business hours, to observe the Manufacturing processes and procedures for such Degrader (e.g., review assays, batch records, and
release processes and procedures) for the purpose of enabling Biogen (or a Third Party contract manufacturer (“CMO”) designated by Biogen) to Manufacture such Degrader and Products that incorporate such Degrader pursuant to
Section 6.3 (Manufacturing Technology Transfer). If C4 utilizes a CMO for the Manufacture of any Degrader, then C4 will take all reasonable actions, including entering into a three party agreement with Biogen and such CMO, to enable Biogen to
exercise its rights under Section 6.1 (General Responsibilities) and this Section 6.2 (Observation by Biogen). 

  

	6.3	 Manufacturing Technology Transfer. In addition to the initial technology transfer set forth in
Section 5.1 (Technology Transfer), on a Development Candidate-by-Development Candidate basis, following selection of such Development Candidate by Biogen, beginning
at the time of selection of a Development Candidate and for a period of [***] thereafter, C4 will work with Biogen to transfer to Biogen (a) all Know-How Controlled by C4 that is necessary or
useful to enable the Manufacture of such Development Candidate, to the extent not previously transferred to Biogen under this Agreement, by providing copies or samples of relevant documentation, materials, and other embodiments of such Know-How, and by making available its qualified technical personnel on a reasonable basis to consult with Biogen with respect to such Know-How, and (b) any materials (as
well as any intermediates and impurities of such materials) used by C4 or its Affiliates or Subcontractors in the Manufacture of such Development Candidate, including any materials, intermediates and impurities used prior to the performance of IND-Enabling Studies for such Development Candidate. Each such Know-How transfer will be conducted pursuant to technology transfer plan developed and agreed by the Parties at
least [***] prior to the anticipated commencement of such transfer, the purpose of which plan will be to ensure the complete and timely transfer of such Know-How and materials in a manner that is
consistent with then-current internal technology transfer corporate standards (or equivalent policy) of Biogen. The JSC will coordinate and ensure that such transfer has been completed under the applicable technology transfer plan.

  

	6.4	 C4 Manufacturing Support. Without limiting the generality of Section 5.6 (C4 Support), the Parties
understand and agree following the technology transfer contemplated by Section 6.3 (Manufacturing Technology Transfer) it may be necessary for Biogen from time to time to seek assistance and cooperation from C4 in connection with the
Manufacture of Development Candidates and Products, including with respect to scale-up activities. C4 hereby agrees to use commercially reasonable efforts to provide any such assistance and cooperation
reasonably requested by Biogen within [***] following such technology transfer, as a consultant. C4 may invoice Biogen for the internal costs (at the FTE Rate) and documented expenses incurred in connection with providing such assistance and
cooperation, and Biogen will pay the undisputed invoiced amounts within[***] after the date of such invoice. 

  
 35 

 ARTICLE 7 PAYMENTS AND ROYALTIES 

 

	7.1	 One-Time R&D Prepayments. 

 

	 	7.1.1	 Initial Collaboration Term. No later than [***] after the Effective Date Biogen will pay to C4 an
upfront payment of $[***] as prepayment for the C4 Candidate Development Activities to be performed hereunder, payable by wire transfer of immediately available funds. 

 

	 	7.1.2	 Extended Collaboration Term. If Biogen elects to extend the Collaboration Term for an additional
[***] period pursuant to Section 3.5.2 (Extension of Collaboration Term), then Biogen will pay to C4 a payment of $[***], payable by wire transfer of immediately available funds. Biogen will pay such amount to C4 no later than
[***] after Biogen’s receipt of an invoice therefor, which invoice C4 may not provide to Biogen until C4’s receipt of written notice from Biogen of Biogen’s desire to so extend the Initial Collaboration Term.

  

	7.2	 Hit Fee. On a Collaboration
Target-by-Collaboration Target basis, Biogen will pay to C4 a one-time payment of $[***] upon receipt of at least
[***] Degraders directed to each Collaboration Target that satisfy the Hit Criteria for such Collaboration Target (as confirmed by the JSC pursuant to Section 4.2.3(d)) (each, a “Hit Fee”). Biogen will pay the Hit Fee to
C4 for each applicable Collaboration Target no later than [***] after Biogen’s receipt of an invoice therefor, which invoice C4 may not provide to Biogen with respect to a Collaboration Target unless and until the JSC confirms that the
applicable Degraders directed to such Collaboration Target satisfy the Hit Criteria for such Collaboration Target. 

  

	7.3	 Lead Fee. On a Collaboration
Target-by-Collaboration Target basis, Biogen will pay to C4 a one-time payment of $[***] in consideration of at least
[***] Degraders directed to each Collaboration Target that satisfy the Lead Criteria for such Collaboration Target (as confirmed by the JSC pursuant to Section 4.2.3(e)) (each, a “Lead Fee”). Biogen will pay the Lead Fee
to C4 for each applicable Collaboration Target no later than [***] after Biogen’s receipt of an invoice therefor, which invoice C4 may not provide to Biogen with respect to a Collaboration Target unless and until the JSC confirms that
the applicable Degraders directed to such Collaboration Target satisfy the Lead Criteria for such Collaboration Target. 

  

	7.4	 IND-Enabling Study Commencement Fee. On a Collaboration Target-by-Collaboration Target basis, Biogen will pay to C4 a one-time payment of $[***] in consideration of the commencement by
or on behalf of Biogen of the [***] IND-Enabling Study for a Development Candidate directed to each Collaboration Target (for each Collaboration Target, a
“IND-Enabling Study Commencement Fee”). Biogen will notify C4 in writing of the commencement (i.e., the first dosing of an animal subject) of an
IND-Enabling Study with respect to the [***] Development Candidate directed to each Collaboration Target. Thereafter, C4 will provide Biogen with an invoice for the
IND-Enabling Study Commencement Fee for the applicable Collaboration Target, and Biogen will pay to C4 such IND-Enabling Study Commencement Fee no later than
[***] after its receipt of invoice therefor. 

  
 36 

	7.5	 Milestone Payments. 

 

	 	7.5.1	 Development Milestones. On a Collaboration Target-by-Collaboration Target basis, Biogen will make one-time milestone payments (each, a “Development Milestone Payment”) to C4 upon the
first achievement by Biogen or its Affiliates or Sublicensees of each of the development milestone events (each, a “Development Milestone Event”) (a) set forth in TABLE 7.5.1(a) below for the first Product directed to each Initial
Term Target that is Covered by a Valid Claim of a C4 Licensed Patent Right (at the time of such achievement) to achieve the applicable Development Milestone Event, and (b) set forth in TABLE 7.5.1(b) below for the first Product directed to each
Extended Term Target that is Covered by a Valid Claim of a C4 Licensed Patent Right (at the time of such achievement) to achieve the applicable Development Milestone Event. For the avoidance of doubt, each Development Milestone Payment hereunder
will be payable only once per Collaboration Target upon the first achievement of the applicable Development Milestone Event by a Product directed to such Collaboration Target. No additional Development Milestone Payments will be made for any
subsequent achievement of such Development Milestone Event by any other Product directed to the same Collaboration Target. If one or more Development Milestone Events are skipped for a Product directed to a particular Collaboration Target, then such
skipped Development Milestone Events will be payable upon the first achievement by a Product that is Covered by a Valid Claim of a C4 Licensed Patent Right (at the time of such achievement) directed to the same Collaboration Target of the subsequent
Development Milestone Event, except that a Development Milestone Event in one territory will not be deemed to be skipped solely because a subsequent Development Milestone Event was achieved in a different territory (e.g., [***]).
Biogen will notify C4 in writing of the achievement of a Development Milestone Event by Biogen or its Affiliates or Sublicensees no later than [***] after Biogen becomes aware of the achievement thereof. Thereafter, C4 will provide Biogen
with an invoice for the corresponding Development Milestone Payment, and Biogen will pay to C4 such Development Milestone Payment no later than [***] after its receipt of invoice for such Development Milestone Payment. If Biogen or its
Affiliates or Sublicensees achieve all Development Milestone Events with respect to Products directed to a particular Collaboration Target (regardless of the number of times such events occur or the number of Products that trigger such event), then
(a) the maximum amount payable by Biogen with respect to a particular Initial Term Target under this Section 7.5.1 (Development Milestones) is $[***], and (b) the maximum amount payable by Biogen with respect to a particular
Extended Term Target under this Section 7.5.1 (Development Milestones) is $[***]. 

  

			
	 TABLE 7.5.1(a) – Development
Milestones
 Products Directed to Initial Term Targets

	 Development Milestone Event
	  	Development Milestone
Payment
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 37 

			
	 TABLE 7.5.1(b) – Development
Milestones
 Products Directed to Extended Term Targets

	 Development Milestone Event
	  	Development Milestone
Payment
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  

	 	7.5.2	 Sales Milestones. On a Collaboration
Target-by-Collaboration Target basis, Biogen will make one-time sales milestone payments (each, a “Sales Milestone
Payment” and together with the Development Milestone Payments, the “Milestone Payments”) to C4 upon the achievement by Biogen or its Affiliates or Sublicensees of each of the sales-based milestones events (each, a
“Sales Milestone Event”) (a) set forth in TABLE 7.5.2(a) below with respect to aggregate annual Net Sales of Products directed to each Initial Term Target and Covered by a Valid Claim of a C4 Licensed Patent Right (at the
time of sale in the applicable country), and (b) set forth in TABLE 7.5.2(b) below with respect to aggregate annual Net Sales of Products directed to each Extended Term Target and Covered by a Valid Claim of a C4 Licensed Patent Right (at the
time of sale in the applicable country). Each of the Sales Milestone Payments set forth below will be payable only one time, for the first Calendar Year in which the corresponding Sales Milestone Event is achieved. Biogen will notify C4 in writing
of the achievement of a Sales Milestone Event by Biogen or its Affiliates or Sublicensees no later than [***] after the end of the Calendar Year in which such Sales Milestone Payment is payable pursuant to the preceding sentence. Thereafter,
C4 will provide Biogen with an invoice for the corresponding Sales Milestone Payment, and Biogen will pay to C4 such Sales Milestone Payment no later than [***] after its receipt of invoice for such Sales Milestone Payment. If Biogen or its
Affiliates or Sublicensees achieve all Sales Milestone Events with respect to Products directed to a particular Collaboration Target (regardless of the number of times such events occur or the number of Products that trigger such event), then
(i) the maximum amount payable by Biogen with respect to a particular Initial Term Target under this Section 7.5.2 (Sales Milestones) is $[***], and (ii) the maximum amount payable by Biogen with respect to a particular
Extended Term Target under this Section 7.5.2 (Sales Milestones) is $[***]. 

  

			
	 TABLE 7.5.2(a) – Sales
Milestones
 Products Directed to Initial Term Targets

	 Sales Milestone Event
	  	Sales Milestone
Payment
	[***]	  	[***]
	[***]	  	[***]

  
 38 

			
	 TABLE 7.5.2(b) – Sales
Milestones
 Products Directed to Extended Term Targets

	 Sales Milestone Event
	  	Sales Milestone
Payment
	[***]	  	[***]
	[***]	  	[***]

  

	7.6	 Royalties. 

  

	 	7.6.1	 Royalty Payments. Subject to the provisions of Section 7.6.4 (Royalty Adjustments), on a Product-by-Product and country-by-country basis, Biogen will pay to C4 royalties in the amount
of the marginal royalty rates set forth in TABLE 7.6.1 below of the aggregate Net Sales resulting from the sale of Products in the Territory during each Calendar Year of the applicable Royalty Term for each Product in each country (each, the
“Per Product Annual Net Sales”). 

  

			
	 TABLE 7.6.1 – Marginal Royalty
Rates

	 Per Product Annual Net Sales
	  	Marginal Royalty Rate (% of Per
Product Annual Net Sales)
	[***]	  	[***]
	[***]	  	[***]

 Each marginal royalty rate set forth in TABLE 7.6.1 above will apply only to that portion of the Net Sales of
a given Product in the Territory during a given Calendar Year that falls within the indicated range. For example, [***]. 
  

	 	7.6.2	 Royalty Term. On a
Product-by-Product and country-by-country basis, Biogen’s obligation to pay
royalties will begin upon the First Commercial Sale of a Product in a country and will expire upon the expiration of the last-to-expire Valid Claim of a C4 Licensed
Patent Right, Product-Specific Patent Right, or Target-Specific Patent Right, in each case, Covering the composition of matter or method of use in the approved label of such Product in such country (the “Royalty Term”). Upon
expiration of the Royalty Term for a given Product in a given country (a) no further royalties will be payable in respect of sales of such Product in such country, and (b) the licenses granted to Biogen under Section 2.1.2 (Commercial
License) with respect to the Exploitation of such Product in such country will automatically become fully paid-up, perpetual, irrevocable, and royalty free. For clarity, only a single royalty will be payable
as a result of one or more Valid Claims Covering a Product during the Royalty Term. 

  

	 	7.6.3	 Royalty Reports; Payments. 

 

	 	(a)	 Royalty Reports. No later than [***] after the end of each Calendar Quarter during which any
royalty payments are owed, Biogen will submit to C4 a written report of Net Sales of Products sold, in the currency for which such Products were sold (and, if the currency of sale was not Dollars, also in Dollars), by or on behalf of Biogen and its
Affiliates and Sublicensees during such Calendar Quarter, and the royalty payments payable on such Net Sales in sufficient detail to permit confirmation of the accuracy of royalty payments paid hereunder. 

  
 39 

	 	(b)	 Royalty Payments. Royalties will be payable on a Calendar Quarter basis and Biogen will make any such
payments within [***] after the end of the Calendar Quarter during which the applicable Net Sales of Products occurred. 

  

	 	7.6.4	 Payment Adjustments. 

 

	 	(a)	 Generic Competition. If, in a particular country, a Third Party obtains approval for and sells a Generic
Product with respect to a particular Product, then the royalties payable by Biogen pursuant to Section 7.6 (Royalties) for such Product in such country will be reduced by [***] for the remainder of the Royalty Term for such Product in
such country. 

  

	 	(b)	 Third Party Payments. If Biogen enters into an agreement with a Third Party to obtain rights under a
Patent Right or other Intellectual Property owned or controlled by such Third Party (whether by acquisition or license) that is necessary or useful to Exploit one or more Products, then Biogen may reduce the [***] royalties due to C4 by
[***] of the amounts paid to such Third Party [***]. 

  

	 	(c)	 Maximum Payment Adjustments. In no event will the [***] royalties payable to C4 in a given
Calendar Quarter reduced by more than [***] of the aggregate amount that would otherwise be payable to C4 in respect such [***] royalties in such Calendar Quarter as a result of the reductions permitted pursuant to
Section 7.6.4(a) (Generic Competition) and Section 7.6.4(b) (Third Party Payments). Biogen may carry forward any such reductions permitted under Section 7.6.4(a) (Generic Competition) and Section 7.6.4(b) (Third Party Payments)
that are incurred or accrued in a Calendar Quarter but are not applied against [***] royalties due to C4 in such Calendar Quarter as a result of the foregoing floor and apply such amounts against [***] royalties due to C4 in any
subsequent Calendar Quarter (subject to the minimum floor set forth in this Section 7.6.4(c) (Maximum Royalty Adjustments)) until the amount of such reduction has been fully applied against [***] royalties due to C4.

  

	 	7.6.5	 Third Party Agreements. C4 will be responsible for obtaining and maintaining rights to use any and all
Third Party Intellectual Property (whether through acquisition or license) that would, absent such right, be infringed, misappropriated, or otherwise violated by the practice of the C4 Degrader Platform or the performance of C4’s obligations
under this Agreement. Upon Biogen’s written notice identifying any such Third Party Intellectual Property, or promptly upon C4 otherwise becoming aware of any such Third Party Intellectual Property (“Biogen Identified Rights”),
C4 will, subject to Section 7.6.6 (Biogen Identified Rights Dispute), use diligent efforts to promptly obtain rights to such Biogen Identified Rights. C4 will ensure that any such rights acquired under license are freely sublicenseable to
Biogen to the extent of the licenses and rights granted to Biogen under this Agreement. C4 will be solely responsible for (a) all obligations (including any royalty or other obligations that relate to the C4 Licensed Technology) under any
agreement between C4 and any Third Party that is in effect as of the Effective Date or that C4 enters into during the Term, including any agreements entered into pursuant to this Section 7.6.5 (Third Party Agreements) for Biogen Identified
Rights, and (b) all payments to inventors (other than inventors that are representatives of Biogen) of C4 Licensed Know-How, Results, Deliverables, and Sandbox
Know-How, including payments under inventorship compensation laws. 

  
 40 

	 	7.6.6	 Biogen Identified Rights Dispute. If a Party disputes whether certain Biogen Identified Rights would,
absent obtaining rights to use such Biogen Identified Rights, be infringed, misappropriated, or otherwise violated by the practice of the C4 Degrader Platform or the performance of C4’s obligations under this Agreement, then each Party may
refer the matter to the IP Counsel of Biogen and the outside intellectual property counsel of C4 or their designees (the “IP Counsels”) to determine whether such Biogen Identified Rights would, absent obtaining rights to use such
Biogen Identified Rights, be infringed, misappropriated, or otherwise violated by the practice of the C4 Degrader Platform or the performance of C4’s obligations under this Agreement. The IP Counsels will meet promptly to discuss and resolve
the matter within [***] after referral of such matter to such IP Counsels. If the IP Counsels cannot agree on a resolution to the matter within such [***] period, then either Party may refer such matter for resolution to an independent
Third Party expert agreed upon by the Parties within [***] after the IP Counsels have failed to resolve such matter. Such independent Third Party expert will be an attorney who has practiced United States patent law for at least [***]
(or who has such other similar credentials as agreed by the Parties), and unless otherwise agreed in writing by the Parties, must not be a current or former employee, contractor, agent, or consultant of either Party or its Affiliates. The Party
bringing a dispute pursuant to this Section 7.6.6 (Biogen Identified Rights Dispute) will promptly engage such expert and the Parties will share the out-of-pocket
costs incurred in connection with the engagement of such expert equally (50:50). Within [***] of the engagement of such expert by the disputing Party, such expert will deliver its written decision to the Parties (including a detailed report
as to such expert’s rationale for such decision), and such decision will be binding on the Parties. Notwithstanding anything to the contrary set forth in this Agreement, at any time during the Term (including during the pendency of any such
dispute), Biogen will have the right to obtain rights to such Biogen Identified Rights from the applicable Third Party. If such expert determines that such Biogen Identified Rights would, absent obtaining rights to use such Biogen Identified Rights,
be infringed, misappropriated, or otherwise violated by the practice of the C4 Degrader Platform or the performance of C4’s obligations under this Agreement, then C4 will reimburse Biogen for [***] of the amounts paid to such Third Party
under any agreement between Biogen and such Third Party with respect to such Biogen Identified Rights (including any upfront payments, milestone payments, royalties, and profit-sharing payments). C4 will pay the amounts set forth in any invoice for
such payments within [***] after the date of such invoice. 

  

	7.7	 Payment Method. All payments to be made between the Parties under this Agreement will be made in Dollars
and may be paid by wire transfer in immediately available funds to a bank account designated by C4; provided that in no event will Biogen be obligated to make payments under this Agreement to any Affiliate of C4 that is organized in any
jurisdiction outside of the U.S. without Biogen’s prior written consent. 

  

	7.8	 Currency Exchange. Biogen’s then-current standard exchange rate methodology will be employed for
the translation of foreign currency sales into Dollars. 

  

	7.9	 Late Payments. If a Party does not receive payment of any undisputed sum due to it on or before the due
date set forth under this Agreement, then simple interest will thereafter accrue on the sum due to such Party from the due date until the date of payment at a per-annum rate of [***] percentage point
over the then-current prime rate reported in The Wall Street Journal or the maximum rate allowable under Applicable Law, whichever is lower. 

  
 41 

	7.10	 Taxes. 

  

	 	7.10.1	 Responsibility. Except as expressly set forth in Section 7.10.2 (Withholding Taxes), C4 will pay
any and all taxes levied on account of all payments it receives under this agreement. 

  

	 	7.10.2	 Withholding Taxes. C4 will provide such information and documentation to Biogen as are reasonably
requested by Biogen to determine if any withholding taxes apply to any payments to be made by Biogen to C4 under this Agreement. Solely to the extent that Applicable Law require that taxes be withheld with respect to any such payments to be made by
Biogen to C4 under this Agreement, Biogen will: (a) deduct those taxes from the remittable payment, (b) pay the taxes to the proper taxing authority, and (c) send evidence of the obligation together with proof of tax payment to C4 on
a reasonable and timely basis following such tax payment. Each Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty that is in effect. The
Parties will discuss applicable mechanisms for minimizing such taxes to the extent possible in compliance with Applicable Law. C4 will pay any and all other taxes levied on account of all payments it receives under this Agreement.

  

	 	7.10.3	 Cooperation. The Parties will cooperate in accordance with Applicable Law to minimize indirect taxes
(such as value added tax, sales tax, consumption tax, and other similar taxes) in connection with payments to be made under this Agreement. 

  

	7.11	 Financial Audits. 

 

	 	7.11.1	 Record Retention; Audits. Each Party will keep (and will cause its Affiliates and Sublicensees to keep)
complete and accurate records pertaining to (a) in the case of Biogen, the sale or other disposition of Products (the “Biogen Records”) and (b) in the case of C4, all costs and expenses incurred with the performance of its
Sandbox Activities (the “C4 Records”), in each case ((a) and (b)), in reasonable detail to permit the other Party to confirm the accuracy of all payments or costs reported, for at least the preceding [***]. Upon reasonable
(but in any case no less than [***]) [***] advance notice by one Party (the “Auditing Party”) to the other Party (the “Audited Party”) and not more than once in each Calendar Year and once per audited
period (in each case, except for cause), the Audited Party and its Affiliates will permit, and will cause their Sublicensees to permit, an independent certified public accounting firm of internationally recognized standing, selected by the Auditing
Party and reasonably acceptable to the Audited Party, to have access during normal business hours to such of the records of the Audited Party and its Affiliates and, if applicable, their Sublicensees, as may be reasonably necessary to verify the
accuracy of (i) in the case of Biogen as the Audited Party, the Biogen Records and (ii) in the case of C4 as the Audited Party, the C4 Records, for any year ending not more than [***] prior to the date of such request. The
accounting firm will enter a confidentiality agreement reasonably acceptable to the Audited Party governing the use and disclosure of the Audited Party’s information disclosed to such firm, and such firm will disclose to the Auditing Party only
whether information provided by the Audited Party to the Auditing Party as described in clauses (a) and (b) above was accurate and the specific details concerning any discrepancies, which information will be Confidential Information of the
Audited Party. 

  
 42 

	 	7.11.2	 Audit Disputes. Any disputes with respect to the findings of such accounting firm may be referred by
either Party to the dispute resolution procedure set forth in Section 13.8 (Dispute Resolution). If either Party is found to have been underpaid any amounts payable to such Party hereunder or to have overpaid to the other Party any amounts
payable hereunder, then such first Party will be entitled to recover any undisputed discrepancy, plus interest as set forth in Section 7.9 (Late Payments), no later than [***] after delivery to the Parties of the final report of such
accounting firm. The fees charged by such accounting firm will be paid by the Auditing Party; provided that if the audit discloses a net underpayment of amounts owed or overreporting of expenses by the Audited Party of more than [***]
of total amounts owed or expenses reported by the Audited Party for any Calendar Year period covered by the audit, then the Audited Party will pay the reasonable fees and expenses charged by such accounting firm. The Auditing Party will treat all
financial information disclosed by its accounting firm pursuant to this Section 7.11 (Financial Audits) as Confidential Information of the Audited Party for purposes of Article 9 (Confidentiality) of this Agreement, and will cause its
accounting firm to do the same. 

 ARTICLE 8 REPRESENTATIONS, WARRANTIES, AND COVENANTS 

 

	8.1	 Mutual Representations and Warranties of the Parties. Each Party represents and warrants to the other
Party as of the Effective Date that: 

  

	 	8.1.1	 it is duly organized, validly existing and in good standing under the Applicable Law of the jurisdiction of its
incorporation and has all requisite corporate power and authority to enter into this Agreement and to perform its obligations, in each case, under this Agreement; 

 

	 	8.1.2	 the execution of this Agreement and the performance by such Party of its obligations hereunder have been duly
authorized; 

  

	 	8.1.3	 this Agreement has been duly executed and delivered on behalf of such Party, and is valid, legally binding, and
enforceable against such Party in accordance with its terms; 

  

	 	8.1.4	 the performance of this Agreement by such Party does not create a breach or default under any other agreement
to which it is a Party; 

  

	 	8.1.5	 the execution, delivery, and performance of this Agreement by such Party does not conflict with any agreement,
instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law or regulation of any Governmental Authority; and 

 

	 	8.1.6	 it has obtained all necessary government authorizations, consents, approvals, licenses, exemptions of, or
filings or registrations with Governmental Authorities, under any Applicable Law currently in effect, that are or will be necessary for the transactions contemplated by this Agreement or any other agreement or instrument executed in connection
herewith, or for the performance by it of its obligations under this Agreement. 

  
 43 

	8.2	 Additional Representations and Warranties of C4. C4 represents and warrants to Biogen as of the
Effective Date that: 

  

	 	8.2.1	 it has and will have the full right, power, and authority to grant all of the licenses and rights granted to
Biogen under this Agreement; 

  

	 	8.2.2	 (a) Schedule 1.42 (C4 Licensed Patent Rights) sets forth a complete and accurate list of all Patent Rights
existing as of the Effective Date that are owned, Controlled, or held by C4 or any of its Affiliates and necessary or useful to (i) perform the Sandbox Activities or the Candidate Development Activities, or (ii) Exploit any Degrader or
Product, (b) C4 owns or otherwise Controls all Patent Rights listed on Schedule 1.42 (C4 Licensed Patent Rights); and (c) except as otherwise noted on Schedule 1.42 (C4 Licensed Patent Rights), C4 exclusively owns all rights,
title, and interests in and to such Patent Rights; 

  

	 	8.2.3	 there is no pending litigation, or litigation that has been threatened in writing, that alleges, or any written
communication alleging, that C4’s practice of the C4 Licensed Technology or the C4 Degrader Platform prior to the Effective Date has infringed, misappropriated, or otherwise violated, or would infringe, misappropriate, or otherwise violate, any
of the Intellectual Property of any Third Party; 

  

	 	8.2.4	 there are no claims, judgments, or settlements against or pending, or amounts with respect thereto, owed by C4
or any of its Affiliates, with respect to the C4 Licensed Technology or the C4 Degrader Platform, and C4 has not received written notice threatening any such claims, judgments, or settlements; 

 

	 	8.2.5	 to C4’s Knowledge, practice by C4 or Biogen under the C4 Licensed Technology or C4 Degrader Platform or
the Exploitation by C4 or Biogen (or their respective Affiliates or Sublicensees) of any Degrader or Product, in each case, as contemplated under this Agreement, does not and will not infringe any issued patent of any Third Party or, if and when
issued, any claim within any published patent application of any Third Party; 

  

	 	8.2.6	 to C4’s Knowledge no Third Party has challenged the ownership, scope, duration, validity, enforceability,
priority, or right to use any C4 Licensed Patent Rights or the Patent Rights Covering the C4 Degrader Platform (including, by way of example, through the institution of or written threat of institution of interference, inter partes review,
reexamination, protest, opposition, nullity, or similar invalidity proceeding before the United States Patent and Trademark Office or any foreign patent authority or court); 

 

	 	8.2.7	 to C4’s Knowledge, no Third Party is infringing, misappropriating, or otherwise violating, or threatening
to infringe, misappropriate, or otherwise violate the C4 Licensed Technology or the C4 Degrader Platform; 

  

	 	8.2.8	 all fees required to be paid by C4 in any jurisdiction in order to maintain the C4 Licensed Patent Rights have
been timely paid and the C4 Licensed Patent Rights and the Patent Rights Covering the C4 Degrader Platform are valid, subsisting, and to C4’s Knowledge, enforceable; 

 

	 	8.2.9	 C4 has not previously assigned, transferred, conveyed, or granted any license or other rights under the C4
Licensed Technology that would conflict with or limit the scope of any of the rights or licenses granted to Biogen hereunder; 

  

	 	8.2.10	 C4’s rights, title, and interests to all the C4 Licensed Technology are free of any lien or security
interest; 

  
 44 

	 	8.2.11	 C4 has obtained, or caused its Affiliates, as applicable, to obtain, assignments from the inventors of all
inventorship rights to the C4 Licensed Patent Rights and the Patent Rights Covering the C4 Degrader Platform, and all such assignments are valid and enforceable; 

 

	 	8.2.12	 the inventorship of the C4 Licensed Patent Rights is properly identified on each issued patent or patent
application in the C4 Licensed Patent Rights; 

  

	 	8.2.13	 there are no Third Party agreements pursuant to which C4 Controls any of the C4 Licensed Technology or C4
Degrader Platform, and no Third Party has any rights, title, or interests in or to, or any license under, any of the C4 Licensed Technology or C4 Degrader Platform that would conflict with the rights and licenses granted to Biogen hereunder.

  

	 	8.2.14	 No written notice of default or termination has been received or given under any agreement pursuant to which C4
Controls any C4 Licensed Technology or Patent Rights Covering or Know-How related to the C4 Degrader Platform, and there is no act or omission by C4 or its Affiliates that would provide a right to terminate
any such agreement; 

  

	 	8.2.15	 C4 and its Affiliates have taken commercially reasonable measures consistent with industry practices to protect
the secrecy, confidentiality, and value of all C4 Licensed Know-How that constitutes trade secrets under Applicable Law (including requiring all employees, consultants, and independent contractors to execute
binding and enforceable agreements requiring all such employees, consultants, and independent contractors to maintain the confidentiality of such C4 Licensed Know-How) and such C4 Licensed Know-How has not been used, disclosed to, or discovered by any Third Party except pursuant to such confidentiality agreements and there has not been a breach by any party to such confidentiality agreements;

  

	 	8.2.16	 the C4 Licensed Technology has not been created pursuant to, and are not subject to, any funding agreement with
any Governmental Authority or any Third Party, and are not subject to the requirements of the Bayh-Dole Act or any similar provision of any Applicable Law; 

  

	 	8.2.17	 to C4’s Knowledge, all information disclosed to Biogen by C4 relating to the C4 Degrader Platform, the C4
Licensed Technology, and the materials and methods to be employed by C4 in the performance by or on behalf of C4 of the C4 Candidate Development Activities under the Candidate Development Plans and the Sandbox Activities under the Sandbox Plans and
otherwise under this Agreement is, at the time of disclosure, accurate in all respects; 

  

	 	8.2.18	 neither C4, nor its Affiliates, nor any of their employees, officers, Subcontractors, or consultants who have
rendered services relating to the C4 Degrader Platform: (a) has ever been Debarred or is subject to debarment or convicted of a crime for which an entity or person could be Debarred; or (b) have ever been under indictment for a crime for
which a person or entity could be so Debarred; and 

  

	 	8.2.19	 C4 has not intentionally failed to furnish Biogen with any information requested by Biogen, or intentionally
concealed from Biogen any information in its possession, including information relating to the C4 Licensed Technology or C4 Degrader Platform, in each case, that C4 reasonably believes would be material to Biogen’s decision to enter into this
Agreement and undertake the commitments and obligations set forth herein. 

  
 45 

	8.3	 Covenants of C4. C4 covenants to Biogen that: 

 

	 	8.3.1	 during the Term, C4 will not assign, transfer, convey, or grant any license or other rights to its rights,
title, and interests in or to the C4 Licensed Technology in any way that would conflict with or limit the scope of any of the rights or licenses granted to Biogen hereunder; 

 

	 	8.3.2	 C4 will not, and will cause its Affiliates not to (a) license, sell, assign, or otherwise transfer to any
Person any Product-Specific Know-How, Product-Specific Patent Rights, Target-Specific Know-How, or Target-Specific Patent Rights (or agree to do any of the foregoing),
or (b) incur or permit to exist, with respect to any Product-Specific Know-How, Product-Specific Patent Rights, Target-Specific Know-How, or Target-Specific Patent
Rights, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties, or other restriction (including in connection with any indebtedness); 

 

	 	8.3.3	 C4 will, and will ensure that its Affiliates, Sublicensees, and Subcontractors obtain written agreements from
any and all Persons involved in or performing any Collaboration Activities by or on behalf of C4 that assign such Persons’ rights, title, and interests in and to any C4 Licensed Technology, Sandbox Technology, or Results to C4 prior to any such
person performing such activities; 

  

	 	8.3.4	 in the performance of activities under this Agreement, C4 will not employ or use any Person who to C4’s
Knowledge: (a) has ever been Debarred or is subject to debarment or convicted of a crime for which an entity or person could be Debarred; or (b) has ever been under indictment for a crime for which a person or entity could be so Debarred;
and 

  

	 	8.3.5	 during the Collaboration Term, C4 will maintain sufficient resources to perform the Collaboration Activities
for which it is responsible under this Agreement in accordance herewith. 

  

	8.4	 DISCLAIMER OF WARRANTIES. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES ANY
REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. IN
PARTICULAR, BIOGEN DOES NOT MAKE ANY REPRESENTATION OR EXTEND ANY WARRANTY THAT THE DEVELOPMENT CANDIDATES OR PRODUCTS WILL BE SUCCESSFULLY DEVELOPED OR COMMERCIALIZED HEREUNDER. 

 

	8.5	 LIMITATION OF LIABILITY. EXCEPT FOR DAMAGES RESULTING FROM BREACHES OF SECTION 3.5 (EXCLUSIVITY),
ARTICLE 9 (CONFIDENTIALITY), OR ANY REPRESENTATIONS OR WARRANTIES CONTAINED IN SECTION 8.2.2, OR INDEMNIFIABLE CLAIMS UNDER ARTICLE 11 (INDEMNIFICATION), IN NO EVENT WILL EITHER PARTY HAVE ANY CLAIMS AGAINST OR LIABILITY TO THE OTHER PARTY WITH
RESPECT TO ANY INDIRECT, PUNITIVE, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES (INCLUDING ANY CLAIMS FOR LOST PROFITS OR REVENUES) ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT UNDER ANY THEORY OF LIABILITY, EVEN IF SUCH PARTY HAS BEEN
INFORMED OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 46 

 ARTICLE 9 CONFIDENTIALITY 

 

	9.1	 Confidential Information. It is understood and agreed by the Parties that: 

 

	 	9.1.1	 The terms and conditions of this Agreement will be considered Confidential Information of both Parties and kept
confidential by each of the Parties in accordance with this Article 9 (Confidentiality). 

  

	 	9.1.2	 The C4 Licensed Technology, Biogen Technology, Sandbox Technology, all royalty reports provided to C4 pursuant
to Section 7.6.3(a) (Royalty Reports), all Development Candidate Reports, all reports provided to Biogen pursuant to Section 3.1.9 (Reports of Candidate Development Activities) and Section 3.2.4 (Reports of Sandbox Activities), the
identities of the Collaboration Targets, the Degraders, the Products, and all Deliverables and Results will each be considered the Confidential Information of Biogen, with Biogen deemed to be the disclosing Party in respect thereof (the
“Disclosing Party”) and C4 deemed to be the receiving Party (the “Receiving Party”) with respect thereto. 

  

	9.2	 Non-Disclosure and Non-Use
Obligation. Except as otherwise expressly set forth herein, the Receiving Party will, during the Term and for a period of [***] thereafter, keep the Confidential Information of the Disclosing Party confidential using at least the same
degree of care with which the Receiving Party holds its own confidential information (but in no event less than a reasonable degree of care) and will not (a) disclose such Confidential Information to any Person without the prior written
approval of the Disclosing Party, except, solely to the extent necessary to exercise its rights or perform its obligations under this Agreement, to its employees, Affiliates, Sublicensees, and Subcontractors, consultants, or agents who have a need
to know such Confidential Information, all of whom will be similarly bound by confidentiality, non-disclosure, and non-use provisions at least as restrictive or
protective of the Parties as those set forth in this Agreement and for whom the Disclosing Party will be responsible, or (b) use such Confidential Information for any purpose other than for the purposes contemplated by this Agreement. The
Receiving Party will use diligent efforts to cause the foregoing Persons to comply with the restrictions on use and disclosure set forth in this Section 9.2 (Non-Disclosure and Non-Use Obligation), and will be responsible for ensuring that such Persons maintain the Disclosing Party’s Confidential Information in accordance with this Article 9 (Confidentiality). Each Party will promptly
notify the other Party of any misuse or unauthorized disclosure of the other Party’s Confidential Information. 

  

	9.3	 Return of Confidential Information. Upon the expiration or termination of this Agreement, the Receiving
Party will return (or, as directed by the Disclosing Party, destroy) all Confidential Information of the Disclosing Party to the Disclosing Party that is in the Receiving Party’s possession or control (other than any Confidential Information
required to continue to exercise a Party’s rights that survive termination of this Agreement), provided, however, copies may be retained and stored solely for the purpose of determining its obligations under this Agreement, subject to
the non-disclosure and non-use obligation under this Article 9 (Confidentiality). In addition, the Receiving Party will not be required to return or destroy Confidential
Information contained in any computer system back-up records made in the ordinary course of business; provided that such Confidential Information may not be accessed without the Disclosing Party’s
prior written consent or as required by Applicable Law. 

  

	9.4	 Exemptions. Information of a Disclosing Party will not be Confidential Information of such Disclosing
Party to the extent that the Receiving Party can demonstrate through competent evidence that such information: (a) is already in the possession of the Receiving Party at the time of its receipt from the Disclosing Party and not through a prior
disclosure by or on behalf of the 

  
 47 

	 	
Disclosing Party, as evidenced by contemporaneous written records, (b) is generally available to the public before its receipt from the Disclosing Party, (c) became generally available
to the public or otherwise part of the public domain after its disclosure by the Disclosing Party and other than through any act or omission of the Receiving Party or any of its Affiliates or discloses in breach of this Agreement, including pursuant
to Section 9.9.3 (Publication Rights), (d) is subsequently disclosed to the Receiving Party or any of its Affiliates without obligation of confidentiality by a Third Party who may rightfully do so and is not under a conflicting obligation of
confidentiality to the Disclosing Party, or (e) is developed independently by employees, subcontractors, consultants or agents of the Receiving Party or any of its Affiliates without use of or reliance upon the Disclosing Party’s
Confidential Information, as evidenced by contemporaneous written records. No combination of features or disclosures will be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general
public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party. 

 

	9.5	 Permitted Disclosures. In addition to the exceptions contained in Sections 9.2 (Non-Disclosure and Non-Use Obligation) and 9.4 (Exemptions), the Receiving Party may disclose Confidential Information of the Disclosing Party to the extent (and solely to
the extent) that such disclosure is reasonably necessary in the following instances: 

  

	 	9.5.1	 (a) the prosecution and maintenance of C4 Licensed Patent Rights and Joint Patent Rights, in each case, as
contemplated by this Agreement; or (b) Regulatory Submissions and other filings with Governmental Authorities (including Regulatory Authorities), as necessary for the Exploitation of a Degrader or Product; 

 

	 	9.5.2	 disclosure of the existence and applicable terms of this Agreement and the status and results of Exploitation
of one or more Degraders or Products to actual or bona fide potential investors, acquirors, Sublicensees, lenders, and other financial or commercial partners (including in connection with any royalty factoring transaction), and their
respective attorneys, accountants, banks, investors, and advisors, solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, sublicense, debt transaction, or collaboration; provided that, in each
such case, on the condition that such Persons are bound by obligations of confidentiality, non-disclosure, and non-use provisions at least as restrictive or protective
of the Parties as those set forth in this Agreement or otherwise customary for such type and scope of disclosure any such disclosure is limited to the maximum extent practicable for the particular context in which it is being disclosed;

  

	 	9.5.3	 to comply with Applicable Law (whether generally or in pursuit of an application for listing of securities)
including the United States Securities and Exchange Commission or equivalent foreign agency or regulatory body, or otherwise required by judicial or administrative process, provided that in each such event, as promptly as reasonably
practicable and to the extent not prohibited by Applicable Law or judicial or administrative process, such Party will notify the other Party of such required disclosure and provide a draft of the disclosure to the other Party reasonably in advance
of such filing or disclosure for the other Party’s review and comment. The non-disclosing Party will provide any comments as soon as practicable, and the disclosing Party will consider in good faith any
timely comments provided by the non-disclosing Party; provided that the disclosing Party may or may not accept such comments in its sole discretion. Confidential Information that is disclosed in order
to comply with Applicable Law or by judicial or administrative process pursuant to this Section 9.5.3, in each case, will remain otherwise subject to the confidentiality and non-use provisions of this
Article 9 (Confidentiality) with respect to the 

  
 48 

	 	
Party disclosing such Confidential Information, and such Party will take all steps reasonably necessary, including seeking of confidential treatment or a protective order for a period of at least
[***] (to the extent permitted by Applicable Law or Governmental Authority), to ensure the continued confidential treatment of such Confidential Information, and each Party will be responsible for its own legal and other external costs in
connection with any such filing or disclosure pursuant to this Section 9.5.3; 

  

	 	9.5.4	 to prosecute or defend litigation so long as there is [***] prior written notice given by the Receiving
Party before filing, and to enforce Patent Rights in connection with the Receiving Party’s rights and obligations pursuant to this Agreement; and 

  

	 	9.5.5	 to allow the Receiving Party to exercise its rights and perform its obligations hereunder, provided that
such disclosure is covered by terms of confidentiality and non-use at least as restrictive as those set forth herein. 

  

	9.6	 Confidential Treatment. Notwithstanding anything to the contrary set forth in this Agreement, if a Party
is required or permitted to make a disclosure of the other Party’s Confidential Information pursuant to Section 9.5 (Permitted Circumstances), then it will, to the extent not prohibited by Applicable Law or judicial or administrative
process, except where impracticable, give reasonable advance notice to the other Party of such proposed disclosure and use reasonable efforts to secure confidential treatment of such information and will only disclose that portion of Confidential
Information that is legally required to be disclosed as advised by its legal counsel. In any event, each Party agrees to take all reasonable action to avoid disclosure of Confidential Information of the other Party hereunder. 

 

	9.7	 Use of Name and Logo. Subject to Section 9.9.2 (Announcement), neither C4 nor Biogen will use the
other Party’s or its Affiliates’ name or logo in any label, press release, or product advertising, or for any other promotional purpose, without first obtaining the other Party’s written consent. 

 

	9.8	 Residual Knowledge. Notwithstanding anything to the contrary set forth in this Agreement, Confidential
Information will not include any knowledge, technique, experience, or Know-How that is retained in the unaided memory of any authorized representative of the Receiving Party after having access to such
Confidential Information (“Residual Knowledge”). Any use made by the Receiving Party of any such Residual Knowledge is on an “as is, where is” basis, with all faults and all representations and warranties disclaimed and at
its sole risk. 

  

	9.9	 Publications. 

 

	 	9.9.1	 Coordination. C4 and Biogen will, from time to time and at the request of the other Party, discuss the
general information content relating to this Agreement that may be publicly disclosed; provided, however, that Biogen will have no obligation to consult with C4 with respect to any scientific publication or public announcement
concerning Biogen’s Exploitation of any Development Candidate or Product (except as otherwise expressly set forth in Section 9.9.3 (Publication Rights)). 

 

	 	9.9.2	 Announcements. Except as may be expressly permitted under Section 9.5 (Permitted Disclosures),
neither Party will make any public announcement regarding this Agreement without the prior written approval of the other Party. For clarity, nothing in this Agreement will prevent Biogen from making any scientific publication or public announcement
concerning Biogen’s Exploitation of any Product under this Agreement; provided that, except as permitted under Section 9.5 (Permitted Disclosures), Biogen will not disclose

  
 49 

	 	
any of C4’s Confidential Information in any such publication or announcement without obtaining C4’s prior written consent to do so. The Parties intend to release the joint press release
attached hereto as Schedule 9.9.2 (Press Release) regarding the signing of this Agreement promptly after the Effective Date. After the issuance of such press release or other public disclosure by a Party, the disclosing Party may make subsequent
public disclosures reiterating such information without having to obtain the other Party’s prior consent and approval so long as the information in such press release or other public announcement remains true, correct, and the most current
information with respect to the subject matters set forth therein. 

  

	 	9.9.3	 Publication Rights. Biogen will be the exclusive owner of any publication rights with respect to the
Results, the Degraders, and the Products, and will have the sole and exclusive right to publish on such Results, Degraders, and Products without the prior consent of C4, provided that any portion of such publication or presentation that
contains Results prepared as a result of, or in connection with the performance of (a) the C4 Candidate Development Activities under a Candidate Development Plan or (b) Sandbox Activities performed by or on behalf of C4 under the Sandbox
Plan will, in each case ((a) and (b)), be subject to the prior review of C4 and will be provided by Biogen to C4 at least [***] prior to its submission for publication or presentation. C4 will use reasonable efforts to complete such review at
least [***] prior to Biogen’s intended publication or presentation date Biogen will, as reasonably requested by C4, (i) delete from such publication any of C4’s Confidential Information, or (ii) upon a determination that
(A) such publication includes patentable material and (B) C4 has the right to file a patent application claiming such material in accordance with Section 10.4 (Patent Prosecution and Maintenance), delay the submission of such
publication or presentation for an additional period of up to [***] in order to allow C4 to pursue patent protection. 

ARTICLE 10 INTELLECTUAL PROPERTY 
  

	10.1	 Ownership. 

  

	 	10.1.1	 Inventions. Except as expressly set forth in this Agreement, (a) each Party will own all rights,
title, and interests in and to (i) any and all Know-How made solely by or on behalf of such Party or its Affiliates in connection with the performance of such Party’s activities under this Agreement
and (ii) any and all Patent Rights claiming any such Know-How described in clause (a)(i) of this Section 10.1.1 (Inventions), and (b) the Parties will jointly own any and all (i) Know-How made jointly by or behalf of the Parties or their Affiliates in connection with the performance of the Parties’ activities under this Agreement and (ii) Patent Rights claiming any such Know-How described in clause (b)(i) of this Section 10.1.1 (Inventions). Notwithstanding anything to the contrary set forth in this Agreement, as between the Parties, (A) Biogen will solely own all Biogen
Technology, including all Target-Specific Technology and Product-Specific Technology, but excluding all Joint Technology; (B) C4 will solely own all C4 Technology, including all Assigned Platform Technology, but excluding all Joint Technology,
and (C) both Parties will jointly own all Joint Technology. All determinations of inventorship under this Agreement will be made in accordance with U.S. patent law. 

 

	 	10.1.2	 Disclosure. (a) Biogen will promptly disclose to C4 all Inventions within the Assigned
Platform Know-How, (b) C4 will promptly disclose to Biogen all Inventions within the Target-Specific Know-How or Product-Specific
Know-How, and (c) each Party will promptly disclose to the other Party all Inventions within the Joint Know-How, in each

  
 50 

	 	
case ((a) through (c)), that it develops or invents, whether solely or jointly with others (in any event, prior to the filing of any patent application with respect to such Inventions), including
all invention disclosures or other similar documents submitted to such Party by its or its Affiliates’ employees, agents, or independent contractors relating thereto. Each Party will also promptly respond to reasonable requests from the other
Party for additional information relating thereto. 

  

	10.2	 Assignments. 

  

	 	10.2.1	 Assignment by Biogen. 

 

	 	(a)	 Assignment. Biogen will and hereby does assign to C4 (a) all of Biogen’s rights, title, and
interests in and to Assigned Platform Technology, and (b) a joint and undivided interest in and to (i) any Sandbox Know-How developed or invented solely by Biogen’s or its Affiliates’,
licensees’, Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any Persons contractually required to assign or license such Sandbox Know-How to Biogen or any
Affiliate of Biogen, and (ii) any Sandbox Patent Rights Covering such Sandbox Know-How, and, in each case ((a) and (b)), C4 hereby accepts such assignment. 

 

	 	(b)	 Covenants in Support of Assignment. Biogen will take (and cause its Affiliates and Sublicensees, and
their respective employees, agents, and contractors to take) such further actions reasonably requested by C4 to evidence such assignment and to assist C4 in obtaining Patent Rights and other Intellectual Property protection for Inventions within the
Assigned Platform Know-How including executing further assignments, consents, releases, and other commercially reasonable documentation and providing good faith testimony by affidavit, declaration, in-person, or other proper means in support of any effort by C4 to establish, perfect, defend, or enforce its rights in any Assigned Platform Technology through prosecution of governmental filings, regulatory
proceedings, litigation, and other means, including through the filing, prosecution, maintenance, and enforcement of the Assigned Platform Technology. Biogen will obligate its Affiliates, Sublicensees, and Subcontractors to assign all Assigned
Platform Technology to Biogen (or directly to C4) so that Biogen can comply with its obligations under this Section 10.2.1 (Assignment by Biogen), and Biogen will promptly obtain such assignment. Without limitation, Biogen will cooperate with
C4 if C4 applies for U.S. or foreign patent protection for Inventions within the Assigned Platform Technology and will obtain the cooperation of the individual inventors of any such Assigned Platform Technology. If Biogen is unable to assign any
Assigned Platform Technology as set forth in Section 10.2.1(a) (Assignment), then Biogen hereby grants and agrees to grant to C4 a royalty-free, fully paid-up, worldwide, exclusive, perpetual, irrevocable
license (with the right to grant sublicenses through multiple tiers) under such Assigned Platform Technology for any and all purposes. 

  
 51 

	 	10.2.2	 Assignment by C4. 

 

	 	(a)	 Assignment. 

  

	 	(i)	 On a Degrader-by-Degrader
basis, effective upon the earlier of (A) C4’s completion of the C4 Candidate Development Activities set forth under the applicable Candidate Development Plan for the Collaboration Target that is degraded by such Degrader, or (B) the
commencement of IND-Enabling Studies for a Degrader in accordance with Section 3.1.8(b) (IND-Enabling Study Commencement Fee), in each case ((A) and (B)), but in no
event later than the expiration (or earlier termination) of the Collaboration Term in accordance with Section 3.5 (Collaboration Term), C4 will and hereby does assign to Biogen all of its rights, title, and interests in and to all
(I) Target-Specific Technology relating to (1) the Collaboration Target that is degraded by such Degrader or (2) any Target Binding Moiety that is directed to such Collaboration Target and (II) Product-Specific Technology
relating to such Degrader, and, in each case ((I) and (II)), Biogen hereby accepts such assignment. 

  

	 	(ii)	 C4 will and hereby does assign to Biogen a joint and undivided interest in and to (A) any Sandbox Know-How developed or invented solely by C4’s or its Affiliates’, licensees’, Sublicensees’, or Subcontractors’ employees, agents, or independent contractors, or any Persons contractually
required to assign or license such Sandbox Know-How to C4 or any Affiliate of C4, and (B) any Sandbox Patent Rights Covering such Sandbox Know-How, and Biogen
hereby accepts such assignment. 

  

	 	(b)	 Covenants in Support of Assignment. C4 will take (and cause its Affiliates and Sublicensees, and their
respective employees, agents, and contractors to take) such further actions reasonably requested by Biogen to evidence such assignment and to assist Biogen in obtaining Patent Rights and other Intellectual Property protection for Inventions within
the Target-Specific Know-How and Product-Specific Know-How including executing further assignments, consents, releases, and other commercially reasonable documentation
and providing good faith testimony by affidavit, declaration, in-person, or other proper means in support of any effort by Biogen to establish, perfect, defend, or enforce its rights in any Target-Specific
Technology and Product-Specific Technology through prosecution of governmental filings, regulatory proceedings, litigation, and other means, including through the filing, prosecution, maintenance, and enforcement of the Target-Specific Technology
and Product-Specific Technology. C4 will obligate its Affiliates, Sublicensees, and Subcontractors to assign all Target-Specific Technology and Product-Specific Technology to C4 (or directly to Biogen) so that C4 can comply with its obligations
under this Section 10.2.2(a) (Assignment), and C4 will promptly obtain such assignment. Without limitation, C4 will cooperate with Biogen if Biogen applies for U.S. or foreign patent protection for Inventions within the Target-Specific
Technology and Product-Specific Technology and will obtain the cooperation of the individual inventors of any such Target-Specific Technology and Product-Specific Technology. If C4 is unable to assign any Target-Specific Technology and
Product-Specific Technology, then C4 hereby grants and agrees to grant to Biogen a royalty-free, fully paid-up, worldwide, exclusive (even as to C4, subject to the terms and conditions of this Agreement,
including the licenses granted to C4 pursuant to Section 2.2 (Licenses to C4)), perpetual, irrevocable license (with the right to grant sublicenses through multiple tiers) under such Target-Specific Technology and Product-Specific Technology
for any and all purposes. 

  
 52 

	10.3	 Joint Technology. Subject to the terms and conditions set forth in this Agreement, including the
licenses granted in Section 2.1 (Licenses and Assignment to Biogen) and Section 2.2 (Licenses to C4), the Parties will jointly own all Joint Technology, and each Party is entitled to practice the Joint Technology for all purposes on a
worldwide basis and to license such Joint Technology through multiple tiers without consent of the other Party (where consent is required by Applicable Law, such consent is deemed hereby granted) and without a duty of accounting to the other Party.
Each Party will grant and hereby does grant to the other Party all further permissions, consents, and waivers with respect to, and all licenses under, the Joint Technology, throughout the world, necessary to provide the other Party with full rights
of use and Exploitation of the Joint Technology. Without limitation, each Party will cooperate with the other Party if the Parties determine to apply for U.S. or foreign patent protection for any Joint Technology and will obtain the cooperation of
the individual inventors of any such Joint Technology. 

  

	10.4	 Patent Prosecution and Maintenance. 

 

	 	10.4.1	 Right to File and Prosecute. 

 

	 	(a)	 Biogen’s Rights. Biogen will have (i) the sole right (but not the obligation) to
prepare, file, prosecute, and maintain all Biogen Patent Rights (other than Biogen Collaboration Patent Rights), and (ii) the first right (but not the obligation) to prepare, file, prosecute, and maintain all Biogen Collaboration Patent Rights
and Joint Patent Rights (the Patent Rights described in the foregoing clause (ii), the “Biogen First Right Patent Rights” and the Patent Rights described in the foregoing clauses (i) and (ii), collectively, the
“Biogen-Prosecuted Patent Rights”). Biogen will be the Prosecuting Party with respect to all Biogen-Prosecuted Patent Rights. Biogen will be responsible for and pay all future costs and expenses incurred in connection with the
preparation, filing, prosecution, and maintenance of the Biogen-Prosecuted Patent Rights and will keep C4 reasonably informed as to material developments with respect to the preparation, filing, prosecution, issuance, and maintenance of the Biogen
First Right Patent Rights, including providing to C4 notice in advance of abandoning any such Biogen First Right Patent Rights. 

  

	 	(b)	 C4’s Rights. C4 will have (i) the sole right (but not the obligation) to
prepare, file in its name, prosecute, and maintain all Collaboration Platform Patent Rights, and (ii) the first right (but not the obligation) to prepare, file, prosecute, and maintain all other C4 Licensed Patent Rights (the Patent Rights
described in the foregoing clause (ii), the “C4 First Right Patent Rights” and the Patent Rights described in clauses (i) and (ii), collectively, the “C4-Prosecuted Patent
Rights”). C4 will be the Prosecuting Party with respect to all C4-Prosecuted Patent Rights. C4 will be responsible for and pay all future costs and expenses incurred in connection with the
preparation, filing, prosecution, and maintenance of the C4-Prosecuted Patent Rights and will keep Biogen reasonably informed as to material developments with respect to the preparation, filing, prosecution,
issuance, and maintenance of the C4 First Right Patent Rights, including providing notice in advance of abandoning any such C4 First Right Patent Rights. 

  

	 	(c)	 Coordination in Prosecution. Notwithstanding Biogen’s right to prepare, file, prosecute, and maintain the
Biogen-Prosecuted Patent Rights or C4’s right to prepare, file, prosecute, and maintain the C4-Prosecuted Patent Rights, the Parties will, and will cause their Affiliates to, cooperate and implement
reasonable patent 

  
 53 

	 	
filing and prosecution strategies (including filing divisionals, continuations or otherwise) so that, to the extent reasonably feasible Product-Specific Patent Rights, Target-Specific Patent
Rights, and Collaboration Platform Patent Rights are pursued in mutually exclusive patent applications. 

  

	 	10.4.2	 Step-In Right. 

 

	 	(a)	 C4’s Rights. If, during the Term, Biogen decides that it is no longer interested in
the preparation, filing, prosecution, or maintenance of a particular Biogen First Right Patent Right, then it will promptly provide written notice to C4 of such decision. C4 may, upon written notice to Biogen, assume the preparation, filing,
prosecution, and maintenance of such Patent Right at C4’s sole cost and expense. In such event C4 will be responsible for [***] of the costs and expenses of the preparation, filing, prosecution, and maintenance of such Patent Right, and
C4 will thereafter be the “Prosecuting Party” with respect thereto for all purposes under this Agreement. 

  

	 	(b)	 Biogen’s Rights. If, during the Term, C4 decides that it is no longer interested in
the preparation, filing, prosecution, or maintenance of a particular C4 First Right Patent Right, then it will promptly provide written notice to Biogen of such decision. Biogen may, upon written notice to C4, assume the preparation, filing,
prosecution, and maintenance of such Patent Right at Biogen’s sole cost and expense. In such event Biogen will be responsible for [***] of the costs and expenses of the preparation, filing, prosecution, and maintenance of such Patent
Right and Biogen will thereafter be the “Prosecuting Party” with respect thereto for all purposes under this Agreement. 

  

	 	10.4.3	 Defense of Patent Rights. As between the Parties, the Party controlling the preparation, filing,
prosecution, and maintenance of any Patent Right under this Section 10.4 (Patent Prosecution and Maintenance) will have the right, but not the obligation, to defend against a declaratory judgment action, inter partes review,
opposition proceeding, interference, or other action challenging any such patent, other than with respect to (a) any counter-claims or defenses in any Infringement Action brought by the other Party
pursuant to Section 10.5.2 (Infringement Actions), or (b) any action by a Third Party in response to an Infringement Action brought by the other Party, which, in both cases ((a) and (b)), will be controlled by such other Party.

  

	 	10.4.4	 Cooperation and Coordination. The non-Prosecuting Party
will (a) obtain and deliver to the Prosecuting Party any necessary documents for the Prosecuting Party to exercise its rights to prepare, prosecute, defend, and maintain all Patent Rights pursuant to Section 10.4.1 (Right to File and
Prosecute) or Section 10.4.2 (Step-In Right), as applicable, (b) render all signatures that will be necessary in connection with all such patent filings, and (c) assist the Prosecuting Party in
all other reasonable ways that are necessary for the issuance of those Patent Rights for which such Prosecuting Party is responsible, as well as for the preparation, prosecution, defense, and maintenance of such Patent Rights. Additionally, prior to
the assignment of Product-Specific Technology and Target-Specific Technology to Biogen in accordance with Section 10.2.2(a) (Assignment), the Parties will consult no less than [***] per Calendar Year regarding the prosecution, defense,
and maintenance of all Patent Rights pursuant to Section 10.4.1 (Right to File and Prosecute) or Section 10.4.2 (Step-In Right), as applicable. The purpose of such consultation will be to ensure, to
the extent reasonable, that the prosecution, defense, and maintenance of the C4-Prosecuted Patent Rights does not adversely affect the prosecution, defense, and maintenance of the Biogen-Prosecuted Patent
Rights, and vice versa. 

  
 54 

	10.5	 Patent Enforcement. 

 

	 	10.5.1	 Third Party Infringement. During the Term, the Parties will promptly inform each other in writing if
either Party becomes aware of any suspected, threatened, or actual infringement by any Third Party of any Biogen Licensed Patent Rights, C4 Licensed Patent Rights, or Joint Patent Rights (an “Infringement”), including any
Infringement that arises as a result of the making, using, offering to sell, selling, or importing of a product that would be competitive with a Product in the Territory (a “Competing Infringement”). Each Party will provide any
available evidence of such Infringement with such notification. 

  

	 	10.5.2	 Infringement Actions. 

 

	 	(a)	 Infringement Actions for Competing Infringements. 

 

	 	(i)	 Biogen Rights. During the Term, Biogen will have (A) the sole right, but not the obligation, to
initiate an infringement, misappropriation, or other appropriate suit (an “Infringement Action”) against any Competing Infringement with respect to any Biogen Patent Rights, and (B) the first right, but not the obligation, to
initiate an Infringement Action against a Competing Infringement with respect to any C4 Licensed Patent Rights or Joint Patent Rights, in each case ((A) and (B)), at Biogen’s sole discretion and at Biogen’s sole cost and expense.

  

	 	(ii)	 C4 Rights. During the Term, if Biogen fails to initiate an Infringement Action against any Competing
Infringement with respect to any C4 Licensed Patent Rights, or Joint Patent Rights within [***] after written notice of such Competing Infringement is first provided by a Party under Section 10.5.1 (Third Party Infringement), then C4
will have the right to initiate and control an Infringement Action with respect to such Competing Infringement by counsel of its own choice, at its own discretion and at C4’s cost and expense and Biogen will have the right, at its own expense,
to be represented in any such action by counsel of its own choice; provided that if Biogen notifies C4 during such [***] period that it is electing in good faith not to institute any Infringement Action against such Competing
Infringement for strategic reasons, then C4 will not have the right to initiate and control any Infringement Action with respect to such Competing Infringement. 

 

	 	(b)	 Infringement Actions for Other Infringements. During the Term, (i) Biogen will have the sole right,
but not the obligation, to initiate an Infringement Action against any Infringement that is not a Competing Infringement with respect to any Biogen-Prosecuted Patent Rights, at Biogen’s sole discretion and at Biogen’s sole cost and
expense, and (ii) C4 will have the sole right, but not the obligation, to initiate an Infringement Action against any Infringement that is not a Competing Infringement with respect to any C4-Prosecuted
Patent Rights, at C4’s sole discretion and at C4’s sole cost and expense. 

  
 55 

	 	(c)	 Procedures. If the Party having the right to initiate an Infringement Action under this
Section 10.5.2 (Infringement Actions) (the “Initiating Party”) desires to initiate such Infringement Action but may not do so due to Applicable Law or regulation (even as the assignee or exclusive licensee of such infringed
Patent Right), then such Initiating Party may require that the other Party join as a named party in such action or itself initiate such Infringement Action, at the Initiating Party’s sole cost and expense. The Initiating Party will take the
lead in the control and conduct of any such Infringement Action under this Section 10.5.2 (Infringement Actions) and will keep the other Party reasonably informed of any such Infringement Action, and the other Party will reasonably assist the
Initiating Party in any such Infringement Action under this Section 10.5.2 (Infringement Actions) at the Initiating Party’s expense. In no event may the Initiating Party settle any such Infringement Action in a manner that would limit the
rights of the other Party or impose any obligation on the other Party, in each case, without the other Party’s prior written consent, which consent will not be unreasonably withheld, delayed, or conditioned. 

 

	 	(d)	 Recoveries. Any amount recovered in any Infringement Action under this Section 10.5.2 (Infringement
Actions), including any amount recovered in any settlement of such Infringement Action, will first be used to reimburse each Party’s costs and expenses with respect to such Infringement Action (which reimbursement will be on a pro rata
basis to the extent such costs and expenses exceed such recovered amount, provided that Biogen may carry forward and deduct from any future payments due to C4 under this Agreement any such costs and expenses of Biogen that are not reimbursed)
and will thereafter be for (a) with respect to any Competing Infringement, the benefit of Biogen; provided, however, that to the extent any such amount is awarded as compensation for lost profits relating to sales of Products,
then such amount will, on a Product-by-Product basis, be deemed to be Net Sales of such Product and C4 will receive royalties on such deemed Net Sales pursuant to
Section 7.6 (Royalties), and (b) with respect to any Infringement that is not a Competing Infringement, for the benefit of the Initiating Party.  

 

	10.6	 Defense of Claims. C4 will promptly inform Biogen in writing if C4 receives written, or otherwise
becomes aware, of alleged infringement, misappropriation, or other violation of a Third Party’s Intellectual Property based upon C4’s performance of its obligations or exercise of its rights hereunder. Except as otherwise set forth under
this Agreement (including under Article 11 (Indemnification)), C4 will be solely responsible for the defense of any such claim brought against it. C4 will each keep Biogen advised of all material developments in the conduct of any proceedings in
defending any claim of alleged infringement, misappropriation, or other violation related to any Degraders or Products and will reasonably cooperate with Biogen in the conduct of such defense. In no event may C4 settle any such infringement,
misappropriation, or other violation claim in a manner that would limit the rights of Biogen or impose any obligation on Biogen, in each case, without Biogen’s prior written consent, which consent will not be unreasonably withheld, delayed, or
conditioned. 

  

	10.7	 Patent Listing. Biogen will have the full and exclusive right, in its sole discretion, to determine and
control the listing of any C4 Licensed Patent Right, Joint Collaboration Patent Right, or Biogen Patent Right in the then-current edition of the United States Food and Drug Administration publication “Approved Drug Products with Therapeutic
Equivalence Evaluations” in connection with the Regulatory Approval of any Product, or in equivalent patent listings in any other country within the Territory. 

  
 56 

	10.8	 Patent Term Extensions. Biogen will have the full and exclusive right and discretion to determine and
control all filings of requests for patent term extensions, supplementary protection certificates, or equivalents thereto in any country in the Territory, in each case where applicable to a Product (hereinafter “Patent Term
Extensions”), including for any C4 Licensed Patent Right, Joint Collaboration Patent Right, or Biogen Patent Right. All costs and expenses relating to the Patent Term Extensions will be born solely by Biogen. Upon request of Biogen and at
Biogen’s cost and expense, C4 will provide support, assistance, and all necessary documents, in full executed form if needed, to Biogen for the purpose of supporting, filing, obtaining, and maintaining Patent Term Extensions.

  

	10.9	 Summary of Activities. Upon the request of either Party, the Prosecuting Party will provide to the other
Party, no more frequently than on an annual basis, a written report summarizing all material activities undertaken by such Prosecuting Party in the preceding Calendar Year with respect to the preparation, filing, prosecution, maintenance,
enforcement, and defense of the Biogen-Prosecuted Patent Rights or C4-Prosecuted Patent Rights (as applicable) in the exercise of the rights granted to such Prosecuting Party under this Article 10
(Intellectual Property). Such report will be considered the Confidential Information of the Prosecuting Party. 

ARTICLE 11 INDEMNIFICATION 
  

	11.1	 Indemnification by C4. C4 will indemnify, defend, and hold harmless Biogen, its Affiliates,
Sublicensees, distributors and each of its and their respective employees, officers, directors, and agents (each, a “Biogen Indemnified Party”) from and against any and all liabilities, losses, damages, expenses (including
reasonable attorneys’ fees and expenses), and costs (collectively, a “Liability”) that the Biogen Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: 

[***] 
  

	11.2	 Indemnification by Biogen. Biogen will indemnify, defend, and hold harmless C4, each of its Affiliates,
and each of its and its Affiliates’ employees, officers, directors, and agents (each, a “C4 Indemnified Party”) from and against any and all Liabilities that the C4 Indemnified Party may be required to pay to one or more Third
Parties resulting from or arising out of: 

 [***] 

 

	11.3	 Procedure. Each Party will notify the other Party in writing in the event it becomes aware of a claim
for which indemnification may be sought hereunder. In case any proceeding (including any governmental investigation) will be instituted involving any Party in respect of which indemnity may be sought pursuant to this Article 11 (Indemnification),
such Party (the “Indemnified Party”) will promptly notify the other Party (the “Indemnifying Party”) in writing and the Indemnifying Party and Indemnified Party will meet to discuss how to respond to any claims that
are the subject matter of such proceeding. The Indemnified Party will cooperate fully with the Indemnifying Party in defense of such matter. In any such proceeding, the Indemnified Party will have the right to retain its own counsel, but the fees
and expenses of such counsel will be at the expense of the Indemnified Party unless (a) the Indemnifying Party and the Indemnified Party will have agreed to the retention of such counsel or (b) the named parties to any such proceeding
(including any impleaded parties) include both the Indemnifying Party and the Indemnified Party and representation of both Parties by the same counsel would be inappropriate due to actual or potential differing interests between them. All such fees
and expenses will be reimbursed as they are incurred. The Indemnifying Party will not be liable for any settlement of any proceeding effected 

  
 57 

	 	
without its written consent, but, if settled with such consent or if there is a final judgment for the plaintiff, then the Indemnifying Party agrees to indemnify the Indemnified Party from and
against any Liability by reason of such settlement or judgment. The Indemnifying Party will not, without the written consent of the Indemnified Party, effect any settlement of any pending or threatened proceeding in respect of which the Indemnified
Party is, or could have been, a party and indemnity could have been sought hereunder by the Indemnified Party, unless such settlement includes an unconditional release of the Indemnified Party from all liability on claims that are the subject matter
of such proceeding. 

 ARTICLE 12 TERM AND TERMINATION 

 

	12.1	 Term. This Agreement will commence upon the Effective Date and, if not otherwise terminated earlier
pursuant to this Article 12 (Term and Termination), will continue, on a Product-by-Product and
country-by-country basis, in full force and effect until the expiration of the Royalty Term applicable to such Product and such country (the “Term”).

  

	12.2	 Termination for Cause. 

 

	 	12.2.1	 By Biogen. In the event of a material breach of this Agreement by C4, which material breach
remains uncured for [***] measured from the date of written notice of such material breach by Biogen that identifies the material breach and the actions or conduct that Biogen considers would be an acceptable cure of such material breach,
Biogen may terminate this Agreement in whole or with respect to one or more Development Candidates, Products, or Collaboration Targets at any time during the Term of this Agreement by written notice of termination to C4. 

 

	 	12.2.2	 By C4. In the event of a material breach of this Agreement by Biogen, which material breach
remains uncured for [***] measured from the date written of written notice of such material breach by C4 that identifies the material breach and the actions or conduct that it considers would be an acceptable cure of such material breach, C4
may terminate this Agreement solely with respect to those Development Candidates, Products, or Collaboration Targets to which such material breach relates at any time during the Term of this Agreement by written notice of termination to Biogen.

  

	 	12.2.3	 Disputes Regarding Material Breach. In case the Party alleged by the other Party to have committed a
material breach under Section 12.2.1 (By Biogen) or Section 12.2.2 (By C4) (the “Defaulting Party”) disputes occurrence of such material breach (the “Non-Defaulting
Party”), then the issue of whether the Non-Defaulting Party may properly terminate this Agreement on expiration of the applicable cure period will be resolved in accordance with Section 13.8
(Dispute Resolution). If as a result of such dispute resolution process, it is determined that the Defaulting Party committed a material breach of this Agreement and the Defaulting Party does not cure such material breach within [***] after
the date of such determination, (the “Additional Cure Period”), then such termination will be effective as of the expiration of the Additional Cure Period. If the Parties dispute whether such material breach was so cured, then such
dispute will also be determined in accordance with Section 13.8 (Dispute Resolution). This Agreement will remain in full force and effect during the pendency of any such dispute resolution proceeding and the cure periods set forth in
Section 12.2.1 (By Biogen) or Section 12.2.2 (By C4), as applicable, and any Additional Cure Period, in each case, will be tolled during any such dispute resolution proceeding, such proceeding will not suspend any obligations of either
Party hereunder, and each Party will use reasonable efforts to mitigate any damage. If as 

  
 58 

	 	
a result of such dispute resolution proceeding it is determined that the Defaulting Party did not commit such material breach (or such material breach was cured in accordance with this
Section 12.2 (Termination for Cause)), then no termination will be effective, and this Agreement will continue in full force and effect. 

  

	12.3	 Termination for Insolvency. To the extent permitted by Applicable Law, either Party may terminate this
Agreement upon the filing or institution of bankruptcy, reorganization, liquidation, or receivership proceedings, upon the appointment of a receiver or trustee over all or substantially all property, or upon an assignment of a substantial portion of
the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate will only become effective if the Party consents to the involuntary
bankruptcy or such proceeding is not dismissed within [***] after the filing thereof. In the event of any termination pursuant to this Section 12.3 (Termination for Insolvency): 

 

	 	12.3.1	 All rights and licenses now or hereafter granted by C4 to Biogen under or pursuant to this Agreement are, for
all purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined in the U.S. Bankruptcy Code. Upon the filing or institution of bankruptcy, reorganization, liquidation, or
receivership proceedings, upon the appointment of a receiver or trustee over all or substantially all property, or upon an assignment of a substantial portion of the assets for the benefit of creditors by C4, C4 agrees that Biogen, as licensee of
such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. C4 will, during the Term, create and maintain current copies or, if not amenable to copying, detailed descriptions
or other appropriate embodiments, to the extent feasible, of all intellectual property rights licensed under this Agreement. Each Party acknowledges and agrees that “embodiments” of intellectual property rights within the meaning of
Section 365(n) include laboratory notebooks, cell lines, product samples, and inventory, research studies and data, all Regulatory Approvals (and all applications for Regulatory Approval) and rights of reference therein, the C4 Licensed
Technology, Results, and all information related to the C4 Licensed Technology. If (A) a case under the U.S. Bankruptcy Code is commenced by or against C4, (B) this Agreement is rejected as provided in the U.S. Bankruptcy Code, and
(C) Biogen elects to retain its rights hereunder as provided in Section 365(n) of the U.S. Bankruptcy Code, C4 (in any capacity, including
debtor-in-possession) and its successors and assigns (including a trustee) will: 

 

	 	(a)	 provide Biogen with all such intellectual property rights (including all embodiments thereof) held by C4 and
such successors and assigns, or otherwise available to them, immediately upon Biogen’s written request. Whenever C4 or any of its successors or assigns provides to Biogen any of the intellectual property rights licensed hereunder (or any
embodiment thereof) pursuant to this Section 12.3.1(a) (Termination for Insolvency), Biogen will have the right to perform C4’s obligations hereunder with respect to such intellectual property rights, but neither such provision nor such
performance by Biogen will release C4 from liability resulting from rejection of the license or the failure to perform such obligations; and 

  

	 	(b)	 not interfere with Biogen’s rights under this Agreement, or any agreement supplemental hereto, to such
intellectual property rights (including such embodiments), including any right to obtain such intellectual property rights (or such embodiments) from another entity, to the extent provided in Section 365(n) of the U.S. Bankruptcy Code.

  
 59 

	 	12.3.2	 All rights, powers, and remedies of Biogen provided in this Section 12.3 (Termination for Insolvency) are
in addition to and not in substitution for any other rights, powers, and remedies now or hereafter existing at law or in equity (including the U.S. Bankruptcy Code) in the event of the commencement of a case under the U.S. Bankruptcy Code with
respect to C4. The Parties intend the following rights to extend to the maximum extent permitted by Applicable Law, and to be enforceable under U.S. Bankruptcy Code Section 365(n): 

 

	 	(a)	 the right of access to any intellectual property rights (and all embodiments thereof) of C4, or any Third Party
with whom C4 contracts to perform any obligation of C4 under this Agreement, and, in the case of any such Third Party, that is necessary for the Exploitation of Degraders or Products; and 

 

	 	(b)	 the right to contract directly with any Third Party to complete the contracted work. 

 

	12.4	 Termination for Convenience. Biogen will be entitled to terminate this Agreement, in whole or with
respect to one or more Development Candidates, Products, or Collaboration Targets, at its sole discretion at any time upon [***] prior written notice to C4 thereof. 

 

	12.5	 Effects of Termination. 

 

	 	12.5.1	 Generally. Upon termination of the Agreement in whole or with respect to one or more Development
Candidates, Products, or Collaboration Targets: 

  

	 	(a)	 The Receiving Party will promptly return to the other Party or destroy all Confidential Information of the
Disclosing Party that is solely related to any terminated Development Candidate, Product, or Collaboration Target in accordance with Section 9.3 (Return of Confidential Information); and 

 

	 	(b)	 Except as expressly set forth in this Agreement, all licenses granted by a Party to the other Party under this
Agreement with respect to any terminated Development Candidate, Product, or Collaboration Target will immediately terminate. 

  

	 	12.5.2	 Knowledge Transfer. Upon termination of the Agreement in its entirety or with respect to one or more
Development Candidates, Products, or Collaboration Targets by Biogen (a) pursuant to Section 12.2.1 (By Biogen) in the event of an uncured material breach by C4 or (b) Section 12.3 (Termination for Insolvency) in the event of
C4’s insolvency, in each case ((a) and (b)), to the extent not provided by the effective date of termination of this Agreement pursuant to Section 5.1 (Technology Transfer) or Section 6.3 (Manufacturing Technology Transfer): C4 will
promptly transfer to Biogen, on a Product-by-Product basis, all Results, Deliverables, and Sandbox Technology, the costs of which transfer will be borne by C4.

  

	 	12.5.3	 C4 Right of Reversion. Upon termination of the Agreement by C4 pursuant to Section 12.2.2
(By C4) or Section 12.4 (Termination for Convenience), in whole or with respect to one or more Development Candidates, Products, or Collaboration Targets: Biogen will assign to C4 Biogen’s rights, title, and interests in and to any
Product-Specific Patent Rights that (a) were assigned to Biogen pursuant to Section 10.2.2(a) (Assignment) and (b) Cover such terminated Development Candidates, Products, or Collaboration Targets. 

  
 60 

	12.6	 Alternative Remedy in Lieu of Termination. If, during the Collaboration Term, Biogen has the right to
terminate this Agreement pursuant to [***], then in addition to any other remedies available to Biogen at law or in equity, in lieu of terminating this Agreement Biogen may, in its sole discretion, exercise an alternative remedy as follows:

 [***] 
 For the avoidance
of doubt, except as set forth in this Section 12.6 (Alternate Remedy in Lieu of Termination), if Biogen exercises the alternative remedy set forth above in this Section 12.6 (Alternate Remedy in Lieu of Termination), then all rights and
obligations of both Parties under this Agreement will continue unaffected, unless and until this Agreement is subsequently terminated by either Party pursuant to this Article 12 (Term and Termination). 

 

	12.7	 Rights Accruing Prior to Expiration or Termination. Expiration or termination of this Agreement will not
relieve the Parties of any obligation accruing prior to such expiration or termination. Any expiration or termination of this Agreement will be without prejudice to the rights of either Party against the other accrued or accruing under this
Agreement prior to expiration or termination, including any payment obligation that accrued prior to the effective date of such expiration or termination. 

  

	12.8	 Survival. The following provisions, as well as any other provisions which by their nature are intended
to survive termination or expiration, will survive termination or expiration of this Agreement: Article 1 (Definitions), Section 2.1.3 (C4 Collaboration Technology License), Section 3.3 (Records), Section 7.11 (Financial Audits),
Section 8.4 (Disclaimer of Warranties), Section 8.5 (Limitation of Liability), Article 9 (Confidentiality), Section 10.1.1 (Inventions), Section 10.3 (Joint Technology), Section 10.4 (Patent Prosecution and Maintenance),
Section 

  

	12.9	 (Patent Enforcement), Section 10.6 (Defense of Claims), Section 10.7 (Patent Listing),
Section 10.8 (Patent Term Extensions), Article 11 (Indemnification), Section 12.1 (solely in the case of expiration), Section 12.5 (Effects of Termination), this Section 12.8 (Survival), and Article 13 (Miscellaneous).

 ARTICLE 13 MISCELLANEOUS 
  

	13.1	 Assignment. Neither this Agreement nor any interest hereunder will be assignable by C4 without the prior
written consent of Biogen, except as follows: (a) C4 may, subject to the terms of this Agreement, assign its rights and obligations under this Agreement in whole to its
successor-in- interest in connection with the sale of all or substantially all of its assets to which this Agreement relates, whether in a merger, acquisition, or
similar transaction or series of related transactions, provided that such sale is not primarily for the benefit of its creditors, and (b) C4 may assign its rights and obligations under this Agreement to any of its Affiliates,
provided that C4 will remain liable for all of its rights and obligations under this Agreement. Biogen may freely assign this Agreement or any interest hereunder, in whole or in part. C4 will promptly notify Biogen of any assignment or
transfer under the provisions of this Section 13.1 (Assignment). This Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such
Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 13.1 (Assignment) will be null, void, and of no legal effect.

  
 61 

	13.2	 Entire Agreement; Amendments. This Agreement sets forth the entire agreement between the Parties and
supersedes all previous and contemporaneous negotiations, representations, or agreements, written or oral, regarding the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments,
either oral or written, with respect to the Candidate Development Programs and the licenses granted hereunder are superseded by the terms of this Agreement, including the Confidentiality Agreement, which Confidentiality Agreement is hereby
terminated effective as of the Effective Date. This Agreement may be amended only by an instrument in writing duly executed on behalf of the Parties. In case of inconsistencies between this Agreement and any Schedule hereof, the terms of this
Agreement will prevail unless agreed to explicitly that the Schedule should prevail. 

  

	13.3	 Force Majeure. Neither Party will be liable or deemed in default for failure to perform any duty or
obligation that such Party may have under this Agreement where such failure has been occasioned by any act of God, fires, earthquakes, strikes and labor disputes, acts of war, terrorism, civil unrest, or intervention of any Governmental Authority,
and occurring without its fault or negligence; provided that the Party affected will promptly notify the other of the force majeure condition and will exert all reasonable efforts to eliminate, cure, or overcome any such causes and to resume
performance of its obligations as soon as possible. 

  

	13.4	 Waiver. The failure of either Party to require performance by the other Party of any of that other
Party’s obligations under this Agreement will in no manner affect the right of such Party to enforce the same at a later time. No waiver by any Party of any condition, or of the breach of any provision, term, representation or warranty
contained in this Agreement will be deemed to be or construed as a further or continuing waiver of any such condition or breach, or of any other condition or of the breach of any other provision, term, representation, or warranty hereof. The
remedies provided in this Agreement are not exclusive and the Party suffering from a breach or default of this Agreement may pursue all other remedies, both legal and equitable, alternatively, or cumulatively. 

 

	13.5	 Severability. If any provision or portion thereof in this Agreement is for any reason held to be
invalid, illegal, or unenforceable, then the same will not affect any other portion of this Agreement and its validity, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity,
and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such provision or portion thereof had never been contained in this Agreement, and there will be deemed substituted therefore such provision
as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law unless doing so would have the effect of materially altering the right and obligations of the Parties in which
event this Agreement may be terminated by mutual written agreement of the Parties. 

  

	13.6	 Notices. All notices that are required or permitted hereunder will be in writing and sufficient if
delivered by internationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, and in each case, addressed as follows (with a courtesy copy sent by email, which will not constitute
notice): 

 If to C4: 

C4 Therapeutics, Inc. 
 490
Arsenal Street 
 Watertown, MA 02474 

U.S.A. 
 Attention: Chief
Executive Officer 
 E-mail: aphillips@c4therapeutics.com 

  
 62 

 With a copy to: 

Goodwin Procter LLP 
 100 Northern
Avenue 
 Boston, MA 02210 

Attention: Lawrence S. Wittenberg 

E-mail: lwittenberg@goodwinprocter.com 

If to Biogen: 
 Biogen MA Inc.

 225 Binney Street 

Cambridge, MA 02142 
 Attention:
Chief Legal Officer 
 E-mail: legaldepartment@biogen.com 

With a copy to: 
 Ropes &
Gray LLP 
 Prudential Tower 

800 Boylston Street 
 Boston, MA
02199-3600 
 Attention: Mark W. Bellomy, Esq. 

Email: mark.bellomy@ropesgray.com 

or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.
Any such notice will be deemed to have been given: (a) on the Business Day after dispatch if sent by internationally-recognized overnight courier; or (b) on the fifth Business Day after dispatch if sent by registered or certified mail,
postage prepaid, return receipt requested. 
  

	13.7	 Governing Law. This Agreement, and all claims arising under or in connection therewith, will be governed
by and interpreted in accordance with the substantive laws of the State of New York, without regard to conflict of law principles thereof. 

  

	13.8	 Dispute Resolution. Any dispute arising out of or in connection with this Agreement (except for disputes
arising at the JSC, which will be resolved pursuant to Section 4.2.4 (Decision Making Authority)) will be settled, if possible, through good faith negotiations between the Parties. If the Parties are unable to settle such dispute within
[***] after first considering such dispute, then such dispute will be referred to the Chief Executive Officer of C4 and the Executive Vice President, Research & Development of Biogen (the “Executive Officers”). The
Executive Officers of both Parties will meet to attempt to resolve such dispute. Such resolution, if any, of a referred issue will be final and binding on the Parties. All negotiations pursuant to this Section 13.8 (Dispute Resolution) are
confidential and will be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. If the Executive Officers cannot resolve such dispute within [***] after either Party requests such a meeting in writing,
then either Party will have the right to pursue any and all remedies available at law or equity, consistent with Section 13.9 (Jurisdiction; Venue). 

  

	13.9	 Jurisdiction; Venue. Each Party irrevocably submits to the exclusive jurisdiction of (a) the
Supreme Court of the State of New York, New York County, and (b) the United States District Court for the Southern District of New York, for the purposes of any suit, action, or other proceeding arising out of this Agreement or out of any
transaction contemplated hereby. Each Party 

  
 63 

	 	
agrees to commence any such action, suit, or proceeding either in the United States District Court for the Southern District of New York or if such suit, action, or other proceeding may not be
brought in such court for jurisdictional reasons, in the Supreme Court of the State of New York, New York County. Each Party irrevocably and unconditionally waives any objection to the laying of venue of any action, suit, or proceeding arising out
of this Agreement or the transactions contemplated hereby in (i) the Supreme Court of the State of New York, New York County or (ii) the United States District Court for the Southern District of New York, and hereby and thereby further
irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit, or proceeding brought in any such court has been brought in an inconvenient forum. Each Party irrevocable consents to service of
process in the manner provided under Section 13.6 (Notices) or by first class certified mail, return receipt requested, postage prepaid. THE PARTIES EXPRESSLY, IRREVOCABLY, AND UNCONDITIONALLY WAIVE AND FOREGO ANY RIGHT TO TRIAL BY JURY.

  

	13.10	 Relationship of the Parties. Nothing in this Agreement is intended or will be deemed to constitute a
partnership, agency, employer-employee or joint venture relationship between the Parties. No Party will incur any debts or make any commitments for the other. There are no express or implied third party beneficiaries hereunder (except for Biogen
Indemnified Parties and C4 Indemnified Parties for purposes of Sections 11.1 (Indemnification by C4) or 11.2 (Indemnification by Biogen), as applicable). 

  

	13.11	 Performance by Affiliates. Each Party recognizes that the other Party may perform some or all of its
obligations under this Agreement through Affiliates to the extent permitted under this Agreement; provided, however, that such other Party will remain responsible for the performance by its Affiliates as if such obligations were
performed by such other Party. 

  

	13.12	 Interpretation. Except where the context expressly requires otherwise, (a) the use of any gender
herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” will
be deemed to be followed by the phrase “without limitation,” (c) the word “will” will be construed to have the same meaning and effect as the word “shall,” (d) any definition of or reference to any agreement,
instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or
modifications set forth herein), (e) any reference herein to any person or entity will be construed to include the person’s or entity’s successors and assigns, (f) the words “herein,” “hereof,” and
“hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Schedules will be construed to refer to
Sections or Schedules of this Agreement, and references to this Agreement include all Schedules hereto, (h) the word “notice” means notice in writing (whether or not specifically stated) and will include notices, consents, approvals
and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent,” or “approve” or the like will require that
such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific
law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, (k) the term “or” will be
interpreted in the inclusive sense commonly associated with the term “and/or,” and (l) references to any Sections include Sections and subsections that are part of the related Section (e.g., a section numbered
“Section 2.2” would be part of “Section 2”, and references to “Section 2.2” would also refer to material contained in the subsection described as “Section 2.2(a)”). 

  
 64 

	13.13	 Further Assurances. Each of C4 and Biogen agrees to duly execute and deliver, or cause to be duly
executed or delivered, such further instruments and do and cause to be done such further acts, including the filing of additional assignments, agreements, documents and instruments, as the other Party may at any time and from time to time reasonably
request in connection with this Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party its rights and remedies under, this Agreement. 

 

	13.14	 Counterparts. This Agreement may be executed in counterparts, all of which taken together will be
regarded as one and the same instrument. Counterparts may be delivered via electronic mail, including AdobeTM Portable Document Format (PDF) or any electronic signature complying with the U.S.
Federal ESIGN Act of 2000, and any counterpart so delivered will be deemed to be original signatures, will be valid and binding upon the Parties, and, upon delivery, will constitute due execution of this Agreement. 

  
 65 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
respective duly authorized officers. 
  

			
	BIOGEN MA INC.
		
	By:	 	 /s/ Anabella Villalobos

	Name:	 	Anabella Villalobos
	Title:	 	Senior Vice President
		
	Date:	 	December 28, 2018
	
	C4 THERAPEUTICS, INC.
		
	By:	 	 /s/ Andrew J. Phillips

	Name:	 	Andrew J. Phillips
	Title:	 	CEO & President
		
	Date:	 	December 28, 2018

 [Signature Page to Collaborative Research and License Agreement] 

 SCHEDULE 1.42 

C4 LICENSED PATENT RIGHTS 

[***] 

 [***] 

CANDIDATE DEVELOPMENT PLAN FOR [***] 

[***] 

 SCHEDULE 3.1.3(B) 

CANDIDATE DEVELOPMENT PLAN FOR [***] 

[***] 

 [***] 

CANDIDATE DEVELOPMENT PLAN FOR [***] 

[***] 

 SCHEDULE 3.1.9 

FORM OF CANDIDATE DEVELOPMENT FINANCIAL REPORT 
  

															
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 A-6 

 SCHEDULE 4.1.1 

CONTACT LIST 
  

							
	 Name
	  	 Role
	  	 Email
	  	 Phone Number

	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]

 SCHEDULE 9.9.2 

PRESS RELEASE 
 [To be
provided]EX-10.11

 Exhibit 10.11 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would
be competitively harmful if publicly disclosed. 
 Confidential 

Amended and Restated License Agreement 

This Amended and Restated License Agreement is entered into with effect as of the Restatement Date (as defined below) 

by and between 
 F. Hoffmann-La Roche Ltd 
 with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland
(“Roche Basel”) 
 and 
 Hoffmann-La Roche Inc. 
 with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey
07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”) 
 on the one hand 

and 
 C4 Therapeutics, Inc. 

with an office and place of business at 490 Arsenal Way, Suite 200, Watertown, MA 02472, U.S.A. (“C4T”) 

on the other hand. 

 Table of Contents 

 

									
	 1.
	 	Definitions	  	 	8	 
		 	 1.1
	 	Affiliate	  	 	8	 
		 	 1.2
	 	Agreement	  	 	8	 
		 	 1.3
	 	Agreement Term	  	 	8	 
		 	 1.4
	 	Applicable Law	  	 	8	 
		 	 1.5
	 	[***]	  	 	8	 
		 	 1.6
	 	C4T Base Patent Rights	  	 	8	 
		 	 1.7
	 	C4T Co-Detail Option Period	  	 	8	 
		 	 1.8
	 	C4T Co-Dev Option Period	  	 	9	 
		 	 1.9
	 	C4T Co-Dev Product	  	 	9	 
		 	 1.10
	 	C4T Compound IP	  	 	9	 
		 	 1.11
	 	C4T Group	  	 	9	 
		 	 1.12
	 	C4T IP	  	 	9	 
		 	 1.13
	 	C4T Know-How	  	 	9	 
		 	 1.14
	 	C4T Net Sales	  	 	9	 
		 	 1.15
	 	C4T Patent Rights	  	 	9	 
		 	 1.16
	 	C4T Pipeline	  	 	9	 
		 	 1.17
	 	C4T Platform IP	  	 	10	 
		 	 1.18
	 	C4T Technology	  	 	10	 
		 	 1.19
	 	Calendar Quarter	  	 	10	 
		 	 1.20
	 	Calendar Year	  	 	10	 
		 	 1.21
	 	CCS Achieved	  	 	10	 
		 	 1.22
	 	CCS Criteria	  	 	10	 
		 	 1.23
	 	Change of Control	  	 	10	 
		 	 1.24
	 	Change of Control Group	  	 	10	 
		 	 1.25
	 	Clinical Study	  	 	11	 
		 	 1.26
	 	CLS Achieved	  	 	11	 
		 	 1.27
	 	Co-Detail Territory	  	 	11	 
		 	 1.28
	 	Collaboration Patent Rights	  	 	11	 
		 	 1.29
	 	Combination Product	  	 	11	 
		 	 1.30
	 	Commercially Reasonable Efforts	  	 	11	 
		 	 1.31
	 	Companion Diagnostic	  	 	11	 
		 	 1.32
	 	Competitor Company	  	 	12	 
		 	 1.33
	 	Completion	  	 	12	 
		 	 1.34
	 	Compulsory Sublicense Compensation	  	 	12	 
		 	 1.35
	 	Confidential Information	  	 	12	 
		 	 1.36
	 	Continuation Election Notice	  	 	12	 
		 	 1.37
	 	Control	  	 	12	 
		 	 1.38
	 	Cover	  	 	13	 
		 	 1.39
	 	Degronimid	  	 	13	 
		 	 1.40
	 	“Detail” “Detailing”	  	 	13	 
		 	 1.41
	 	Development Costs	  	 	13	 
		 	 1.42
	 	Dose Range Finding Study	  	 	13	 
		 	 1.43
	 	[***]	  	 	13	 
		 	 1.44
	 	EU	  	 	14	 
		 	 1.45
	 	Expert	  	 	14	 
		 	 1.46
	 	FBMC	  	 	14	 
		 	 1.47
	 	FDA	  	 	14	 
		 	 1.48
	 	FDCA	  	 	14	 

  
 - 2 - 

									
		 	 1.49
	 	Field	  	 	14	 
		 	 1.50
	 	Filing	  	 	14	 
		 	 1.51
	 	First Commercial Sale	  	 	14	 
		 	 1.52
	 	FTE	  	 	14	 
		 	 1.53
	 	GAAP	  	 	14	 
		 	 1.54
	 	Generic Product	  	 	14	 
		 	 1.55
	 	GLP Data Package	  	 	15	 
		 	 1.56
	 	GLP Tox Study	  	 	15	 
		 	 1.57
	 	Handle	  	 	15	 
		 	 1.58
	 	HSR	  	 	15	 
		 	 1.59
	 	ICD-10	  	 	15	 
		 	 1.60
	 	IFRS	  	 	15	 
		 	 1.61
	 	IND	  	 	15	 
		 	 1.62
	 	Indication	  	 	15	 
		 	 1.63
	 	Initiation	  	 	15	 
		 	 1.64
	 	Insolvency Event	  	 	16	 
		 	 1.65
	 	Invention	  	 	16	 
		 	 1.66
	 	Joint Know-How	  	 	16	 
		 	 1.67
	 	Joint Patent Rights	  	 	16	 
		 	 1.68
	 	JOT	  	 	16	 
		 	 1.69
	 	JRC	  	 	16	 
		 	 1.70
	 	Know-How	  	 	16	 
		 	 1.71
	 	Lead Identification	  	 	16	 
		 	 1.72
	 	Lead Optimization	  	 	16	 
		 	 1.73
	 	LSI Achieved	  	 	17	 
		 	 1.74
	 	Major Countries	  	 	17	 
		 	 1.75
	 	NDA	  	 	17	 
		 	 1.76
	 	Net Sales	  	 	17	 
		 	 1.77
	 	New Target	  	 	17	 
		 	 1.78
	 	Original Product	  	 	17	 
		 	 1.79
	 	Out of Pocket Costs	  	 	17	 
		 	 1.80
	 	Party	  	 	17	 
		 	 1.81
	 	Patent Rights	  	 	17	 
		 	 1.82
	 	Pharmacovigilance Agreement	  	 	18	 
		 	 1.83
	 	Phase I Data Package	  	 	18	 
		 	 1.84
	 	Phase I Plan	  	 	18	 
		 	 1.85
	 	Phase I Study	  	 	18	 
		 	 1.86
	 	Phase II Study	  	 	18	 
		 	 1.87
	 	Phase III Study	  	 	18	 
		 	 1.88
	 	Pivotal Clinical Study	  	 	18	 
		 	 1.89
	 	Prescriber	  	 	19	 
		 	 1.90
	 	Prodrug	  	 	19	 
		 	 1.91
	 	Product	  	 	19	 
		 	 1.92
	 	Promotional Materials	  	 	19	 
		 	 1.93
	 	Regulatory Approval	  	 	19	 
		 	 1.94
	 	Regulatory Authority	  	 	19	 
		 	 1.95
	 	Research Plan	  	 	19	 
		 	 1.96
	 	Research Program	  	 	19	 
		 	 1.97
	 	Research Term	  	 	20	 
		 	 1.98
	 	Restatement Date	  	 	20	 

  
 - 3 - 

									
		 	 1.99
	 	Reverted Target	  	 	20	 
		 	 1.100
	 	Roche Compound	  	 	20	 
		 	 1.101
	 	Roche Group	  	 	20	 
		 	 1.102
	 	Roche IP	  	 	20	 
		 	 1.103
	 	Roche Know-How	  	 	20	 
		 	 1.104
	 	Roche Option Period	  	 	20	 
		 	 1.105
	 	Roche Option Right	  	 	20	 
		 	 1.106
	 	Roche Patent Rights	  	 	20	 
		 	 1.107
	 	Roche Product	  	 	21	 
		 	 1.108
	 	Royalty Term	  	 	21	 
		 	 1.109
	 	Sales	  	 	21	 
		 	 1.110
	 	Sales Representatives	  	 	21	 
		 	 1.111
	 	[***]	  	 	21	 
		 	 1.112
	 	Sublicensee	  	 	21	 
		 	 1.113
	 	Tactical Plan	  	 	21	 
		 	 1.114
	 	Target	  	 	21	 
		 	 1.115
	 	Territory	  	 	22	 
		 	 1.116
	 	Third Party	  	 	22	 
		 	 1.117
	 	US	  	 	22	 
		 	 1.118
	 	US$	  	 	22	 
		 	 1.119
	 	Valid Claim	  	 	22	 
		 	 1.120
	 	Valid Composition of Matter Claim	  	 	22	 
		 	 1.121
	 	Additional Definitions	  	 	22	 
	 2.
	 	Grant of Licenses and Exclusivity	  	 	24	 
		 	 2.1
	 	Licenses	  	 	24	 
		 	 2.2
	 	Exclusivity	  	 	26	 
	 3.
	 	Option of Roche	  	 	26	 
		 	 3.1
	 	Option Right	  	 	26	 
		 	 3.2
	 	Data Reporting, Due Diligence and License Right	  	 	27	 
	 4.
	 	Research Collaboration	  	 	28	 
		 	 4.1
	 	Conduct of the Research Program	  	 	28	 
		 	 4.2
	 	Records; Reports	  	 	30	 
	 5.
	 	Diligence	  	 	30	 
	 6.
	 	Development.	  	 	30	 
		 	 6.1
	 	Roche Products	  	 	30	 
		 	 6.2
	 	Phase I Completed Original Products	  	 	31	 
		 	 6.3
	 	C4T Co-Dev Products	  	 	31	 
	 7.
	 	Manufacturing	  	 	33	 
		 	 7.1
	 	General	  	 	33	 
		 	 7.2
	 	Roche Option; C4T Co-Dev Products	  	 	33	 
		 	 7.3
	 	Technology Transfer	  	 	33	 
	 8.
	 	Commercialization	  	 	34	 
		 	 8.1
	 	General	  	 	34	 
		 	 8.2
	 	Co-Detailing	  	 	34	 
	 9.
	 	Regulatory	  	 	35	 
		 	 9.1
	 	Phase I Completed Original Products	  	 	35	 
		 	 9.2
	 	Licensed Products	  	 	35	 
	 10.
	 	Adverse Events	  	 	35	 
	 11.
	 	Governance	  	 	36	 
		 	 11.1
	 	Committees	  	 	36	 

  
 - 4 - 

									
		 		 		  			
		 	 11.2
	 	Members	  	 	36	 
		 	 11.3
	 	Meetings	  	 	36	 
		 	 11.4
	 	Minutes	  	 	36	 
		 	 11.5
	 	Decisions	  	 	37	 
		 	 11.6
	 	Joint Research Committee	  	 	37	 
		 	 11.7
	 	Responsibilities of the JRC	  	 	37	 
		 	 11.8
	 	Lifetime of the JRC	  	 	38	 
		 	 11.9
	 	Joint Development Committee	  	 	38	 
		 	 11.10
	 	Responsibilities of the JDC	  	 	39	 
		 	 11.11
	 	Lifetime of JDC	  	 	40	 
		 	 11.12
	 	Joint Commercialization Committee	  	 	40	 
		 	 11.13
	 	Responsibility of the JCC	  	 	40	 
		 	 11.14
	 	Lifetime of the JCC	  	 	40	 
		 	 11.15
	 	Alliance Director	  	 	40	 
		 	 11.16
	 	Limitations of Authority	  	 	40	 
		 	 11.17
	 	Expenses	  	 	41	 
		 	 11.18
	 	Lifetime	  	 	41	 
	 12.
	 	Payments	  	 	41	 
		 	 12.1
	 	Initial Payment	  	 	41	 
		 	 12.2
	 	Cost under the Research Plan	  	 	41	 
		 	 12.3
	 	Development Costs for Dose Range Finding Studies and GLP Tox Studies	  	 	41	 
		 	 12.4
	 	Costs for Phase I Completed Original Products.	  	 	41	 
		 	 12.5
	 	Development Costs for C4T Co-Dev Products.	  	 	41	 
		 	 12.6
	 	Shared Development Costs	  	 	41	 
		 	 12.7
	 	Fee upon LSI Achieved.	  	 	42	 
		 	 12.8
	 	Fee Upon Initiation of GLP Tox Studies,	  	 	42	 
		 	 12.9
	 	Option Exercise Fees	  	 	43	 
		 	 12.10
	 	Development Event Payments	  	 	43	 
		 	 12.11
	 	Sales Based Events	  	 	45	 
		 	 12.12
	 	Royalty Payments	  	 	45	 
		 	 12.13
	 	Disclosure of Payments	  	 	48	 
		 	 12.14
	 	Late Issuing Valid Claims	  	 	48	 
	 13.
	 	Accounting and reporting	  	 	48	 
		 	 13.1
	 	Timing of Payments	  	 	48	 
		 	 13.2
	 	Late Payment	  	 	48	 
		 	 13.3
	 	Method of Payment	  	 	49	 
		 	 13.4
	 	Currency Conversion	  	 	49	 
		 	 13.5
	 	Reporting	  	 	49	 
	 14.
	 	Taxes	  	 	49	 
	 15.
	 	Auditing	  	 	49	 
		 	 15.1
	 	C4T Right to Audit	  	 	49	 
		 	 15.2
	 	Audit Reports	  	 	50	 
		 	 15.3
	 	Over-or Underpayment	  	 	50	 
	 16.
	 	Intellectual Property	  	 	50	 
		 	 16.1
	 	Ownership of Inventions	  	 	50	 
		 	 16.2
	 	German Statute on Employee’s Inventions	  	 	53	 
		 	 16.3
	 	Trademarks and Labeling	  	 	53	 
		 	 16.4
	 	Prosecution of Patent Rights	  	 	54	 
		 	 16.5
	 	Patent Coordination Team	  	 	54	 
		 	 16.6
	 	Unified Patent Court (Europe)	  	 	54	 

  
 - 5 - 

									
		 	 16.7
	 	CREATE Act	  	 	54	 
		 	 16.8
	 	Infringement	  	 	54	 
		 	 16.9
	 	Defense	  	 	56	 
		 	 16.10
	 	Common Interest Disclosures	  	 	56	 
		 	 16.11
	 	Hatch-Waxman	  	 	57	 
		 	 16.12
	 	Patent Term Extensions	  	 	57	 
	 17.
	 	C4T Representations, Warranties and Covenants	  	 	57	 
		 	 17.1
	 	Safety Data	  	 	57	 
		 	 17.2
	 	Third Party Patent Rights	  	 	57	 
		 	 17.3
	 	Ownership of Patent Rights	  	 	57	 
		 	 17.4
	 	Inventors	  	 	58	 
		 	 17.5
	 	Grants	  	 	58	 
		 	 17.6
	 	Authorization	  	 	58	 
		 	 17.7
	 	Validity of Patent Rights	  	 	58	 
		 	 17.8
	 	Ownership and Validity of Know-How	  	 	58	 
		 	 17.9
	 	No Claims	  	 	58	 
		 	 17.10
	 	No Conflict	  	 	58	 
		 	 17.11
	 	Protection of Know-How	  	 	59	 
		 	 17.12
	 	No Other Representations	  	 	59	 
	 18.
	 	Indemnification	  	 	59	 
	 19.
	 	Liability	  	 	59	 
		 	 19.1
	 	Limitation of Liability	  	 	59	 
		 	 19.2
	 	Disclaimer	  	 	59	 
	 20.
	 	Obligation Not to Disclose Confidential Information	  	 	60	 
		 	 20.1
	 	Communication and Information Exchange	  	 	60	 
		 	 20.2
	 	Non-Use and Non-Disclosure	  	 	60	 
		 	 20.3
	 	Permitted Disclosure	  	 	60	 
		 	 20.4
	 	Press Releases	  	 	60	 
		 	 20.5
	 	Publications	  	 	60	 
		 	 20.6
	 	Commercial Considerations	  	 	60	 
	 21.
	 	Term and Termination	  	 	61	 
		 	 21.1
	 	Commencement and Term	  	 	61	 
		 	 21.2
	 	Termination and Change of Control	  	 	62	 
		 	 21.3
	 	Consequences of Termination and Change of Control	  	 	62	 
		 	 21.4
	 	Survival	  	 	62	 
	 22.
	 	Bankruptcy	  	 	63	 
	 23.
	 	Miscellaneous	  	 	68	 
		 	 23.1
	 	US Manufacture	  	 	69	 
		 	 23.2
	 	Other Government Laws	  	 	69	 
		 	 23.3
	 	Patent Marking	  	 	69	 
		 	 23.4
	 	Publicity – Use of Name	  	 	69	 
		 	 23.5
	 	Governing Law	  	 	69	 
		 	 23.6
	 	Disputes	  	 	69	 
		 	 23.7
	 	Arbitration	  	 	69	 
		 	 23.8
	 	Assignment	  	 	70	 
		 	 23.9
	 	Debarment	  	 	70	 
		 	 23.10
	 	Independent Contractor	  	 	71	 
		 	 23.11
	 	Unenforceable Provisions and Severability	  	 	72	 
		 	 23.12
	 	Waiver	  	 	72	 
		 	 23.13
	 	Appendices	  	 	72	 
		 	 23.14
	 	Entire Understanding	  	 	72	 
		 	 23.15
	 	Invoices	  	 	72	 
		 	 23.16
	 	Notice	  	 	72	 

  
 - 6 - 

 Amended and Restated License Agreement 

WHEREAS, C4T owns or controls a proprietary degronimid platform that conjugates an    E3 ligase binding small molecule to a target-binding
small molecule via a linker to form a degronimid that can cause proteosomal degradation of the target within the cell, and possesses proprietary technology and intellectual property rights relating thereto; and 

WHEREAS, Roche has expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic products, including owning or
controlling target-binding small molecules; and 
 WHEREAS, Roche wishes to develop for commercialization such degronimids incorporating target-binding
molecules that bind to targets of interest to Roche primarily for the treatment of solid and/or liquid cancers but potentially for other indications as well, and to explore their potential applications; and 

WHEREAS, C4T is willing to grant to Roche rights to use certain of its intellectual property rights to make, use, offer for sale, sell and import and export
degronimids and products containing degronimids in the Territory for use in the Field (as such terms are respectively defined below), as contemplated herein; and 

WHEREAS, the Parties previously entered into that certain License Agreement effective as of March 4, 2016 (the “Effective Date”), as
amended on June 2, 2016 and March 7, 2017 (collectively, the “Original Agreement”); and 
 WHEREAS, the Parties now desire to
amend and restate the Original Agreement in its entirety and replace the Original Agreement with this Agreement to, among other things, modify the governance structure, with C4T leading early research and development, until, on a Target-by-Target basis, Roche exercises its Roche Option Right; include various opt-in points for the Targets (as defined below); and
to allow for C4T to co-Detail (as such terms are respectively defined below) certain Products. 
 NOW, THEREFORE, in
consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby
agree that the Original Agreement shall be, and hereby is, amended and restated in its entirety to read as set forth in this Amended and Restated License Agreement (“Restated Agreement”): 

  
 - 7 - 

 1. Definitions 

As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 

 

	 	1.1	 Affiliate 

The term “Affiliate” shall mean any individual, corporation, association or other business entity that directly or indirectly controls, is controlled
by, or is under common control with the Party in question. As used in this definition of “Affiliate,” the term “control” shall mean the direct or indirect ownership of more than fifty percent (>50%) of the stock having the
right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business entity whether through the ownership of voting securities, by contract, resolution, regulation or otherwise. Anything to the
contrary in this paragraph notwithstanding, neither Chugai Pharmaceutical Co., Ltd, a Japanese corporation (“Chugai”) and/or its subsidiaries (if any) nor Foundation Medicine, Inc., a Delaware corporation (“FMI”)
and/or its subsidiaries (if any) shall be deemed as Affiliates of Roche unless Roche provides written notice to C4T of its desire to include Chugai, FMI and/or their respective subsidiaries (as applicable) as Affiliate(s) of Roche. 

 

	 	1.2	 Agreement 

The term “Agreement” shall mean this document including any and all appendices and amendments to it as may be added and/or amended from time to time
in accordance with the provisions of this Agreement. 
  

	 	1.3	 Agreement Term 

The term “Agreement Term” shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided
in Article 21, expiring on the date when no royalty or other payment obligations under this Agreement are or will become due. 
  

	 	1.4	 Applicable Law 

The term “Applicable Law” shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including
without limitation, any Regulatory Authority) and is in force as of the Effective Date or comes into force during the Agreement Term, in each case to the extent that the same is applicable to the performance by the Parties of their respective
obligations under this Agreement. 
  

	 	1.5	 [***] 

The term [***] means [***]. 
  

	 	1.6	 C4T Base Patent Rights 

The term “C4T Base Patent Rights” shall mean the Patent Rights that C4T Controls at the Effective Date relating to or arising from the discovery,
manufacture, development or commercialization of or Covering a Degronimid or a Product. A complete listing of the C4T Base Patent Rights is in Appendix 1.5. 
  

	 	1.7	 C4T Co-Detail Option Period 

The term “C4T Co-Detail Option Period” shall mean, with respect to [***] and Targets originating from
the C4T Pipeline, the period beginning upon[***] and [***]. 

  
 - 8 - 

	 	1.8	 C4T Co-Dev Option Period 

The term “C4T Co-Dev Option Period” shall mean the period commencing upon the receipt of Roche’s written
notice to exercise a Roche Option Right and ending [***]. 
  

	 	1.9	 C4T Co-Dev Product 

The term “C4T Co-Dev Product” shall mean a Roche Product directed to either (a) [***] or (b) a
Target originating from the C4T Pipeline for which C4T has exercised the C4T Co-Dev Option Right pursuant to Section 3.1.2 to convert such Roche Product into a C4T
Co-Dev Product. If C4T has exercised an Opt-Out under Section 6.3.4, then at the time of such Opt-Out the Product shall no
longer be a C4T Co-Dev Product and shall become a Roche Product again. 
  

	 	1.10	 C4T Compound IP 

The term “C4T Compound IP” shall mean all (a) C4T Know-How directed to a Degronimid or a Product and
(b) C4T Patent Rights Covering a Degronimid or Product . 
  

	 	1.11	 C4T Group 

The term “C4T Group” shall mean C4T, its Affiliates and Sublicensees. 
  

	 	1.12	 C4T IP 

The term “C4T IP” shall mean C4T Compound IP and C4T Platform IP. Notwithstanding anything to the contrary herein, after any Change of Control of
C4T, no Know-How or Patent Rights of any C4T Affiliate that becomes a C4T Affiliate after the Change of Control of C4T shall become ”C4T IP” hereunder unless such
Know-How or Patent Rights are intentionally used by C4T in C4T’s performance of research, development, manufacture or commercialization activities under this Agreement. 

 

	 	1.13	 C4T Know-How 

The term “C4T Know-How” shall mean the Know-How that C4T Controls at
the Effective Date and during the Agreement Term pertaining to the subject matter of this Agreement. 
  

	 	1.14	 C4T Net Sales 

The term “C4T Net Sales” shall mean [***]. 

[***]. 
 [***]. 

[***]. 
  

	 	1.15	 C4T Patent Rights 

The term “C4T Patent Rights” shall mean the Patent Rights that C4T Controls at the Effective Date and during the Agreement Term, relating to or
arising from the discovery, manufacture, development or commercialization of or Covering a Degronimid or a Product. The term C4T Patent Rights shall include C4T Base Patent Rights and C4T’s interest in the Collaboration Patent Rights. An
updated listing of the C4T Patent Rights as of the Restatement Date is provided in Appendix 1.15. 
  

	 	1.16	 C4T Pipeline 

The term “C4T Pipeline” shall mean those targets for which C4T has started to characterize degronimids in vitro but for which it has not yet
reached LSI Achieved or the standard C4T criteria that result in advancement to the lead optimization phase of development. As of the Restatement Date, [***] is a Target that has originated from the C4T Pipeline. 

  
 - 9 - 

	 	1.17	 C4T Platform IP 

The term “C4T Platform IP” shall mean all (a) C4T Know-How that is necessary or useful for the
discovery, manufacture, development or commercialization of a Degronimid or a Product, or that relates to C4T Technology and (b) C4T Patent Rights that are necessary or useful for the discovery, manufacture, development or commercialization of
a Degronimid or a Product, or that relate to C4T Technology, but in all cases excluding C4T Compound IP. C4T Platform IP includes the Linker and E3 Ligase Binding Moiety and the Linker bound to an E3 Ligase Binding Moiety (without the Target
Binding Moiety) and their manufacture, and including as incorporated in or used in the manufacture of the Degronimid or Product. 
  

	 	1.18	 C4T Technology 

The term “C4T Technology” shall mean Linker, E3 Ligase Binding Moiety, and the Linker bound to an E3 Ligase Binding Moiety (without the Target
Binding Moiety). 
  

	 	1.19	 Calendar Quarter 

The term “Calendar Quarter” shall mean each period of three (3) consecutive calendar months, ending March 31, June 30,
September 30, and December 31. 
  

	 	1.20	 Calendar Year 

The term “Calendar Year” shall mean the period of time beginning on January 1 and ending December 31, except for the first year which shall
begin on the Effective Date and end on December 31. 
  

	 	1.21	 CCS Achieved 

The term “CCS Achieved” shall mean that a Degrominid for a Target meets CCS Criteria. 

 

	 	1.22	 CCS Criteria 

The term “CCS Criteria” means the clinical candidate selection criteria as set forth in Appendix 1.22. 

 

	 	1.23	 Change of Control 

The term “Change of Control” shall mean, with respect to a Party: (a) the acquisition by any Third Party of beneficial ownership of fifty
percent (50%) or more of the then outstanding common shares or voting power of such Party, other than acquisitions by employee benefit plans sponsored or maintained by such Party; (b) the consummation of a business combination involving such
Party, unless, following such business combination, the stockholders of such Party immediately prior to such business combination beneficially own directly or indirectly more than fifty percent (50%) of the then outstanding common shares or voting
power of the entity resulting from such business combination; or (c) the sale of all or substantially all of such Party’s assets or business relating to the subject matter of the Agreement. For clarity, a change in ownership as the result
of financing transactions shall not qualify as a Change of Control. 
  

	 	1.24	 Change of Control Group 

The term “Change of Control Group” shall mean with respect to a Party, the person or entity, or group of persons or entities, that is the acquirer
of, or a successor to, a Party in connection with a Change of Control, together with affiliates of such persons or entities that are not Affiliates of such Party immediately prior to the completion of such Change of Control of such Party. 

  
 - 10 - 

	 	1.25	 Clinical Study 

The term “Clinical Study” shall mean a Phase I Study, Phase II Study Phase III Study, or Pivotal Clinical Study as applicable. 

 

	 	1.26	 CLS Achieved 

The term “CLS Achieved” shall mean that a Degronimid for a Target meets the CLS criteria (a) as set forth in the [***] Research Plan
attached as Appendix 1.26 or (b) set forth in any future Research Plan approved by the JRC (“CLS Criteria”). 
  

	 	1.27	 Co-Detail Territory 

The term “Co-Detail Territory” shall mean the US. 

 

	 	1.28	 Collaboration Patent Rights 

The term “Collaboration Patent Rights” shall mean Patent Rights Covering an Invention made under a Research Plan during the Research Term. A
listing of the Collaboration Patent Rights as of the Restatement Date is attached as Appendix 1.28. 
  

	 	1.29	 Combination Product 

The term “Combination Product” shall mean 
  

	 	a)	 a single pharmaceutical formulation containing as its active ingredients both a Degronimid and one or more
other therapeutically or prophylactically active ingredients, 

  

	 	b)	 a combination therapy comprised of a Degronimid and one or more other therapeutically or prophylactically
active products, priced and sold in a single package containing such multiple products or packaged separately but sold together for a single price, or 

  

	 	c)	 a combination therapy comprised of a Degronimid and a Companion Diagnostic, priced and sold in a single package
containing such multiple products or packaged separately but sold together for a single price, 

 in each case, including all dosage
forms, formulations, presentations, line extensions, and package configurations. All references to Product in this Agreement shall be deemed to include Combination Product. 
  

	 	1.30	 Commercially Reasonable Efforts 

The term “Commercially Reasonable Efforts” shall mean [***]. 

[***]. 
  

	 	1.31	 Companion Diagnostic 

The term “Companion Diagnostic” shall mean any product or service that: 

(a) identifies a person having a disease or condition, or a molecular genotype or phenotype that predisposes a person to such disease or
condition, for which a Product could be used to treat and/or prevent such disease or condition; 
 (b) defines the prognosis or monitors the
progress of a disease or condition in a person for which a Product could be used to treat and/or prevent such disease or condition; 
 (c) is
used to select a therapeutic or prophylactic regimen, wherein at least [***] potential therapeutic or prophylactic regimen involves a Product, and where the selected regimen is determined, based on the use of such product or service, to
likely be effective and/or to be safe for a person; and/or 
 (d) is used to confirm a Product’s biological activity and/or to optimize
dosing or the scheduled administration of a Product. 

  
 - 11 - 

	 	1.32	 Competitor Company 

The term “Competitor Company” shall mean any pharmaceutical or biotechnology company having one or more programs in the field of oncology or
hematology. 
  

	 	1.33	 Completion 

The term “Completion” shall mean the availability of the final study report. 

 

	 	1.34	 Compulsory Sublicense Compensation 

The term “Compulsory Sublicense Compensation” shall mean, for a given country or region in the Territory, the compensation paid to Roche by a Third
Party (a “Compulsory Sublicensee”) under a license or sublicense of any applicable Patent Rights granted to the Compulsory Sublicensee (the “Compulsory Sublicense”) through the order, decree or grant of a
governmental authority having competent jurisdiction in such country or region, authorizing such Third Party to manufacture, use, sell, offer for sale, import or export a Degronimid or a Product in such country or region. 

 

	 	1.35	 Confidential Information 

The term “Confidential Information” shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical, oral or written, that is disclosed by one Party or its Affiliates (“Disclosing Party”) to the other Party or
its Affiliates (“Receiving Party”). Confidential Information shall not include any information, data or know-how that: 
  

	 	(a)	 was generally available to the public at the time of disclosure, or becomes available to the public after
disclosure by the Disclosing Party other than through fault (whether by action or inaction) of the Receiving Party or its Affiliates, 

  

	 	(b)	 can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior
to its receipt from the Disclosing Party, 

  

	 	(c)	 is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure,

  

	 	(d)	 is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than
through knowledge of Confidential Information, or 

  

	 	(e)	 is approved in writing by the Disclosing Party for release by the Receiving Party. 

The terms of this Agreement shall be considered Confidential Information of the Parties. 

 

	 	1.36	 Continuation Election Notice 

The term “Continuation Election Notice” shall mean the notice C4T provides to Roche under Section 21.3.1 describing (a) C4T’s bona
fide intentions to continue ongoing development and commercialization of Reversion Product and (b) C4T’s request for Roche’s continuation of activities during the termination period and/or transfer of the data, material and
information relating to the Reversion Products in accordance with Section 21.3.1. 
  

	 	1.37	 Control 

The term “Control” shall mean (as an adjective or as a verb including conjugations and variations such as “Controls” “Controlled”
or “Controlling”) (a) with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the possession by a Party of the ability to supply such
proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. For clarity, Controlled includes owned if the above requirements are satisfied. 

  
 - 12 - 

	 	1.38	 Cover 

The term “Cover” shall mean (as an adjective or as a verb including conjugations and variations such as “Covered,” “Coverage” or
“Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given compound, formulation or product would infringe a claim of a Patent Right upon issuance in the absence of a license
under or ownership in the Patent Rights to which such claim pertains. The determination of whether a compound, formulation, process or product is Covered by a particular claim shall be made on a country-by-country basis. 
  

	 	1.39	 Degronimid 

The term “Degronimid” shall mean, with respect to a Target, (a) a compound comprising (i) a moiety that binds to that particular Target
(“Target Binding Moiety”), (ii) a linker (“Linker”), and (iii) a moiety that binds to the E3 ligase cereblon or another E3 ligase, in possession of or Controlled by C4T or Roche (“E3 Ligase Binding
Moiety”), generated under a Research Plan, whose primary mechanism of action is, by design, degradation of such Target, or (b) any salt, polymorph, metabolite, Prodrug, isomer or stereoisomer of the compound in clause (a). The Target
Binding Moiety can be a Roche Compound, a compound identified by C4T that binds to Target, or compound identified in literature and agreed-upon by the Parties as part of the Research Plan, or any derivative thereof identified by C4T or Roche during
the execution of the Research Plan. For clarity, Target Binding Moiety and Degronimid exclude a separate Linker, a separate E3 Ligase Binding Moiety and a separate Linker bound to an E3 Ligase Binding Moiety. A listing of the Roche Patent Rights on
the E3 Ligase Binding Moiety as of the Restatement Date is attached as Appendix 1.39. 
  

	 	1.40	 “Detail” “Detailing” 

The term “Detail” or “Detailing” shall mean, with respect to a C4T Co-Dev Product, the
communication by a Sales Representative to a Prescriber during a sales call (a) involving face-to-face contact or, if permitted by the Co-Detailing Agreement, contact by means of an e-detail or video, (b) describing in a fair and balanced manner the FDA-approved
indicated uses and other relevant characteristics of such C4T Co-Dev Product, (c) using the Promotional Materials in an effort to inform Prescribers about a C4T
Co-Dev Product for its FDA-approved indicated uses, and (d) made at such Prescriber’s office, at another appropriate alternate care setting, or in any other
venue as described in the Co-Detailing Agreement and consistent with Applicable Law, the Co-Detailing Agreement and other industry standards. For the avoidance of doubt,
discussions at conventions or other scientific meetings shall not constitute “Details” or “Detailing”. 
  

	 	1.41	 Development Costs 

The term “Development Costs” shall mean [***]. 
  

	 	1.42	 Dose Range Finding Study 

The term “Dose Range Finding Study” shall mean a toxicology study performed with Degronimids having CLS Achieved to identify Products for which CCS
Criteria would be fulfilled. 
  

	 	1.43	 [***] 

The term “[***]” shall mean [***]. 

  
 - 13 - 

	 	1.44	 EU 

The term “EU” shall mean the European Union and all its then-current member countries. 

 

	 	1.45	 Expert 

The term “Expert” shall mean a person with no less than [***] of pharmaceutical industry experience and expertise having occupied at least
[***] within a large pharmaceutical company relating to product commercialization and/or licensing but excluding any current or former employee or consultant of either Party. Such person shall be fluent in the English language. 

 

	 	1.46	 FBMC 

The term “FBMC” shall mean the sum of: 

[***] 
  

	 	1.47	 FDA 

The term “FDA” shall mean the Food and Drug Administration of the United States of America. 

 

	 	1.48	 FDCA 

The term “FDCA” shall mean the Food, Drug and Cosmetics Act. 
  

	 	1.49	 Field 

The term “Field” shall mean any use. 
  

	 	1.50	 Filing 

The term “Filing” shall mean the filing of an application by the FDA as defined in the FDCA and applicable regulations, or the equivalent application
to the equivalent agency in any other country or group of countries, the official approval of which is required before any lawful commercial sale or marketing of Products. 
  

	 	1.51	 First Commercial Sale 

The term “First Commercial Sale” shall mean, on a country-by-country
basis, the first invoiced sale of a Product to a Third Party by the Roche Group following the receipt of any Regulatory Approval required for the sale of such Product, or if no such Regulatory Approval is required, the date of the first invoiced
sale of a Product to a Third Party by the Roche Group in such country. 
  

	 	1.52	 FTE 

The term “FTE” shall mean a full-time equivalent person-year, based upon a total of no less than [***] working hours per year, undertaken in
connection with the conduct of research in the Research Program. In no circumstance can the work of any given person exceed one (1) FTE. 
  

	 	1.53	 GAAP 

The term “GAAP” shall mean US Generally Accepted Accounting Principles. 
  

	 	1.54	 Generic Product 

The term “Generic Product” shall mean a product that is not produced, licensed or owned by the Roche Group that (a) contains a pharmaceutically
active ingredient that is the same Target Binding Moiety as present in the Degronimid in the Product, (b) contains an E3 ligase binding moiety, and (c) has the same or substantially the same labelling as the applicable Product for at least
one indication of such Product. 

  
 - 14 - 

	 	1.55	 GLP Data Package 

The term “GLP Data Package” shall mean a report of all data and results that are to be provided by C4T to Roche at completion of the GLP Tox Studies
for a Product (containing all data and results generated under the Research Plan with respect to such Product), such compilation shall comprise a study report either generated by C4T or the contract research organization covered by guidelines for
GLP Tox Studies, the CTD (Common Technical Data) table of such report as a separate word document, the SEND (Standard for Exchange of Nonclinical Data) dataset to accompany the final study report, and an independent pathology peer review. 

 

	 	1.56	 GLP Tox Study 

The term “GLP Tox Study” shall mean a toxicology study of the relationship between dose and its effects on the exposed animal, where (a) the
study is to be conducted in accordance with GLP standards and (b) the study has been designed in expectation that the results may support establishment of a safe starting dose of the Product in Clinical Studies. 

 

	 	1.57	 Handle 

The term “Handle” shall mean preparing, filing, prosecuting (including interference and opposition proceedings) and maintaining (including
interferences, reissue, re-examination, post-grant reviews, inter-parties reviews, derivation proceedings and opposition proceedings), including discontinuing or abandoning Patent Rights. 

 

	 	1.58	 HSR 

The term “HSR” shall mean the Hart-Scott-Rodino Antitrust Improvements Act. 

 

	 	1.59	 ICD-10 

The term “ICD-10” shall mean the Tenth Revision of the International Classifications of Diseases and Related
Health Problems, as may be revised or amended from time to time, or a successor classification. 
  

	 	1.60	 IFRS 

The term “IFRS” shall mean International Financial Reporting Standards. 
  

	 	1.61	 IND 

The term “IND” shall mean an application as defined in the FDCA and applicable regulations promulgated by the FDA, or the equivalent application to
the equivalent agency in any other country or group of countries, the filing of which is necessary to commence clinical testing of the Products in humans. 
  

	 	1.62	 Indication 

The term “Indication” shall mean a distinct type of disease or medical condition in humans to which a Product is directed and eventually
approved. [***] 
  

	 	1.63	 Initiation 

The term “Initiation” shall mean the date that a (a) an animal is first dosed with the Product in a GLP Tox Study, or (b) a human is
first dosed with the Product in a Clinical Study approved by the respective Regulatory Authority, as applicable. 

  
 - 15 - 

	 	1.64	 Insolvency Event 

The term “Insolvency Event” shall mean circumstances under which a Party (a) has a receiver or similar officer appointed over all or a material
part of its assets or undertaking; (b) passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent
amalgamation or reconstruction) or a court makes an order to that effect or a court makes an order for administration (or any equivalent order in any jurisdiction); (c) enters into any composition or arrangement with its creditors (other than
relating to a solvent restructuring); (d) ceases to carry on business; (e) is unable to pay its debts as they become due in the ordinary course of business. 
  

	 	1.65	 Invention 

The term “Invention” shall mean an invention that is conceived and reduced to practice in connection with any activity carried out pursuant to this
Agreement. Under this definition, an Invention may be made by employees of C4T solely or jointly with a Third Party (a “C4T Invention”), by employees of the Roche Group solely or jointly with a Third Party (a “Roche
Invention”), or jointly by employees of C4T and employees of the Roche Group with or without a Third Party (a “Joint Invention”). 
  

	 	1.66	 Joint Know-How 

The term “Joint Know-How” shall mean Know-How that is made jointly by
the Parties or their Affiliates or their Sublicensees in connection with any activity carried out pursuant to this Agreement. 
  

	 	1.67	 Joint Patent Rights 

The term “Joint Patent Rights” shall mean all Patent Rights Covering a Joint Invention. 

 

	 	1.68	 JOT 

The term “JOT” shall mean a joint operating team established by the JRC under Section 11.7 or by the JDC under Section 11.10. 

 

	 	1.69	 JRC 

The term “JRC” shall mean the joint research committee described in Article 9. 

 

	 	1.70	 Know-How 

The term “Know-How” shall mean data, knowledge and information, including materials, samples, chemical
manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development or
commercialization of Degronimids or Products. 
  

	 	1.71	 Lead Identification 

The term “Lead Identification” shall mean preclinical development activities performed with respect to each Target with the goal to identify
Degronimids with LSI Achieved. 
  

	 	1.72	 Lead Optimization 

The term “Lead Optimization” shall mean the preclinical development activities performed for each Target following Lead Identification, with the goal
to identify Degronimids suitable for GLP Tox Studies and satisfying CCS Criteria for such Target. 

  
 - 16 - 

	 	1.73	 LSI Achieved 

The term “LSI Achieved” means that a Degronimid for a Target meets the lead series identification criteria as set forth in the [***] Research
Plan attached as Appendix 1.7394 or (b) set forth in any future Research Plan approved by the JRC (“LSI Criteria”). 
  

	 	1.74	 Major Countries 

The term “Major Countries” shall mean USA, Canada, UK, Germany, France, Italy, and Spain. 

 

	 	1.75	 NDA 

The term “NDA” shall mean a new drug application, including all necessary documents, data, and other information concerning a Product, required for
Regulatory Approval of the Product as a pharmaceutical product by the FDA or an equivalent application to the equivalent agency in any other country or group of countries (e.g. the marketing authorization application (MAA) in the EU). 

 

	 	1.76	 Net Sales 

The term “Net Sales” shall mean [***]. 
  

	 	1.77	 New Target 

The term “New Target” shall mean any target not included among the [***] Targets selected by Roche and listed in Appendix 1.114, and shall
include any protein identified by its UniProt number, including all splice variants, mutants, natural variants, etc. reasonably associated with such UniProt number; but excluding the target BRD4 that is reserved for C4T. 

 

	 	1.78	 Original Product 

The term “Original Product” shall mean with respect to a particular Target, a Product subject to the Roche Option Right but for which Roche has not
yet exercised such Roche Option Right. An Original Product for which the Roche Option Right is designated by the Parties under Section 4.1.6 to be one for which Roche can exercise the Roche Option Right upon receipt of the Phase I Data Package
is a “Phase I Completed Original Product”. As of the Restatement Date, Products directed to [***] are deemed Phase I Completed Original Products. For clarity, an Original Product (including a Phase I Completed Original
Product) for which Roche exercises the Roche Option Right ceases to be an Original Product (or, if applicable, a Phase I Completed Original Product) as of the time the Roche Option Right is exercised. 

 

	 	1.79	 Out of Pocket Costs 

The term “Out of Pocket Costs” shall mean direct expenses incurred by either Party or its Affiliates to Third Parties, including payments to contract
personnel (including contractors, consultants, contract research organizations and subcontractors). 
  

	 	1.80	 Party 

The term “Party” shall mean C4T or Roche, as the case may be, and “Parties” shall mean C4T and Roche collectively. 

 

	 	1.81	 Patent Rights 

The term “Patent Rights” shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing
on such patent application, and further including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or
continuation-in-part of any of the foregoing. 

  
 - 17 - 

	 	1.82	 Pharmacovigilance Agreement 

The term “Pharmacovigilance Agreement” shall mean an agreement entered into by the Parties to set forth the responsibilities and obligations of the
Parties with respect to the procedures and timeframes for compliance with Applicable Laws pertaining to safety of a Product and its related activities. 
  

	 	1.83	 Phase I Data Package 

The term “Phase I Data Package” shall mean a report of all data and results that are to be provided by C4T to Roche at completion of the Phase I
Study (containing all data and results generated through completion of the Phase I Study for such Phase I Completed Original Product). For each Target, the report will address the categories of information (including the criteria within such
categories) for a Product in accordance with the Phase I Plan with respect to such Target as set forth in Appendix 1.83. The final criteria within such categories will be determined on a Target-by-Target basis and finalized by the Parties prior to the filing of the first IND for such Target. C4T shall also provide Roche with access to the clinical study database comprising the data in a
reasonably clean and organized format. 
  

	 	1.84	 Phase I Plan 

The term “Phase I Plan” means, for a Phase I Completed Original Product, a plan describing the performance of the Phase I Study for such Phase I
Completed Original Product, which is prepared jointly by C4T and Roche and approved by the JDC. 
  

	 	1.85	 Phase I Study 

The term “Phase I Study” shall mean a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA),
as amended from time to time, and the foreign equivalent thereof. 
  

	 	1.86	 Phase II Study 

The term “Phase II Study” shall mean a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a
preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof. 

 

	 	1.87	 Phase III Study 

The term “Phase III Study” shall mean a human clinical trial that is prospectively designed to demonstrate statistically whether a
product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from
time to time, and the foreign equivalent thereof. 
  

	 	1.88	 Pivotal Clinical Study 

The term “Pivotal Clinical Study” shall mean (a) a Phase III Study, or (b) any other Clinical Study that is designed to establish that a
pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, and which Clinical Study is
intended to be sufficient for filing an application for a Regulatory Approval for the Product in the U.S. 

  
 - 18 - 

	 	1.89	 Prescriber 

The term “Prescriber” shall mean physicians and other health care professionals who are permitted by Applicable Law to prescribe C4T Co-Dev Products. 
  

	 	1.90	 Prodrug 

The term “Prodrug” shall mean a compound that is initially administered to the body in an inactive (or less than fully active) form, and then becomes
converted to its active form through the normal metabolic processes of the body and non-metabolic processes such as pH or hydrolysis driven cleavage processes and intrinsic cleavage based on an internal
cyclization-cleavage mechanism. 
  

	 	1.91	 Product 

The term “Product” shall mean any pharmaceutical product or other product for use in the Field that contains a Degronimid. Products include Original
Products, including Phase I Completed Original Products, Roche Products and C4T Co-Dev Products (Roche Products and C4T Co-Dev Products are collectively referred to as
“Licensed Products” and a Roche Product or a C4T Co-Dev Product alternatively is referred to as a “Licensed Product”) . 

 

	 	1.92	 Promotional Materials 

The term “Promotional Materials” shall mean all written, printed, graphic, electronic, audio or video matter, including without limitation journal
advertisements, sales visual aids, leave-behind items, formulary binders, reprints, direct mail, direct-to-consumer advertising, internet postings and sites and
broadcast advertisements intended for use or used by or on behalf of either Party or their respective Affiliates in connection with any promotion of a C4T Co-Dev Product for which C4T has exercised the C4T Co-Detail Option Right pursuant to Section 3.1.3. 
  

	 	1.93	 Regulatory Approval 

The term “Regulatory Approval” shall mean any approvals (including pricing and reimbursement approvals), licenses, registrations or
authorizations by Regulatory Authority, necessary for the manufacture and sale of a Product in the Field in a regulatory jurisdiction in the Territory. 
  

	 	1.94	 Regulatory Authority 

The term “Regulatory Authority” shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the
European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of Regulatory Approval for the Product. 

 

	 	1.95	 Research Plan 

The term “Research Plan” shall mean, for each Target, a detailed research plan describing preclinical research and development activities up to and
including [***]. The Research Plans for Products directed to [***] is attached as Appendix 1.95. For clarity, this Agreement does not need to be amended if the JRC modifies any Research Plan. 

 

	 	1.96	 Research Program 

The term “Research Program” shall mean, for each Target, the activities undertaken by the Parties pursuant to the Research Plan for that Target to
identify and test Degronimids, and such other activities as the Parties may agree in writing. 

  
 - 19 - 

	 	1.97	 Research Term 

The term “Research Term” shall mean the period of time in which the activities under the Research Plans shall be conducted, commencing on the
Effective Date and continuing until [***] unless terminated earlier pursuant to the terms and conditions of this Agreement. 
  

	 	1.98	 Restatement Date 

The term “Restatement Date” shall mean [***]. 
  

	 	1.99	 Reverted Target 

The term “Reverted Target” shall mean (a) a Target for which Roche did not exercise its Roche Option Right within the applicable Roche Option
Period, including any target that became a Target pursuant to Section 4.1.3, and (b) any Terminated Target. 
  

	 	1.100	 Roche Compound 

The term “Roche Compound” shall mean any compound that (i) is Covered by Roche IP, (ii) is provided by Roche to C4T for use in a Research
Plan or Phase I Plan, and (iii) binds to a Target (including any Target Binding Moiety that contains or incorporates any such compound). Roche shall be free to use Roche Compounds for research, development and commercialization efforts outside
this Agreement. 
  

	 	1.101	 Roche Group 

The term “Roche Group” shall mean collectively Roche, its Affiliates and its Sublicensees. 

 

	 	1.102	 Roche IP 

The term “Roche IP” shall mean Roche Know-How and Roche Patent Rights. 

 

	 	1.103	 Roche Know-How 

The term “Roche Know-How” shall mean all Know-How that Roche Controls
at the Effective Date and during the Agreement Term related to Roche Compounds, Products, or activities conducted under this Agreement. 
  

	 	1.104	 Roche Option Period 

The term “Roche Option Period” shall mean, with respect to [***], the period beginning upon [***], and ending upon the earliest of
[***]. Such report shall contain the information as described in Appendix 1.103. 
 The Roche Option Period for any Target other than [***]
means the period beginning upon [***], as applicable, and ending upon the earliest of [***]. The procedure for designating an Original Product as a Phase I Completed Original Product is outlined in Section 4.1.6, subject to the
escalation procedure in Section 11.5.3. 
  

	 	1.105	 Roche Option Right 

The term “Roche Option Right” shall mean, with respect to a Target, Roche’s right to obtain a commercial license under Section 2.1.2. 

 

	 	1.106	 Roche Patent Rights 

The term “Roche Patent Rights” shall mean all Patent Rights that Roche Controls during the Agreement Term Covering a Roche Compound or Product that
are required to conduct research in accordance with a Research Plan or to allow C4T to conduct its activities in connection with the exercise of the C4T Co-Dev Option Right or the C4T Co-Detail Option Right. The term 

  
 - 20 - 

 
Roche Patent Rights shall include Roche’s interest in the Collaboration Patent Rights. For purposes of clarity, the Patent Rights identified in Appendix 1.106(a) (“Excluded
Patent Rights”) are specifically excluded from the Roche Patent Rights. The Patent Rights identified in Appendix 1.106(b) are the Roche Patent Rights as of the Restatement Date. 

 

	 	1.107	 Roche Product 

The term “Roche Product” shall mean, with respect to a particular Target, (a) an Original Product or (b) Phase I Completed Original Product
for which Roche has exercised the Roche Option Right and C4T has not exercised its C4T Co-Dev Option Right, if applicable, to convert this Product into a C4T Co-Dev
Product, or a C4T Co-Dev Product for which C4T has exercised its Opt-Out under Section 6.3.5. 

 

	 	1.108	 Royalty Term 

The term “Royalty Term” shall mean, with respect to a Licensed Product, and for a given country, the period of time commencing on the date of First
Commercial Sale of the Licensed Product in such country and ending on the later of the date that is (a) [***] after the date of the First Commercial Sale of the Licensed Product in such country, or (b) the expiration of the last to
expire Valid Composition of Matter Claim in such country Covering the use, offering for sale, or sale of the Licensed Product,. [***] 
  

	 	1.109	 Sales 

The term “Sales” shall mean, for a Product in a particular period, the sum of (a) and (b): 

(a) [***]. 
  

	 	1.110	 Sales Representatives 

The term “Sales Representatives” shall mean a pharmaceutical sales representative who is trained with respect to the C4T Co-Dev Products, including its labeling and Promotional Materials, engaged or employed by either Party (as permitted hereunder) to conduct Detailing with respect to the C4T
Co-Dev Products in accordance with the terms of this Agreement and the Co-Detailing Agreement. 
  

	 	1.111	 [***] 

The term “[***]” shall mean [***]. 
  

	 	1.112	 Sublicensee 

The term “Sublicensee” shall mean an entity to which C4T or Roche, as applicable has licensed rights (through one or multiple tiers), other than
through a Compulsory Sublicense, pursuant to this Agreement. 
  

	 	1.113	 Tactical Plan 

The term “Tactical Plan” shall mean [***] or more plans detailing the activities to be performed by each Party in the Co-Detail Territory and the amount of cost to be incurred and anticipated resources to be used during a given Calendar Year period. 
  

	 	1.114	 Target 

The term “Target” shall mean each of the [***] targets selected by Roche a listing of which as of the Restatement Date is in Appendix 1.114,
subject to the target exchange provisions of Section 4.1.3, and shall include any protein identified by its UniProt number, including all splice variants, mutants, natural variants, etc. reasonably associated with such UniProt number. 

  
 - 21 - 

	 	1.115	 Territory 

The term “Territory” shall mean [***]. 
  

	 	1.116	 Third Party 

The term “Third Party” shall mean a person or entity other than (i) C4T or any of its Affiliates or (ii) a member of the Roche Group. 

 

	 	1.117	 US 

The term “US” shall mean the United States of America and its territories and possessions. 

 

	 	1.118	 US$ 

The term “US$” shall mean US dollars. 
  

	 	1.119	 Valid Claim 

The term “Valid Claim” shall mean [***]. 
  

	 	1.120	 Valid Composition of Matter Claim 

The term “Valid Composition of Matter Claim” shall mean, for a given Product in a given country of the Territory, a Valid Claim that claims the
Degronimid per se that is included in such Product. 
  

	 	1.121	 Additional Definitions 

Each of the following definitions is set forth in the Section of this Agreement indicated below: 

 

			
	 Definition
	  	 Section

	“Accounting Period”	  	13.1
	“Acquired Party”	  	21.2.3
	“Alliance Director”	  	11.6
	“Allowable Exception”	  	12.5
	“Arbitral Tribunal”	  	23.7.1
	“Bankruptcy Code”	  	22
	“Breaching Party”	  	21.2.1
	“C4T Co-Detail Option Right”	  	3.1.3
	C4T Exclusivity Obligations	  	2.1.3
	“C4T Invention”	  	1.65
	“Chairperson”	  	11.2
	“Co-Detailing Agreement”	  	8.2.1
	“Co-Detail Opt-Out	  	8.2.5
	“Compulsory Profit Share Percentage”	  	12.12.3
	“Compulsory Sublicense”	  	1.34
	“Compulsory Sublicensee”	  	1.34
	“Decision Period”	  	16.5
	“Deferrable Amount”	  	6.3.3
	“degronimid”	  	2.1.1
	“Development Plan”	  	6.3.2
	“DFCI”	  	2.1.7
	“Disclosing Party”	  	1.35
	“E3 Ligase Binding Moiety”	  	1.39
	“Excluded Patent Rights”	  	1.106
	“Expert Committee”	  	12.12.2.1

  
 - 22 - 

			
	 Definition
	  	 Section

	Exploit	  	2.1.2
	“Funding Reduction Notice”	  	6.3.5
	“H-W Suit Notice”	  	16.11
	“Indemnified Party”	  	18.3
	“Indemnifying Party”	  	18.3
	“Initial Payment”	  	12.1
	“Initiating Party”	  	16.5
	“JCC”	  	11.12
	“JDC”	  	11.9
	“Joint Invention”	  	1.65
	“Licensed Product”	  	1.91
	“Licensed Products”	  	1.91
	“Linker”	  	1.39
	“Members”	  	11.2
	“Net Sales Threshold”	  	12.11
	“Non-Acquired Party”	  	21.2.3
	“Non-Breaching Party”	  	21.2.1
	“Research Funding”	  	12.2
	“Roche Option Exercise Fee”	  	12.4
	“Roche Option Exercise Period”	  	3.1.2
	“Opt-Out”	  	6.3.5
	“Patent Term Extensions”	  	16.12
	“Payment Currency”	  	13.3
	“Peremptory Notice Period”	  	21.2.1
	“Phase I Completed Original Product	  	1.78
	“Publishing Notice”	  	20.5
	“Publishing Party”	  	20.5
	“Receiving Party”	  	1.35
	“Register”	  	16.6
	“Relative Commercial Value”	  	12.12.2.1
	“Reversion Products”	  	21.3.1
	“Roche Invention”	  	1.65
	“Sensitive Information”	  	21.2.3
	“Settlement”	  	16.5
	“Shared Development Cost Budget”	  	6.3.2
	“SPCs”	  	16.12
	“Suit Notice”	  	16.5
	“Supply Agreement”	  	7.1
	“Target 4”	  	4.1.2
	“Target 5”	  	4.1.2
	“Target 6”	  	4.1.2
	“Target Binding Moiety”	  	1.39
	“Technology Transfer”	  	7.3
	“Terminated Target”	  	21.3.1
	“Unavailable Target”	  	4.1.3

  
 - 23 - 

 2. Grant of Licenses and Exclusivity 

 

	 	2.1	 Licenses 

  

	 	2.1.1	 Research Cross License 

Roche hereby grants to C4T a non-exclusive license under Roche IP necessary or useful for C4T to perform its research
activities under the Research Plan or Phase I Plan during the Research Term and the term of the Phase I Plan, as applicable. C4T grants to Roche a non-exclusive license under C4T IP and C4T Patent Rights to
(a) perform research on degronimids (when not capitalized the term “degronimid” means a Degronimid but the target is not limited to a Target and it need not be generated under a Research Plan), (b) perform its research activities, if
any, under this Agreement, (c) select and optimize Degronimids developed under a Research Plan and Phase I Plan as applicable, (d) generate Products including the Degronimids referenced in clause (c), and (e) perform any activities
authorized under Section 21.3.3. 
  

	 	2.1.2	 Commercial License 

Effective upon Roche exercising its Roche Option Right under Section 3.1.2 with regard to a Target and paying the applicable Roche Option Fee, C4T hereby
grants Roche for such Target an exclusive (even as to C4T but subject to C4T having the right to perform the activities described in (a) this Agreement that are associated with the exercise of the C4T
Co-Dev Option Right and exercise of the C4T Co-Detail Option Right, (b) a Supply Agreement, and (c) a Co-Detailing
Agreement) license, including the right to sublicense through multiple tiers, under C4T IP and C4T Patent Rights to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have
imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold (collectively, “Exploit”) Licensed Products relating to such Target in the Field in the Territory. 

Effective upon the Restatement Date, C4T hereby grants Roche an exclusive license, including the right to sublicense through multiple tiers, under C4T IP and
C4T Patent Rights to Exploit products that contain a Target Binding Moiety and are not Licensed Products in the Field in the Territory. 
 Subject to C4T
exercising its C4T Co-Dev Option Right with respect to the applicable Target as set forth in Section 3.1.2, Roche hereby grants to C4T a non-exclusive right and
license under the Roche IP to perform its activities under the Development Plan. 
 Subject to C4T exercising its C4T
Co-Detail Option Right with respect to the applicable Target as set forth in Section 3.1.3, Roche hereby grants to C4T a non-exclusive right and license under the
(i) Roche Know How and (ii) Patent Rights Controlled by Roche, in each case, that are necessary or useful for C4T to perform its activities pursuant to the Co-Detailing Agreement for C4T or its
Affiliates to perform its activities pursuant to the Co-Detailing Agreement. 
  

	 	2.1.3	 Commercial License Following Research Program Initiation 

Beginning on the date the [***] Research Program is initiated, C4T hereby grants to Roche a non-exclusive, non-revocable, royalty-free license, including the right to sublicense through multiple tiers, under C4T IP and C4T Patent Rights generated after the Effective Date to Exploit products, directed solely to targets
that are not subject to any obligation of exclusivity by C4T with respect to any Third Party license in existence as of the Restatement Date or entered into 

  
 - 24 - 

 
in the field of [***] within [***] after the Restatement Date (“C4T Exclusivity Obligations”), that contain degronimids that are not Licensed Products in the Field
in the Territory. Roche shall confer with a Third Party designated by C4T to hold the information on targets subject to the C4T Exclusivity Obligations before exploiting any such C4T IP or C4T Patent Rights in research directed to a particular
target to ensure that such target is not subject to the C4T Exclusivity Obligations. The Third Party designated by C4T shall not communicate to C4T the identity of the targets discussed. 

 

	 	2.1.4	 Freedom of Operation 

C4T hereby grants to the Roche Group and its collaborators freedom to operate under all unpatented C4T Know-How and
hereby covenants not to bring legal action of any type or nature against any member of the Roche Group or its collaborators with respect to the use of unpatented C4T Know-How. 

 

	 	2.1.5	 Right to Subcontract 

Either Party shall have the right to subcontract the work performed under this Agreement; provided that such Party will remain responsible to the other Party
for the performance of such work. 
  

	 	2.1.6	 Conditions to Sublicense 

Either Party’s right to sublicense through multiple tiers shall be conditioned on its Sublicensees, through each tier, agreeing to be bound by the
applicable provisions of this Agreement. In addition, the sublicensing Party shall forward to other Party a copy of any and all fully executed sublicenses with Third Parties that are not Affiliates or Chugai (in the case of Roche). Such copy may be
redacted with regard to financial terms and confidential information of such Sublicensee and shall be postmarked within [***] after the execution of the sublicense. 
  

	 	2.1.7	 Reserved Rights 

Except as explicitly set forth in this Agreement, neither Party grants to the other Party any license, express or implied, under its intellectual property
rights. The license granted or to be granted by C4T under the C4T IP existing as of the Effective Date is subject to the following reserved rights: 
  

	 	1.	 Rights of the United States of America, as set forth in Public Laws
96-517 and 98-620, the regulations promulgated thereunder, and the policy of any funding agencies. Any rights granted hereunder, which are greater than permitted by
Public Laws 96-517 and 98-620, are subject to modification as required to conform to the provisions of those statutes. 

 

	 	2.	 The right of the Dana Farber Cancer Institute (“DFCI”) to use the C4T IP existing as of the
Effective Date for internal, non-clinical, teaching, education and basic research purposes; provided, however, that in no event shall they be used for any drug discovery activities or commercial activities of
any kind, or for use in the treatment, diagnosis or prevention of any human diseases or conditions. 

  

	 	3.	 DFCI’s right to grant non-exclusive, non-transferable licenses to use the C4T IP existing as of the Effective Date to other academic, governmental or not-for-profit
organizations for non-commercial, internal, basic research purposes (but in no case when sponsored by any for-profit entity) and not for use in human subjects, clinical
trials or for diagnostic purposes involving human subjects. 

  
 - 25 - 

	 	2.2	 Exclusivity 

With respect to a given Target, C4T shall work exclusively with Roche from the Effective Date until [***]. If the maximum number of Target replacements
have occurred as provided for in Section 4.1.3, then the exclusivity provisions regarding the [***] Target set forth in this Section 2.2 shall be waived. 

3. Option of Roche 
  

	 	3.1	 Option Right 

  

	 	3.1.1	 Grant of Roche Option Right 

C4T hereby grants to Roche an exclusive Roche Option Right for each Target to obtain an exclusive (even as to C4T subject to C4T’s rights in the event C4T
exercises its Co-Dev Option Right and/or Co-Detail Option Right)) license, including the right to sublicense through multiple tiers, under C4T IP and C4T Patent Rights
to Exploit Products relating to such Target in the Field in the Territory. 
  

	 	3.1.2	 Grant of C4T Co-Dev Option Right 

Roche hereby grants to C4T an option to co-develop Roche Products relating to [***] or any Target from the C4T
Pipeline as set forth in Section 4.1.3 (“C4T Co-Dev Option Right”). On a Target-by-Target basis, C4T shall
have the right to exercise the C4T Co-Dev Option Right by giving a written notice prior to the end of the C4T Co-Dev Option Period for such Target to Roche. The C4T Co-Dev Option Right to convert a Roche Product into a C4T Co-Dev Product is applicable to a Roche Product that was originally a Phase I Completed Original Product or to an
Original Product for which the start of the Roche Option Period is the receipt of the GLP Data Package. For clarity, as of the Restatement Date, Products directed to [***] are considered C4T Co-Dev
Products and no exercise of the C4T Co-Dev Option Right is required. 
  

	 	3.1.3	 Grant of C4T Co-Detail Option Right 

Roche hereby grants to C4T an option to co-detail C4T Co-Dev Products relating
to a Target originating from the C4T Pipeline using C4T Sales Representatives fully dedicated (for [***] from the First Commercial Sale) to the C4T Co-Dev Product in the
Co-Detail Territory (“C4T Co-Detail Option Right”). On a
Target-by-Target basis, C4T shall have the right to exercise the C4T Co-Detail Option Right by giving a written notice during the
C4T Co-Detail Option Period for such Target to Roche. C4T must establish a sales infrastructure and hire Sales Representatives at least [***] prior to the anticipated First Commercial Sale of the first Co-Dev Product directed to the Target for which the C4T Co-Detail Option Right relates, or such other time period as may be agreed upon by the JCC. 

 

	 	3.1.4	 Exercise of Roche Option Right 

Roche shall have the right to exercise the Roche Option Right for each Target for which a Research Plan has been initiated during the Roche Option Period for
such Target by giving a written notice prior to the end of the Roche Option Period for such Target to C4T and paying the corresponding Roche Option Exercise Fee within [***] after exercise of the Roche Option Right and receipt by Roche of an
invoice from C4T. 

  
 - 26 - 

	 	3.1.5	 Rights if Roche does not exercise a Roche Option 

For any Target to which Roche does not timely exercise its Roche Option Right, effective as of the expiration of the Roche Option Period for such Target,
(a) all research and development activities under this Agreement with respect to such Target shall terminate, (b) such Target shall become a Reverted Target, (c) C4T shall retain all rights, title and interest in and to all Original
Products for such Target, (d) all rights and obligations (including the licenses to Roche) under this Agreement with respect to such Target shall terminate, and (e) the following rights and licenses shall apply: 

3.1.5.1 Roche Know-How/Target License 

If and to the extent that any Roche Know-How is necessary for C4T to conduct its internal research activities related
to the Reverted Target, Roche hereby grants to C4T a fully-paid up, non-exclusive, worldwide license under such Roche Know-How solely for such purpose (which license C4T
may sublicense to Affiliates, collaborators and service providers solely for such purpose, including for any collaboration). To the extent a broader license is desirable by C4T, Roche and C4T will discuss in good faith the terms and conditions for
C4T to obtain either a non-exclusive or exclusive, worldwide license (with the right to sublicense through multiple tiers) under such Roche Know-How, to research,
develop, manufacture, commercialize and otherwise exploit such Reverted Target. 
 3.1.5.2 Collaboration Patent Rights License 

Roche hereby grants to C4T a fully-paid up, non-exclusive, worldwide license under Roche’s interest in
Collaboration Patent Rights related to the Reverted Target for any and all purposes, which license may be sublicensed through multiple tiers to C4T’s Affiliates, collaborators and service providers.] 

 

	 	3.2	 Data Reporting, Due Diligence and License Right 

 

	 	3.2.1	 Data reporting 

C4T shall keep Roche apprised of the status of all activities under each Research Plan using the templates agreed upon under the Original Agreement and
Development Plan, and provide Roche with access to any data generated under each Research Plan or Development Plans requested by the JRC or JDC, as applicable. Throughout the Research Term for a given Target, C4T shall provide a list of all
Degronimids made under such respective Research Plan and their chemical structures. 
  

	 	3.2.2	 Due Diligence 

Roche shall have the right to perform due diligence within [***] after receipt of the report on the Dose Range Finding Studies (in case of Products
directed to [***]), the GLP Data Package or Phase I Data Package (in case of Products directed to [***]), as applicable. During such [***], representatives of Roche shall have the opportunity to ask questions of and receive
answers from representatives of C4T related to the Degronimids, and the Research Program or Phase I Plan and data generated therein. C4T shall respond to Roche’s inquiries in a timely fashion and without delay and shall not withhold any
material information from Roche in response to Roche’s inquiries. Roche shall also have the right to perform in vitro and or in vivo preclinical testing of Degronimids having CLS Achieved or meeting CCS Criteria during Dose Range
Finding Studies or GLP Tox Studies for the purpose of verifying Degronimid properties for the purpose of exercising the Roche Option Right. 

  
 - 27 - 

	 	3.2.3	 License Rights 

If Roche exercises its Roche Option Right in accordance with Section 3.1.2, then the commercial license as set forth in Section 2.1.2 shall
immediately come into effect. 
 4. Research Collaboration 
  

	 	4.1	 Conduct of the Research Program 

 

	 	4.1.1	 Scope 

C4T shall conduct mutually agreed activities pursuant to a Research Plan for each Target. The activities conducted in connection with each Research Program
will be overseen by the JRC. The purpose of each Research Plan is to set forth activities designed to discover, generate, engineer and characterize Degronimids. A Research Plan starts with Lead Identification activities. 

 

	 	4.1.2	 Target Selection and Research Plan Initiation 

As of the Restatement Date, Roche has selected [***] Targets, namely [***]. Research Plans for these [***] Targets have been approved by
the JRC and research is being conducted. As of the Restatement Date, [***] is the most advanced program and has passed LSI Achieved. Roche (via the JRC) will select additional Targets for which to initiate Research Plans (up to a total of
[***] Research Plans). Roche may select such additional Targets in any order and shall thereafter together with C4T (via the JRC) establish Research Plans for approval by the JRC and initiate Research Plans as follows: 

[***] 
  

	 	4.1.3	 Target Exchange 

A Target may be exchanged as long as a Research Plan has not been initiated or, if a Research Plan has been initiated, prior to completion of such Research
Program (i.e., either prior to (a) in the case of [***] the completion of Dose Range Finding Studies or (b) in case of any other Target completion of the GLP-Tox Study). Roche may exchange
such Target with (i) another Target from the pool of [***] Targets listed in Appendix 1.114, (ii) any target outside the C4T Pipeline, or (iii) a target within the C4T Pipeline in addition to the Target [***], in case of
(ii) and (iii) provided such target is not an Unavailable Target. 
 A Target may be exchanged more than once. However, the total number of Target
exchanges is capped at [***], provided, however that from and after initiation of the Research Plan for Target [***], Roche shall not be permitted to exchange Target [***] more than [***] (or [***] if Roche has
already used the [***] Target exchanges). Roche may at its discretion choose [***] from the C4T Pipeline (not counting [***]), and any additional target selection from the C4T Pipeline requires the Parties mutual consent. Such
Target exchange and updated Target list shall be documented by written minutes of a JRC meeting and shall replace the list in Appendix 1.114 as per the Restatement Date. Once a Target pursued under a Research Program is exchanged, it shall become a
Terminated Target. If a Target not pursued under a Research Program is exchanged, it does not become a Terminated Target, and shall cease to be a Target. 

  
 - 28 - 

 A Target is considered not available at the time of Roche’s request if (a) it is a target from the
C4T Pipeline that has reached LSI Achieved, (b) C4T has at least begun the process of licensing such target to a Third Party as evidenced by having has generated a mutually agreed term sheet with such Third Party in relation to the target and
is in active negotiations toward a definitive license agreement, or (c) it is a target subject to C4T’s partnership with a Third Party and is exclusively licensed (“Unavailable Target”). If a target is not available at the
time of Roche’s request, then C4T shall promptly inform Roche if such target becomes available, including the target BRD4. 
  

	 	4.1.4	 Research Plan 

Unless decided otherwise by the JRC, the Research Plan for each Target will be updated annually and approved by the JRC. The Research Plan will set forth
(a) the activities and the resources that will be dedicated, (b) specific objectives for each year, which objectives as proposed to the JRC by the JOT will be approved, if appropriate, by the JRC as research progresses, and
(c) budgets for such activities, including the Shared Development Cost Budget for Dose Range Finding Studies and GLP Tox Studies which are Development Costs under the Research Program. The JRC shall review the Research Plan and Phase I Plan on
an ongoing basis and may amend the Research Plan to reflect the updated or amended objectives and the progress made, subject to JRC approval. Any such changes shall be reflected in written amendments to the Research Plan for each Target. Unless
otherwise set forth in a Research Plan, C4T shall be responsible for conducting the activities in Lead Identification and Lead Optimization and Dose Range Finding Studies for all Targets as well as GLP Tox Studies for any Target except for
[***]. 
  

	 	4.1.5	 Lead Identification 

C4T shall be solely responsible for Lead Identification following the JRC’s approval of the applicable Research Plan, advancing Degronimids with LSI
Achieved properties using C4T Technology, in vitro biology assays, in vivo pharmacology animal studies addressing PK/PD relationships and efficacy in relevant animal disease models, and in vitro ADME and safety methods. 

 

	 	4.1.6	 Lead Optimization 

C4T shall be solely responsible for Lead Optimization following the JRC’s determination that LSI Achieved has been reached for a given Target. C4T shall
use Commercially Reasonable Efforts to advance Collaboration Compounds to CLS Achieved using C4T Technology, and in vivo pharmacology animal studies addressing PK/PD relationships and efficacy in relevant animal disease models as well as
minitox studies, and in vitro ADME and safety methods. Finally C4T shall undertake Dose Range Finding Studies and other studies and in vitro investigations as required to identify Degronimids meeting the CCS Criteria. 

 

	 	4.1.7	 Designation of Phase I Completed Original Product 

For all Targets other than [***], upon CLS Achieved for such Target, the Parties through the JRC shall mutually agree on whether the start of the Roche
Option Period for such Target is upon receipt of the GLP Data Package, deeming the corresponding Product an Original Product, or upon receipt of the Phase I Data Package, deeming the corresponding Product a Phase I Completed Original Product. (For
clarity, Products directed to [***] are considered a Phase I Completed Original Product as of the Restatement Date, and Products directed to [***] are considered Original Products as of the Restatement Date and are not subject to the
designation procedure in this section). 

  
 - 29 - 

	 	4.1.8	 GLP Tox Study 

Except for Products directed to [***], C4T shall be solely responsible for the conduct of GLP Tox Studies in a rodent and
non-rodent species using a CRO approved by the Parties and listed on Appendix 4.1.8) following the JRC’s determination that CCS Achieved has been reached for a Degronimid for a given Target. A GLP Tox
Study shall be started for a Product containing a Degronimid for which the JRD has determined that CCS Achieved has been reached. The study protocols for such GLP Tox Studies shall be mutually agreed by the Parties, and the Parties shall discuss and
align via the JRC on drug substance and drug product specifications of Products used for such GLP Tox Studies. 
  

	 	4.2	 Records; Reports 

 

	 	4.2.1	 Inspection 

Upon the written request of Roche and not more than [***] in each Calendar Year, C4T shall permit Roche, at Roche’s expense, to have access during
normal business hours to those records of C4T that may be necessary to verify the data that were generated under the Research Plans and the basis for any payments hereunder. 
  

	 	4.2.2	 Records 

Each Party will maintain scientific records, in sufficient detail and in sound scientific manner appropriate for Patent and regulatory purposes and in
compliance with cGCP with respect to activities intended to be submitted in regulatory filings (including INDs and BLAs), which will fully and accurately reflect all work done and results achieved in the performance of the Development activities,
Clinical Studies with respect to Original Products, Roche Products, C4T Co-Dev Products by such Party. 
 5.
Diligence 
 Roche and C4T shall use Commercially Reasonable Efforts to perform their respective activities contemplated by this Agreement or as may
be agreed upon in any subsequent written agreements with respect to the subject matter hereof. Specifically, C4T agrees to use Commercially Reasonable Efforts to advance the Research Plans and the Phase I Plans, as applicable, to the defined stage
of the Roche Option Right, and Roche agrees to use Commercially Reasonable Efforts to pursue further development and commercialization of Licensed Products in the Field in the Territory. Roche shall be deemed to use Commercially Reasonable Efforts
if it develops and commercializes for at least [***]. C4T shall ensure that personnel providing work under each Research Plan shall have skills and expertise no les than personnel working on C4T internal projects. Prior to using personnel on
a Research Plan, while ensuring continuity of current team leads and team members for [***] as of the Restatement Date, C4T shall provide to Roche the background and expertise of such personnel and reasonably consider Roche’s input
regarding the appropriateness of such personnel. The exact number of FTEs and their roles shall be discussed and agreed upon by the JRC and specified in each Research Plan. 

6. Development. 
  

	 	6.1	 Roche Products 

After the exercise of its Roche Option for a Target, and so long as a Roche Product does not become a C4T Co-Dev
Product, Roche shall be solely responsible, at Roche’s sole expense, for the manufacture, development, and commercialization of such Roche Products. [***] per Calendar Year, Roche shall inform C4T of the status of its clinical
development activities for Roche Products in the Field in the Territory.     

  
 - 30 - 

	 	6.2	 Phase I Completed Original Products 

 

	 	6.2.1	 Scope 

C4T shall conduct mutually agreed activities pursuant to a Phase I Plan for each Phase I Completed Original Product, subject to the sharing of Development
Costs as set forth in Section 12.5. Such activities will be overseen by the JDC. The purpose of each Phase I Plan is to set forth activities designed to generate results that enable the achievement of the Phase I Data Package. 

 

	 	6.2.2	 Phase I Plan 

Unless decided otherwise by the JDC, the Phase I Plan for each Phase I Completed Original Product will be updated annually and approved by the JDC. The Phase I
Plan will set forth (a) the activities and the resources that will be dedicated, (b) specific objectives for each year, which objectives as proposed to the JDC by the JOT will be approved, if appropriate, by the JDC as development
progresses, and (c) related Development Costs for such activities as part of the Shared Development Cost Budget. The Shared Development Cost Budget shall include the anticipated Development Costs expected to be incurred pursuant to the Phase I
Plan for the remainder of the then current Calendar Year and each of the next up to [***]. Thereafter, annually, the Development Plan and the Shared Development Cost Budget shall be updated by the JDC such that the Shared Development Cost
Budget shall always reflect the planned activities under the Phase I Plan for [***]. The JDC shall review the Phase I Plan on an ongoing basis and may amend the Phase I Plan to reflect the updated or amended objectives and the progress made,
subject to JDC approval. Any such changes shall be reflected in written amendments to the Phase I Plan for each Phase I Completed Original Product. Drafting of the Phase I Plan shall be initiated prior to completion of a GLP Tox Study for such Phase
I Completed Original Product. Roche together with C4T shall establish Phase I Plans for approval by the JDC, satisfying the Phase I Data Package. 
  

	 	6.2.3	 Updates 

C4T shall periodically provide to the JDC an update regarding development activities conducted by or on behalf of C4T with respect to Phase I Completed
Original Products. 
  

	 	6.3	 C4T Co-Dev Products 

 

	 	6.3.1	 C4T-Co Dev Products 

Subject to the terms of this Section 6.3 and Section 12.4, C4T and Roche shall be responsible for the development of C4T Co-Dev Products in the Territory in accordance with this Section 6.3, and subject to the sharing of Development Costs as set forth in Section 12.5. 

 

	 	6.3.2	 Development Plan 

Within [***] after exercising the C4T Co-Dev Option for a Target for which Roche has exercised the Roche Option,
Roche shall provide C4T with an initial development plan (“Development Plan”) and a budget for C4T Co-Dev Products for such Target outlining the planned activities and related Development
Costs (“Shared Development Cost Budget”) for such Development Plan to be approved by the JDC. The Shared Development Cost Budget shall include the anticipated Development Costs pursuant to the Development Plan for the remainder of
the then current Calendar Year and each of the next [***] expected to be incurred. Thereafter, annually, the Development Plan and the Shared Development Cost Budget shall be updated by the JDC such that the Shared Development Cost Budget
shall always reflect the planned activities under the Development Plan for [***]. 

  
 - 31 - 

	 	6.3.3	 Deferrable Amounts. 

If the annual update to the Development Plan for such a C4T Co-Dev Product results in the Shared Development Cost
Budget for the next Calendar Year of the Shared Development Cost Budget increasing by more than [***] from the then current Shared Development Cost Budget for the then-current Calendar Year, after taking into consideration any Allowable
Exceptions, then C4T shall have the right to elect to defer payment of its share of actually incurred Development Costs for such Target for such Calendar Year exceeding such percentage of the previous Shared Development Cost Budget for such Target
for such Calendar Year (such amount a “Deferrable Amount”). If C4T elects to make such deferral, C4T shall pay to Roche any such Deferrable Amount within [***] following the Calendar Year in which such overrun occurred;
provided that, at any time Roche may elect to deduct such Deferrable Amount from the next Development Event milestone payment payable from Roche to C4T if such event occurs prior to repayment by C4T. Notwithstanding the foregoing, all payments that
C4T has deferred pursuant to this Section 6.3.3 shall become payable at the earlier of (a) the end of the [***] period described above and (b) the effective date of termination. 

 

	 	6.3.4	 Updates 

Roche will periodically provide to the JDC an update regarding development activities conducted by or on behalf of Roche with respect to C4T Co-Dev Products. 
  

	 	6.3.5	 C4T’s Opt-Out 

On a C4T Co-Dev Product-by-C4T Co-Dev Product basis, C4T may elect to cease participation in funding and conducting development of such C4T Co-Dev Product (each a
“Opt-Out”) by providing Roche with at least [***] prior written notice before anticipated initiation of the next Clinical Study as described in the Development Plan, and the effective
date of such Opt-Out shall be the date of initiation of such next Clinical Study, and (a) C4T shall continue to be responsible for reimbursement of its share of Development Costs incurred by the Parties
under the Development Plan for any Clinical Studies ongoing as of the effective date of such Opt-Out through Completion of such Clinical Studies; (b) C4T shall have no further responsibility with respect
to Clinical Studies initiated as of or after the effective date of such Opt-Out; (c) the license granted by Roche to C4T with respect to the development of such C4T
Co-Dev Product shall terminate; (d) such C4T Co-Dev Product shall thereafter be considered a “Roche Product” hereunder and C4T shall be entitled to
royalties for Net Sales of such Roche Product in accordance with Section 12.12; and (e) Roche shall have sole discretion over the continued conduct of the development and commercialization with respect to such Product, subject to
Section 6.1. 
 Additionally, on a C4T Co-Dev
Product-by-C4T Co-Dev Product basis, if the Shared Development Costs Budget for the currently ongoing Clinical Trial(s) increases
by greater than [***] from the Shared Development Costs Budget last agreed prior to entry of such Clinical Trial(s) for such Collaboration Product, then C4T shall have the right, exercisable by C4T delivering written notice to Roche, to no
longer fund all or any portion of such amounts in excess of such [***] increase for such ongoing Clinical Trial(s) (“Funding Reduction Notice”), and specifying the portion in excess of such [***] increase it will no
longer fund for such ongoing Clinical Trial(s). If C4T delivers a Funding Reduction Notice pursuant to this Section 6.3.5, then C4T shall not be required to fund such portion of the amounts in excess of such [***] increase with respect
to the applicable C4T Co-Dev Product, subject to a reduction of the royalty increase in Section 12.12.2 (Royalty Rates). 

  
 - 32 - 

 7. Manufacturing 
  

	 	7.1	 General 

Prior to Roche’s exercise of the Roche Option Right for a Target, C4T has responsibility for the manufacture of Degronimids, Original Products and Phase I
Completed Original Products, subject to the oversight of the JRC or JDC, in accordance with the applicable Research Plan and Phase I Plan for such Target. Such manufacturing shall occur at CMOs approved by Roche set forth on Appendix 7.1. Roche
shall assist C4T in receiving access to such CMOs in the Roche network. Notwithstanding the above, 
  

	 	(a)	 for Products directed to [***], Roche shall have the right, but not the obligation, at its own cost, to
take over manufacturing of such Products prior to exercise of the Roche Option for use in GLP Tox Studies or Clinical Studies; and 

  

	 	(b)	 for Products directed to Targets other than [***], Roche shall have the right, but not the obligation,
to take over manufacturing of such Products prior to exercise of the Roche Option for use in GLP Tox Studies or Clinical Studies and subject to the sharing of Development Costs. 

If requested by a Party, the other terms under which a Party will manufacture Degronimids, Original Products and Phase I Completed Original Products will be
set forth in one or more manufacturing and supply agreements to be entered into between the Parties (each a “Supply Agreement”). Such Supply Agreement will contain customary terms and conditions, including quality and supply failure
remedies, and otherwise be consistent with this Agreement and Roche quality standards. 
  

	 	7.2	 Roche Option; C4T Co-Dev Products 

After Roche’s exercise of the Roche Option for a Target, and C4T’s subsequent exercise of its C4T Co-Dev
Option Right, Roche shall have the right, but not the obligation, to take over manufacturing of all C4T Co-Dev Products for such Target. After Roche’s exercise of the Roche Option for a Target (for which
C4T does subsequently not exercise the C4T Co-Dev Option Right, or if a Product ceases to be a C4T Co-Dev Product as a consequence of C4T exercising its Opt-Out right), Roche shall be responsible for manufacturing all such Roche Product for such Target. 
  

	 	7.3	 Technology Transfer 

Roche shall have the right, but not obligation, to request a technology transfer at any time however no later than [***] after exercising the Roche
Option for a given Target. Within [***] upon such request of Roche, C4T shall complete the transfer of all its C4T Know-How relating to the manufacturing of the Degronimids, Roche Products and C4T Co-Dev Products for such Target to Roche and/or one or more CMOs designated by and contracting directly with Roche with the goal of enabling Roche and/or its designated CMO to manufacture such Degronimids, Roche
Products and C4T Co-Dev Products (“Technology Transfer”). The Parties will agree in good faith on a Technology Transfer protocol defining the scope and conditions of transfer. Roche shall
reimburse C4T for any reasonably incurred Out of Pocket Costs incurred in the conduct of such Technology Transfer. 

  
 - 33 - 

 8. Commercialization 
  

	 	8.1	 General 

Roche, at its own expense, shall have sole responsibility and decision making authority for the marketing, promotion, sale and distribution of Roche Products.
For C4T Co-Dev Products, subject to C4T’s Co-Detailing Option as set forth in Section 3.1.3, Roche shall be responsible for the marketing, promotion, sale and
distribution of the C4T Co-Dev Products in the Territory, and all costs associated therewith. Throughout the Territory, Roche shall book all sales of Roche Products and C4T
Co-Dev Products. 
  

	 	8.2	 Co-Detailing 

 

	 	8.2.1	 Tactical Plan and Agreement 

Within [***] after C4T’s exercise of a C4T Co-Detail Option Right, the JCC shall meet and discuss
(a) a plan for co-Detailing the C4T Co-Dev Product prepared by Roche (the “Tactical Plan”), (b) C4T’s obligations under the Tactical Plan, and
(c) expected amount of compensation, on an FTE basis, to be paid for C4T for its co-Detailing efforts. Within [***] after C4T’s exercise of such C4T
Co-Detail Option Right, the Parties shall negotiate in good faith and execute a co-Detailing agreement, which shall specify the terms and conditions of the co-Detailing arrangement between the Parties in the US in the event C4T exercises a C4T Co-Detail Option with respect to the applicable C4
Co-Dev Product, and shall be consistent with the terms and conditions set forth in Appendix 8.2.1 (the “Co-Detailing Agreement”). 

 

	 	8.2.2	 Commercialization Efforts 

In the Co-Detail Territory, C4T shall use Commercially Reasonable Efforts to Detail each C4T Co-Dev Product for which it has exercised its C4T Co-Detail Option Right for such Target, and perform activities assigned to C4T in the Tactical Plan. 

 

	 	8.2.3	 Tactical Plan and Budget 

A Tactical Plan and associated budget for each C4T Co-Dev Product in the
Co-Detail Territory shall be prepared by Roche and approved by the JCC. Either Party may propose amendments to the Tactical Plan, which must be approved by the JCC. 

 

	 	8.2.4	 Recall 

Roche shall provide prompt written notice to C4T in the event of a recall of any C4T Co-Dev Products in the Co-Detail Territory, and shall be solely responsible for handling such recall. For clarity, Roche shall be solely responsible for the expenses of a recall of C4T Co-Dev
Product in the Co-Detail Territory, including without limitation the expenses related to maintaining a call center and responding to consumer and physician inquiries. C4T shall cooperate with Roche in the
event of any such recall, including by providing Sales Representative support during such recall. 

  
 - 34 - 

	 	8.2.5	 Co-Detail Opt-Out

 On a C4T Co-Dev
Product-by-C4T Co-Dev Product basis, C4T may elect to cease participation in the
co-Detailing such C4T Co-Dev Product (each a “Co-Detail Opt-Out”)
by providing Roche with [***] prior written notice. If C4T elects to exercise its Opt-Out with respect to any C4T Co-Dev Product, then upon the effective date of
such Opt-Out, (a) C4T shall continue to be responsible for its obligations under the Tactical Plan and Co-Detailing Agreement prior to the expiration of the
[***] notice period for such Opt-Out; (b) C4T shall have no further responsibility with respect to the Detailing of such C4T Co-Dev Product, except as set
forth in the foregoing clause (a); (c) the license granted by Roche to C4T with respect to co-Detailing such C4T Co-Dev Product shall terminate; (d) such C4T Co-Dev Product shall thereafter remain a C4T Co-Dev Product, for which C4T has not exercised its C4T Co-Detail Option Right and
(e) Roche shall have sole discretion over the continued conduct of the commercialization with respect to such C4T Co-Dev Product in accordance with Section 8.1. 

9. Regulatory 
  

	 	9.1	 Phase I Completed Original Products 

C4T shall have the right and responsibility for all regulatory affairs related to Phase I Completed Original Products, including filing the IND in the US for
each such Phase I Completed Original Product. All proposed communications with Regulatory Authorities shall be provided by C4T to Roche for Roche’s review and comments, which shall be reasonably considered by C4T, and Roche shall have the right
to attend all meetings with Regulatory Authorities as an observer. After exercise of the Roche Option with regard to a Phase I Completed Original Product, C4T shall transfer the IND to Roche. 

 

	 	9.2	 Licensed Products 

After Roche’s exercise of its Roche Option for a Target, Roche shall be solely responsible at its own expense for all regulatory affairs related to
Licensed Products in the Field in the Territory. Roche shall be responsible for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with regulatory agencies, for all Licensed Products in the Field in all
countries in the Territory. Roche or its Affiliates shall own and file in their discretion all regulatory filings and Regulatory Approvals for all Licensed Products in the Field in all countries of the Territory. 

10. Adverse Events 
 Each Party shall inform the other
Party about all serious adverse events of which it becomes aware occurring or having occurred in connection with the use of a Product. 
 C4T, at its sole
cost, shall report to appropriate Regulatory Authorities in accordance with local requirements all adverse events related to use of the Phase I Completed Original Products, as well as any Reversion Product. Roche, at its sole cost, shall report to
appropriate Regulatory Authorities in accordance with local requirements all adverse events related to use of Licensed Products. 
 C4T will maintain a
safety database for Phase I Completed Original Products, and Roche will maintain a safety database for all other Products, to manage safety data collected and fulfill their regulatory requirements. After transfer of historical clinical safety data,
Roche shall maintain the global safety database for the Product, which will be searched to provide answers to safety queries, for the preparation of Analysis of Similar Events (ASIMEs) and for safety reports. All reasonable assistance in responding
to safety inquiries will be provided to each Party upon request. 
 The Parties mutually agree to execute one or more separate Pharmacovigilance
Agreement(s) as deemed applicable by the Parties specifying the procedures and timeframes for compliance with Applicable Law pertaining to safety reporting of each Licensed Product and their related activities. 

  
 - 35 - 

 11. Governance 
  

	 	11.1	 Committees 

The Parties shall establish committees to oversee activities under this Agreement, a JRC to oversee the Research Plan activities under this Agreement, a JDC to
oversee all activities of any Phase I Plans for a Phase I Completed Original Products and clinical development of any C4T Co-Dev Products, and a JCC to oversee
co-Detailing activities for C4T Co-Dev Products for which C4T has exercised its C4T Co-Detail Option. 

 

	 	11.2	 Members 

The JRC, JDC or JCC, as applicable, shall be composed of [***] persons (“Members”). Roche and C4T each shall be entitled to appoint
[***] Members with appropriate seniority and functional expertise to empower the JRC, JDC, or JCC, as applicable, to rapidly make decisions. Andy Phillips shall be one of the [***] Members appointed by C4T to serve on the JRC, or if
Andy Phillips is no longer employed by C4T, then C4T’s Chief Scientific Officer shall be one of the [***] Members appointed by C4T to serve on the JRC. If C4T’s Chief Scientific Officer is already a member, then the next most senior
scientific leader of C4T will also be one of the [***] Members appointed by C4T to serve on the JRC. Each Party may replace any of its Members and appoint a person to fill the vacancy arising from each such replacement. A Party that replaces
a Member shall notify the other Party at least [***] prior to the next scheduled meeting of the JRC, JDC or JCC, as applicable. Both Parties shall use reasonable efforts to keep an appropriate level of continuity in representation. Both
Parties may invite a reasonable number of additional experts, including the Alliance Director, and/or advisors to attend part or the whole committee meeting with prior notification to the committee, provided that such experts and/or advisors are
bound by obligations of confidentiality and non-use consistent with those mandated for the Parties under this Agreement. Members may be represented at any meeting by another person designated by the absent
Member. The JRC, JDC and JCC shall be chaired by a Member of the Party that has final say with respect to decision making (“Chairperson”). 
  

	 	11.3	 Meetings 

The Chairperson or his/her delegate will be responsible for sending invitations and agendas for all JRC, JDC or JCC meetings to all Members at least
[***] before the next scheduled meeting of the JRC, JDC or JCC, as applicable. The venue for the meetings shall be agreed by the JRC JDC, or JCC as applicable. Each committee shall hold meetings at least [***] per Calendar Year, either
in person or by tele-/video-conference, and in any case as frequently as the Members of such committee may agree shall be necessary, but not more than [***] a year, unless the relevant committee agrees unanimously to additional meetings. The
Alliance Director (as defined in Section 11.15) of each Party may attend the committee meetings as a permanent participant. 
  

	 	11.4	 Minutes 

The Chairperson will be responsible for designating a Member to record in reasonable detail and circulate draft minutes of committee meetings to all members of
the committee for comment and review within [***] after the relevant meeting. The Members of the committee shall have [***] to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute
finalized minutes to all Members of the committee within [***] of the relevant meeting. The Chairperson approves the final version of the minutes before its distribution. 

  
 - 36 - 

	 	11.5	 Decisions 

  

	 	11.5.1	 Decision Making Authority 

Each committee shall decide matters within its responsibilities set forth in Section 11.6 for the JRC, Section 11.8 for the JDC, or
Section 11.13 for the JCC. 
  

	 	11.5.2	 Consensus; Good Faith 

The Members of the JRC, JDC and JCC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JRC.
The Parties shall endeavor to make decisions by consensus. 
  

	 	11.5.3	 Escalation 

If the JRC, JDC or JCC, as applicable, is unable to decide a matter by consensus within [***] after the date such matter is referred to such committee,
then such matter shall be referred to the CEO of C4T and the Head of Partnering for Roche, or their designees, who together shall use reasonable and good faith efforts to reach a decision by consensus within [***] after the date such matter
is referred to them. If the Parties still fail to reach a decision within such [***], then the final decision shall be [***]. The Party exercising such final decision shall do so in good faith. Any such decision shall constitute a
decision of the JRC, JDC, or JCC, as applicable. 
 Notwithstanding the above: 

[***] 
  

	 	11.6	 Joint Research Committee 

The Parties have established a Joint Research Committee to oversee the Research Plan activities under this Agreement. The JRC shall remain in effect for so
long as there is Research Plan under this Agreement. 
  

	 	11.7	 Responsibilities of the JRC 

The JRC shall have the responsibility and authority, subject to the other provisions of this Agreement, including Sections 11.5 and 11.16, to: 

 

	 	(a)	 approve each Research Plan and its objectives; 

 

	 	(b)	 update Roche on the C4T Pipeline and the targets in the C4T Pipeline on an ongoing basis, and at least
[***] in advance of lead optimization; 

  

	 	(c)	 approve any revisions to the Research Plans; 

 

	 	(d)	 maintain an updated list of Targets and a tally of the number of Target exchanges; 

 

	 	(e)	 review and oversee the execution of the Research Plan and updates to the Shared Development Cost Budget,
including providing a rolling [***] estimate at each JRC meeting for the [***] period following such JRC meeting; 

  

	 	(f)	 monitor the Shared Development Costs and manage reimbursement to C4T as set forth in Section 11.7;

  
 - 37 - 

	 	(g)	 establish and set expectations and mandates for its JOT; 

 

	 	(h)	 create or disband its JOT as deemed appropriate; 

 

	 	(i)	 oversee its JOTs, if applicable; 

 

	 	(j)	 maintain a list of Degronimids actually reduced to practice under the Research Plans; 

 

	 	(k)	 determine when and where to perform any pre-formulation activities,
salt screening and polymorph screening in accordance with CLS Criteria and CCS Criteria; 

  

	 	(l)	 verify whether Roche manufactures Degronimids for GLP Tox Studies (e.g. manufacturing process optimization, GLP
Tox formulation, GLP analytics), as set forth in Section 7.1.; 

  

	 	(m)	 align on the drug substance and drug product specifications for the batches used for the GLP Tox Studies as set
forth in Section 4.1.6; 

  

	 	(n)	 align on the drug substance and drug product strategy, including stability program, and its execution for the
drug product used for the GLP Tox Studies; 

  

	 	(o)	 review the GLP Tox Study protocol, e.g. with respect to study design, dose selection or GLP exposure
measurements as set forth in Section 4.1.6; 

  

	 	(p)	 oversee manufacture and release of drug substance and drug product batches to be used in GLP Tox Studies;

  

	 	(q)	 establish timelines for research decision points; 

 

	 	(r)	 determine whether success criteria have been met (LSI Achieved, CLS Criteria and CCS Criteria);

  

	 	(s)	 review the efforts of the Parties and allocate those resources for the Research Plan (including the budget);

  

	 	(t)	 monitor and implement the transfer of the C4T Technology to Roche as set forth in Section 7.3;

  

	 	(u)	 monitor and implement the transfer of the Degronimids and Product to Roche; and 

 

	 	(v)	 attempt to resolve any disputes on an informal basis. 

The JRC shall have no responsibility and authority other than that expressly set forth in this Section 11.7. 

 

	 	11.8	 Lifetime of the JRC 

The JRC shall remain in effect during the Research Term and shall be dissolved at the end of the last Research Plan. 

 

	 	11.9	 Joint Development Committee 

The Parties shall form a Joint Development Committee (“JDC”) within [***] after the Initiation of the GLP Tox Study in the first
species for a given Target to oversee all activities of a Phase I Plan of a Phase I Completed Original Product as well as clinical development of any C4T Co-Dev Products. For the Phase I Plan, the JDC shall seek to make decisions by consensus. In
the event of deadlock, there will be an escalation procedure to senior scientific management as set forth in Section 11.5.3. 

  
 - 38 - 

	 	11.10	 Responsibilities of the JDC 

The JDC shall have the responsibility and authority with respect to Phase I Plans for Phase I Completed Original Products and the clinical development of C4T Co-Dev Products to: 
  

	 	(a)	 Approve each Phase I Plan (if for a Phase I Completed Original Product) and Development Plan (if for a C4T Co-Dev Product); 

  

	 	(b)	 Approve any revisions to the Phase I Plan and Development Plan under (a); 

 

	 	(c)	 Review and oversee the execution of the Phase I Plan and Development Plan under (a) and oversee the
progress of activities under such plans; 

  

	 	(d)	 Oversee the Phase I Study of Phase I Completed Original Products; 

 

	 	(e)	 Oversee the Clinical Studies of C4T Co-Dev Products;

  

	 	(f)	 Establish timelines and criteria for development decision points; 

 

	 	(g)	 Review and discuss filing of the IND for each Phase I Completed Original Product; 

 

	 	(h)	 Determine whether development success criteria have been met (Phase I Data Package); 

 

	 	(i)	 Review the efforts of the Parties and allocate those resources for the Phase I Plan and Clinical Studies;

  

	 	(j)	 review regular updates to the Shared Development Cost Budget for Development Costs as set forth in Sections
6.2.2 and 6.3.2; 

  

	 	(k)	 identify appropriate resources necessary to conduct the Development Plan; 

 

	 	(l)	 establish and set expectations and mandates for its JOT; 

 

	 	(m)	 create or disband its JOT as deemed appropriate; 

 

	 	(n)	 oversee its JOT, if applicable; 

 

	 	(o)	 align on the drug substance and drug product strategy, including stability program, and its execution for the
drug product used for the Phase I Studies of Phase I Completed Original Products; (p) oversee manufacture and release of drug substance and drug product batches to be used for Phase I Studies of Phase I Completed Original Products;

  

	 	(p)	 depending on the Clinical Studies following Phase I Studies of C4T
Co-Dev Products, approve the appropriate CMC strategy for drug substance and drug product to be used in either Phase II Studies or Phase III Studies and oversee its execution; 

 

	 	(q)	 define the drug substance and drug product specifications for the batches used for Phase I Studies of Phase I
Completed Original Products and any batches made prior to Roche exercising the Roche Option Right of Phase I Completed Original Products for the subsequent Phase II Studies and/or Phase III Studies after exercise of the Roche Option Right; and

  

	 	(r)	 Attempt to solve any disputes on an informal basis. 

The JDC shall have no responsibility and authority other than that expressly set forth in this Section 11.10. 

  
 - 39 - 

	 	11.11	 Lifetime of JDC 

The JDC shall remain in effect for so long as there is a Phase I Plan under this Agreement, or a C4T Co-Dev Product is
undergoing clinical development under a Development Plan. 
  

	 	11.12	 Joint Commercialization Committee 

If C4T exercises it’s a C4T Co-Detail Option Right, the Parties shall establish a Joint Commercialization
Committee (“JCC”) to coordinate the co-Detailing activities of the Parties. 
  

	 	11.13	 Responsibility of the JCC 

The JCC shall have the responsibility and authority with respect to C4T Co-Dev Products for which C4T has exercised the
C4T Co-Detail Option to: 
  

	 	(a)	 approve each Tactical Plan for each C4T Co-Dev Product for which C4T
has exercised its C4T Co-Detail Option Right; 

  

	 	(b)	 revise and approve any revisions to each Tactical Plan; 

 

	 	(c)	 review and oversee the execution of each Tactical Plan and oversee the progress of activities under such plan;

  

	 	(d)	 coordinate activities designed to create, provide training for, deploy, and manage a sales force for each C4T Co-Dev Product for which C4T has exercised its C4T Co-Detail Option; 

  

	 	(e)	 coordinate sales force responsibilities, and communicate adjustments in sizing of such sales force for each C4T
Co-Dev Product for which C4T has exercised its C4T Co-Detail Option as appropriate; 

 

	 	(f)	 establish timelines and criteria for decision points; 

 

	 	(g)	 determine whether success criteria have been met; 

 

	 	(h)	 identify appropriate resources necessary to conduct each Tactical Plan; and 

 

	 	(i)	 attempt to resolve any disputes on an informal basis. 

The JCC shall have no responsibility and authority other than that expressly set forth in this Section 11.13, unless mutually agreed by the Parties. 

 

	 	11.14	 Lifetime of the JCC 

The JCC shall remain in effect for so long as the Parties are co-detailing a C4T
Co-Dev Product and shall end upon the conclusion of activities under the last Tactical Plan. 
  

	 	11.15	 Alliance Director 

Each Party shall appoint one person to be its point of contact with responsibility for facilitating communication and collaboration between the Parties (each,
an “Alliance Director”). The Alliance Directors shall be permanent participants of the JRC meetings (but not members of the JRC). The Alliance Directors shall facilitate resolution of potential and pending issues and potential
disputes to enable the JRC to reach consensus and avert escalation of such issues or potential disputes. 
  

	 	11.16	 Limitations of Authority 

No committee shall have authority to amend or waive any terms of this Agreement, nor shall any committee have the authority to determine whether a Party is in
breach of this Agreement. 

  
 - 40 - 

	 	11.17	 Expenses 

Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the committees established under this
Agreement. 
  

	 	11.18	 Lifetime 

The JRC shall remain in effect during the Research Term and shall be dissolved at the end of the last Research Plan. 

12. Payments  
  

	 	12.1	 Initial Payment 

Within [***] after the Restatement Date and receipt of an invoice from C4T, Roche shall pay to C4T a
non-refundable initial payment (“Initial Payment”) of [***]. 
  

	 	12.2	 Cost under the Research Plan 

In partial consideration for C4T’s activities under the Research Plans, Roche will pay C4T [***] annually for each active Research Plan. The
payments shall be made in quarterly installments of [***] payable at the end of the Calendar Quarter and within [***] after receipt of an invoice from C4T for each Research Plan until the earliest of ([***] (the
“Research Funding”). Notwithstanding the foregoing, for [***] the annual payment of [***] shall be made in quarterly installments payable on at the end of the Calendar Quarter and within [***] after receipt by
Roche of an invoice from C4T, provided [***] has not been terminated beforehand. For clarity, after [***] there shall be no further Research Funding payable by Roche for [***]. 

 

	 	12.3	 Development Costs for Dose Range Finding Studies and GLP Tox Studies 

The Parties will share equally the Development Costs for (a) Dose Range Finding Studies for all Targets including [***], and (b) GLP Tox
Studies for all Targets excluding [***] (for which Roche shall perform such studies after exercising its Option Right). Except as set forth in this Section 12.3, each Party shall be responsible for its own costs in the conduct of each
Research Plan. 
  

	 	12.4	 Costs for Phase I Completed Original Products. 

The Parties will share equally the Development Costs of the Phase I Studies (i.e. fifty percent (50%) will be paid by C4T and fifty percent (50%) will be paid
by Roche) for Phase I Completed Original Products. 
  

	 	12.5	 Development Costs for C4T Co-Dev Products.

 Following C4T’s exercise of its option to convert a Roche Product into a C4T Co-Dev
Product, C4T and Roche shall share the Development Costs for such C4T Co-Dev Product incurred subsequent to such option exercise as follows: [***] of the Development Costs will be paid by Roche and
[***] of the Development Costs will be paid by C4T until such C4T Co-Dev Product has received Regulatory Approval, as well as any post-approval Clinical Studies supporting the first approved Indication
as well as any Clinical Studies necessary to receive Regulatory Approval for additional Indications and any post-approval Clinical Studies supporting such additional Indication. 

 

	 	12.6	 Shared Development Costs 

This Section 12.6 applies to Development Costs for Dose Range Finding Studies and GLP Tox Studies for Original Products, to Development Costs for Phase I
Completed Original Products and to Development Costs for C4T Co-Dev Products. 

  
 - 41 - 

 12.6.1 Budgetary Overuns 

If a Party’s actually incurred Development Costs for the current Calendar Year exceeds [***] of the then current Shared Development Cost Budget,
such excess portion of Development Costs shall be entirely borne by the Party that exceeded the Shared Development Cost Budget provided that the JDC shall have the right during a Calendar Year to update the Shared Development Cost Budget in the
event of (a) faster than planned Clinical Study enrollment or faster than planned progress in the Development Plan, (b) written guidance or requirements from a Regulatory Authority that would result in amendments to the Development Plan or
(c) mutual agreement by the Parties to amend the Phase I Plan or the Development Plan, each of (a), (b) and (c) an “Allowable Exception”. Additional Development Costs incurred in a Calendar Year resulting from an Allowable
Exception shall be subject to sharing of Development Costs pursuant to this Section 12.5. 
 12.6.2 Reconciliation of Development
Costs. 
 Commencing with the first Calendar Quarter immediately following a Party incurring Development Costs under this Agreement for Original Products,
Phase I Completed Original Products, and C4T Co-Dev Products that are shared in accordance with this Section 12.6.2, within [***] after the end of each Calendar Quarter during which either Party
incurs such Development Costs, each Party shall submit to a finance designee of the other Party a report setting forth a good faith estimate of the Development Costs it incurred in such Calendar Quarter for such Products as detailed in the Research
Plan, Phase I Plan, or Development Plan respectively, as approved by the JRC or JDC, as applicable. Within [***] following the end of such Calendar Quarter, each Party shall update such report to reflect the final amount of Development Costs
incurred by such Party; provided that if there are any Development Costs incurred in such Calendar Quarter that a Party is unable to timely include in such financial report, then such amount shall be included and reconciled in the financial report
in a future Calendar Quarter. Each such report shall specify in reasonable detail costs incurred and shall include reasonably detailed supporting information. Within [***] after receipt of such reports, the finance designees from both Parties
shall confer and agree in writing on the amount of such reconciliation payment, so that the Parties share Development Costs in accordance with this Section 12.6.2. The Party required to pay such reconciliation payment shall make such payment to
the other Party within [***] after the end of each Calendar Quarter and receipt of an invoice from the other Party; provided, however, that in the event of any disagreement with respect to the calculation of such reconciliation payment, any
undisputed portion of such reconciliation payment shall be paid in accordance with the foregoing timetable and the remaining, disputed portion shall be paid within [***] after the date on which the Parties, using good faith efforts, resolve
the dispute and the Party owing the disputed portion receives an invoice from the other Party. 
  

	 	12.7	 Fee upon LSI Achieved. 

For each Target, except [***], within [***] after (a) LSI Achieved for such Target and (b) receipt by Roche of an invoice from C4T,
Roche shall pay C4T [***] per Target. 
  

	 	12.8	 Fee Upon Initiation of GLP Tox Studies, 

For each Target except [***], within [***] after both (a) Initiation of GLP Tox Studies for the first Product directed to such Target and
(b) receipt by Roche of an invoice from C4T, Roche shall pay C4T [***]. 

  
 - 42 - 

	 	12.9	 Option Exercise Fees 

If Roche exercises its Roche Option Right for a Target, then Roche shall pay a Roche Option Right exercise fee (“Roche Option Exercise Fee”)
as set forth below within [***] after exercise of the Roche Option Right and receipt by Roche of an invoice from C4T: 
  

	 	(a)	 [***] for [***]; 

 

	 	(b)	 [***] for [***]; 

 

	 	(c)	 [***] for any Target other than [***] for which the corresponding Product has been designated as
a Phase I Completed Original Product; and 

  

	 	(d)	 [***] for any Target other than a Target mentioned in (a), (b), or (c) above for which
corresponding Product is not a Phase I Completed Original Product. 

  

	 	12.10	 Development Event Payments 

Roche shall make payments in relation to the achievement of events with respect to Products directed towards a given Target. The development event payments
under this Section 12.10 shall be paid as follows: 
 For [***], Roche shall pay C4T up to a total of [***] the following set of one-time milestone event payments for the first achievement of each of the corresponding milestone events by the first Licensed Product covered by Valid Composition of Matter Claim (since Phase I Study Initiation,
Phase II Study Initiation and Phase III Study Initiation are not specific to a given country or region, the presence or absence of a Valid Composition of Matter Claim is to be based on the US Patent Rights): 

 

							
	 Development Event
	  	First Licensed
Product, first
Indication
(US$ million)	 	First Licensed
Product, second
Indication
(US$ million)	 	First Licensed
Product, third
Indication
(US$ million)
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 Total
	  	[***]	 	[***]	 	[***]

 [***] 
 For
[***] as well as any other Target for which the corresponding Roche Product has been designated a Phase I Completed Original Product, Roche shall pay C4T up to a total of [***] in relation to the following one-time milestone event payments for the first achievement of each of the corresponding milestone events by the first Licensed Product covered by a Valid Composition of Matter Claim: 

  
 - 43 - 

							
	 Development Event
	  	First Licensed
Product, first
Indication
(US$ million)	 	First Licensed
Product, second
Indication
(US$ million)	 	First Licensed
Product, third
Indication
(US$ million)
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 Total
	  	[***]	 	[***]	 	[***]

 [***] 

For any other Target for which the corresponding Roche Product had not been designated a Phase I Completed Original Product (and thus the start of the Roche
Option Period was upon receipt of the GLP Data Package), Roche shall pay C4T up to a total of [***] in relation to the following one-time milestone event payments for the first achievement of each of
the corresponding milestone events by the first Licensed Product covered by a Valid Composition of Matter Claim: 
  

							
	 Development Event
	  	First Licensed
Product, first
Indication
(US$ million)	 	First Licensed
Product, second
Indication
(US$ million)	 	First Licensed
Product, third
Indication
(US$ million)
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 Total
	  	[***]	 	[***]	 	[***]

 [***] 

The milestone payments in this Section 12.10 shall be paid in full for Licensed Products that are Covered by a Valid Composition of Matter Claim in the
relevant country or region. For Licensed Products not Covered by a Valid Composition of Matter Claim in the relevant country or region, the above milestone payments beginning with and including Phase III Study Initiation onwards shall be reduced by
[***] in the relevant country or region. For clarity, there shall not be any payment for any of the above milestone events prior to Phase III Study Initiation where the Licensed Product is not covered by a Valid Composition of Matter Claim.

 If development of the first Licensed Product for a given Target is terminated, then the next Licensed Product shall become the first Licensed Product for
that same Target with regard to development event payments that have yet to be achieved, and so on. 

  
 - 44 - 

 For example, [***]. 

[***]. 
 Upon reaching each development event, Roche
shall timely notify C4T and each Development Event Payment shall be paid by Roche to C4T within [***] after both (a) the occurrence of the applicable event and (b) receipt by Roche of an invoice from C4T. 

 

	 	12.11	 Sales Based Events 

For each Target, Roche shall pay C4T the following one-time sales-based event payments for the first Licensed Product
to achieve the following levels of Net Sales in a Calendar Year (“Net Sales Threshold”) for any Licensed Product covered by a Valid Composition of Matter Claim: 

 

			
	 Net Sales Threshold
	  	Payment
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 For each Target, each of the Sales Based Event payments shall be paid no more than once during the Royalty Term at the first
occurrence of the event for a Licensed Product in the Territory first reaching the respective Net Sales Threshold, irrespective of whether or not the previous Sales Based Event payment was triggered by the same or by a different Licensed Product for
such Target, and shall be paid within [***] after the end of the Calendar Year in which the event first occurs. 
 The milestone payments in the
table above shall be paid in full for Licensed Products that are covered by a Valid Composition of Matter Claim. For Products not covered by a Valid Composition of Matter Claim, the above milestone payments shall be reduced by [***]. For
Products where there are some countries in which there is a Valid Composition of Matter Claim and other countries in which there is no Valid Composition of Matter Claim, then if Net Sales in the countries in which there is a Valid Composition of
Matter Claim reach the applicable Net Sales Threshold, then payment will be made at the amounts stated in the table above. However if Net Sales in the countries in which there is a Valid Composition of Matter Claim do not reach the applicable Net
Sales Threshold but Net Sales in all countries of the Territory reach the applicable Net Sales Threshold, then payment will be at [***] of the amounts stated in the table above. 

For clarity the total eligible one-time sales based payments to C4T under the Agreement per Target are [***]
and for all [***] Targets collectively [***]. 
  

	 	12.12	 Royalty Payments 

 

	 	12.12.1	 Royalty Term 

Royalties shall be payable by Roche on Net Sales of Licensed Products during the Royalty Term. Thereafter, the licenses granted to Roche shall be fully paid
up, irrevocable and royalty-free worldwide. 

  
 - 45 - 

	 	12.12.2	 Royalty Rates 

For Licensed Products directed to [***], Roche shall, on a Licensed
Product-by-Licensed Product basis, pay C4T royalties on Calendar Year Net Sales of a given Licensed Product in the Territory as follows: 

 

			
	 Portion of Calendar Year Net Sales of a Licensed Product:
	  	Rate:
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 For [***] as well as any other Target for which the corresponding Licensed Product has been designated a Phase I
Completed Original Product, Roche shall, on a Licensed Product-by-Licensed Product basis, pay C4T royalties on Calendar Year Net Sales of a given Licensed Product in the
Territory as follows: 
  

			
	 Portion of Calendar Year Net Sales of a Licensed Product:
	  	Rate:
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 For any other Target for which the corresponding Roche Product had not been designated a Phase I Completed Original Product
(and thus the start of the Roche Option Period was the receipt of the GLP Data Package), Roche shall, on a Licensed Product-by-Licensed Product basis, pay C4T royalties
on Calendar Year Net Sales of a given Licensed Product in the Territory as follows: 
  

			
	 Portion of Calendar Year Net Sales of a Roche Product:
	  	Rate:
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 For each Licensed Product that is a C4T Co-Dev Product, the above royalty rates shall
be increased by [***] percentage points for each tier. For example, [***]. 
 If C4T delivers a Funding Reduction Notice pursuant to
Section 6.3.5, then the [***] percentage points shall be adjusted proportionately to reflect C4T’s actual share of the Shared Development Costs. For example, [***]. 

  
 - 46 - 

 For the purpose of calculating royalties of a Product, Calendar Year Net Sales and the royalty rates shall
be subject to the following adjustments, as applicable: 
 12.12.2.1 Combination Product 

If Roche or its Affiliates intend to sell a Combination Product, then the Parties shall meet approximately [***] prior to the anticipated First
Commercial Sale of such Combination Product in the Territory to negotiate in good faith and agree to an appropriate adjustment to Net Sales to reflect the relative commercial value contributed by the components of the Combination Product (the
“Relative Commercial Value”). If, after such good faith negotiations not to exceed [***], the Parties cannot agree to an appropriate adjustment, the dispute shall be initially referred to the executive officers of the Parties
in accordance with Section 23.6. If the Parties are unable to agree on the Relative Commercial Value , then Roche will select [***] who would qualify as an Expert, C4T will select [***] who would qualify as an Expert, and those
[***] shall select [***] who would qualify as an Expert and who shall be chairman of a committee of the three Experts (the “Expert Committee”), each with a single deciding vote. The Expert Committee will promptly hold a
meeting to review the issue under review, at which it will consider memoranda submitted by each Party at least [***] before the meeting, as well as reasonable presentations that each Party may present at the meeting. The determination of the
Expert Committee as to the issue under review will be binding on both Parties. The Parties will share equally in the costs of the Expert Committee. Unless otherwise agreed to by the Parties, the Expert Committee may not decide on issues outside the
scope mandated under terms of this Agreement. 
 12.12.2.2 No Valid Composition of Matter Claim or Generic Competition 

If no Valid Composition of Matter Claim Covers the use, offer for sale or sale of a Licensed Product in a given country, then the royalties in such country for
such Licensed Product shall be reduced by [***]. 
 Upon the first entry in a given country of a Generic Product, the royalties in such country for
such Licensed Product shall be further reduced as follows: 
 a) If after entry of a Generic Product there has been a decline of the
quarterly Net Sales of the applicable Licensed Product in such country in any Calendar Quarter greater than [***] of the average level of the quarterly sales of such Licensed Product achieved in the [***] consecutive calendar quarters
immediately prior to such entry, then the royalty payments payable by Roche to C4T for such Licensed Product in such country [***]. 

b) If after entry of a Generic Product there has been a decline of the quarterly Net Sales of the applicable Licensed Product in such country
greater than [***] of the average level of the quarterly sales of such Licensed Product achieved in the [***] consecutive Calendar Quarters immediately prior to such entry, then the royalty payments payable by Roche to C4T for such
Roche Product in such country [***]. 
 12.12.2.3 Third Party Payments 

If Roche is obligated to remit payments to a Third Party in relation to Third Party intellectual property that would be infringed by the making, using or
selling of a Licensed Product, then Roche shall have the right to deduct [***] of such consideration actually paid to a Third Party from payments otherwise due and payable by Roche to C4T under this Agreement; provided that such offsets shall
not reduce amounts payable to C4T by more than [***] of the amount otherwise payable after reductions under Sections 12.12.2.1 and 12.12.2.2; and further provided that Roche shall have the right to carry forward any amounts unable to be
offset because of this reduction limit and apply such amounts as an offset against future payments. Any such deduction shall be permitted on a Licensed Product-by-
Licensed Product and country-by-country basis. 

  
 - 47 - 

	 	12.12.3	 Apportionment of Compulsory Sublicensee Consideration 

Compulsory Sublicense Compensation, if any, paid by a Compulsory Sublicensee of the Product shall be shared between the Parties based on a profit share
percentage (the “Compulsory Profit Share Percentage”). The Compulsory Profit Share Percentage shall be calculated for the respective Calendar Year to which the Compulsory Sublicense Compensation relates, as follows: 

[***] 
 The amount owed to C4T shall be the
Compulsory Profit Share Percentage multiplied by the amount of the Compulsory Sublicense Compensation received by Roche from the Compulsory Sublicensee. 

For clarity, any Compulsory Sublicense Compensation by Compulsory Sublicensees under a Compulsory Sublicense shall not be considered as Net Sales for the
purposes of giving rise to any royalty payment under Section 12.12.2 of this Agreement and sales by such Compulsory Sublicensees shall not be included in Net Sales. 
  

	 	12.13	 Disclosure of Payments 

C4T acknowledges that Roche may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as may be advisable
or required under Applicable Law, including the US Sunshine Act. 
  

	 	12.14	 Late Issuing Valid Claims 

If there is no Valid Composition of Matter Claim at the time a Development Event Payment under Section 12.10 is payable but subsequently a Valid
Composition of Matter Claim is issued, then Roche shall pay to C4T retroactively the difference between the payment previously made by Roche to C4T under Section 12.10 and the payment that would have been payable by Roche to C4T had a Valid
Composition of Matter Claim existed at the time the payment was originally due.    Such payment shall be payable within [***] after C4T provides notice to Roche of such Valid Composition of Matter Claim issuing and an
invoice in the amount now payable. 
 13. Accounting and reporting 
  

	 	13.1	 Timing of Payments 

Roche shall calculate royalties on Net Sales quarterly as of March 31, June 30, September 30 and December 31 (each being the last day of an
“Accounting Period”) and shall pay royalties on Net Sales within [***] after the end of each Accounting Period in which such Net Sales occur. 
  

	 	13.2	 Late Payment 

Any payment under this Agreement that is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at
[***] percentage points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of days such payment is overdue. 

  
 - 48 - 

	 	13.3	 Method of Payment 

Royalties on Net Sales and all other amounts payable by Roche hereunder shall be paid by Roche in US dollars (the “Payment Currency”) to
account(s) designated by C4T. 
  

	 	13.4	 Currency Conversion 

When calculating the Sales of any Product that occur in currencies other than the Payment Currency, Roche shall convert the amount of such sales into Swiss
Francs and then into the Payment Currency using Roche’s then-current internal foreign currency translation method actually used on a consistent basis in preparing its audited financial statements (at the Restatement Date, YTD average rate as
reported by Reuters). 
  

	 	13.5	 Reporting 

With each payment Roche shall provide C4T in writing for the relevant Calendar Quarter on a
Product-by-Product basis the following information: 
 [***] 

14. Taxes 
 C4T shall pay all sales, turnover, income,
revenue, value added, and other taxes levied on account of any payments accruing or made to C4T under this Agreement. 
 If provision is made in law or
regulation of any country for withholding of taxes of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to C4T, then Roche shall promptly pay such tax, levy or charge for and on behalf of C4T
to the proper governmental authority, and shall promptly furnish C4T with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due C4T or be promptly reimbursed by C4T if no
further payments are due to C4T. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the
amount required to be so withheld or deducted. 
 15. Auditing 
  

	 	15.1	 C4T Right to Audit 

Roche shall keep, and shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars that may be
necessary for the purpose of calculating all royalties payable under this Agreement. Such books of accounts shall be kept at their principal place of business. At the expense of C4T, C4T shall have the right to engage an internationally recognized
independent public accountant reasonably acceptable to Roche to perform, on behalf of C4T, an audit of such books and records of Roche and its Affiliates that are deemed necessary by the independent public accountant to report on Net Sales of
Product for the period or periods requested by C4T and the correctness of any financial report or payments made under this Agreement. 
 Upon timely request
and at least [***] prior written notice from C4T, such audit shall be conducted in the countries specifically requested by the independent public accountant, during regular business hours in such a manner as to not unnecessarily interfere
with Roche’s normal business activities. Such audit shall be limited to results in the [***] prior to audit notification. 

  
 - 49 - 

 Accordingly, if C4T does not request an audit of a given Calendar Year for a given country on or before the
[***] of the end of such Calendar Year, then C4T will be deemed to have accepted the royalty payments and reports for such country in such Calendar Year. 

Such audit shall not be performed more frequently than [***] per Calendar Year nor more frequently than [***] with respect to records covering
any specific period of time. 
 All information, data documents and abstracts herein referred to shall be used only for the purpose of verifying royalty
statements, shall be treated as Roche’s Confidential Information subject to the obligations of this Agreement and need neither be retained more than [***]r after completion of an audit hereof, if an audit has been requested; nor more
than [***] from the end of the Calendar Year to which each shall pertain; nor more than [***] after the date of termination of this Agreement. 
  

	 	15.2	 Audit Reports 

The auditors shall only state factual findings in the audit reports and shall not interpret the agreement. The auditors shall share all draft audit reports
with the Parties before the final document is issued and either Party shall have the right to provide comments to the auditors. The final audit report shall be shared with Roche at the same time it is shared with C4T. 

 

	 	15.3	 Over-or Underpayment 

If the audit reveals an overpayment, C4T shall reimburse Roche for the amount of the overpayment within [***]. If the audit reveals an underpayment,
Roche shall make up such underpayment with the next royalty payment or, if no further royalty payments are owed by Roche, Roche shall reimburse C4T for the amount of the underpayment within [***]. Roche shall pay for the audit costs if the
underpayment of Roche exceeds [***] of the aggregate amount of royalty payments owed with regard to the royalty statements subject to the audit. Section 13.2 shall apply to this Section 15.3. 

16. Intellectual Property 
  

	 	16.1	 Ownership of Inventions 

Unless provided for otherwise in this Agreement C4T shall own all C4T Inventions and shall Handle and pay at its discretion for the Patent Rights covering such
C4T Inventions, Roche shall own all Roche Inventions and shall Handle and pay at its discretion for the Patent Rights covering such Roche Inventions, and C4T and Roche shall jointly own all Joint Inventions subject to the following: 

 

	 	(a)	 Collaboration Patent Rights solely covering a Target Binding Moiety that is not part of a Degronimid or Product
shall be solely owned by Roche and deemed Roche Patent Rights regardless of inventorship. Subject to Section 16.1(e), effective [***] after the first filing of said Collaboration Patent Rights, C4T hereby assigns its rights to said
Patent Rights to Roche, such assignment to survive termination of this Agreement (prior to the [***] assignment date, the Parties share equally the costs of Handling, thereafter Roche Handles and pays); 

  
 - 50 - 

 
					
	(b)	 	 (i)  Collaboration Patent Rights solely covering a Linker, E3 Ligase
Binding Moiety and/or a Linker bound to an E3 Ligase Binding Moiety that are not part of a Degronimid or Product shall be solely owned by C4T and deemed C4T Patent Rights regardless of inventorship. Effective [***] after the first filing of
said Collaboration Patent Rights, Roche hereby assigns its rights to said Patent Rights to C4T, such assignment to survive termination of this Agreement (prior to the [***] assignment date, the Parties share equally the costs of Handling,
thereafter C4T Handles and pays);

		 	 ii)   Any E3 Ligase Binding Moiety that is not generated under a
Research Plan or Phase I Plan, but rather is provided by Roche to C4T for use in a Research Plan, and is not part of a Degronimid or Product, and any intellectual property covering such E3 Ligase Binding Moiety shall be solely owned by C4T and
deemed C4T Patent Rights regardless of inventorship and C4T shall Handle and pay at its discretion for the Patent Rights covering such intellectual property. Upon the Effective Date, Roche hereby assigns its rights to said E3 Ligase Binding Moiety
to C4T, such assignment to survive termination of this Agreement. C4T hereby grants to Roche a non-exclusive, worldwide, royalty-free, irrevocable, sublicensable (including the right to sublicense through
multiple tiers), license to such E3 Ligase Binding Moiety, such license to survive termination of this Agreement (prior to the assignment date, Roche pays the costs of Handling, thereafter C4T Handles and pays);

		 	 (iii)   C4T will provide Roche with written notice if it desires to
abandon anyof the foregoing assigned Patent Rights, and if Roche desires to Handle and pay for any of such Patent Rights, Roche shall let C4T know within [***] after receipt of the C4T notice. C4T will assign such Patent Rights to Roche and
Roche shall bear the costs for this transfer of rights, such assignment to survive termination of this Agreement. If C4T provides Roche with written notice of its desire to abandon such assigned Patent Rights and Roche does not desire to Handle and
pay for any of such Patent Rights, the parties shall agree to abandon such assigned Patent Rights not earlier than [***] after receipt of such notice.

		
	(c)	 	Prior to Roche’s exercise of its Roche Option Right with respect to a Target, Roche shall Handle all Collaboration Patent Rights that claim in a single application both (1) C4T Technology and (2) a
Product, Degronimid or Target Binding Moiety and the Parties shall share equally any external expenses associated therewith; provided that, if C4T does not choose to pay for its share of any such Collaboration Patent Right on a country-by-country, Patent Right-by-Patent Right basis, and Roche desires to pay for such
Collaboration Patent Right, then C4T hereby assigns its rights in such Collaboration Patent Right to Roche, at the latest effective [***] after the notification by C4T, such assignment to survive termination of this Agreement. Prior to
Roche’s exercise of its Roche Option Right with respect to a Target, Roche shall Handle and pay for Collaboration Patent Rights that cover a Degronimid or a Product and that do not claim C4T Technology in the same application.

  
 - 51 - 

 Upon and after Roche’s exercise of its Roche Option Right with respect to a Target,
all Collaboration Patent Rights covering a Degronimid or Product shall be Handled by Roche. At the latest effective [***] after such exercise of the Roche Option Right, C4T hereby assigns its rights to Roche and Roche shall solely own such
Collaboration` Patent Rights covering a Degronimid or Product that binds such Target. Roche shall pay for such assigned Collaboration Patent Rights and Roche shall bear the costs for this transfer of rights, such assignment to survive termination of
this Agreement. Roche shall provide C4T with written notice if it desires to abandon any such assigned Collaboration Patent Rights, and if C4T desires to Handle and pay for any of such Patent Rights, C4T shall let Roche know within [***]
after receipt of the Roche notice. Roche will assign such Patent Rights to C4T and C4T shall bear the costs for this transfer of rights and Handle and pay for such assigned Patent rights, such assignment to survive termination of this Agreement. If
Roche provides C4T with written notice of its desire to abandon such assigned Collaboration Patent Rights and C4T does not desire to Handle and pay for any of such Patent Rights, the parties shall agree to abandon such assigned Collaboration Patent
Rights not earlier than [***] after receipt of such notice. 
  

	 	(d)	 For all Collaboration Patent Rights that cover a Joint Invention and do not cover a Degronimid or Product,
other than those set forth in 16.1(a, (b) or (c) above, subject to the licenses granted under this Agreement, C4T and Roche will each have an equal undivided share in such Collaboration Patent Rights, without obligation to account to the other
for exploitation thereof, or to seek consent of the other Party for the grant of any license thereunder. 

  

	 	(e)	 Notwithstanding anything in this Agreement to the contrary, if Collaboration Patent Rights Handled by Roche
covering a Degronimid or Product to be assigned to Roche under this Section 16.1 cannot be reasonably separated from Patent Rights owned or co-owned by C4T without a negative effect, (e.g. loss of patent
rights, inability to file a terminal disclaimer in the case of double patenting, etc.), then such Collaboration Patent Rights covering a Degronimid or Product shall not be assigned to Roche and Roche shall maintain its commercial license set forth
in Section 2.1.2 with respect to Targets for which Roche has exercised its Roche Option Right or that are still under an Roche Option Period. Both Parties will continue to share equally any external expenses associated therewith. Such a
decision shall be made on a country-by-country and Patent Right-by-Patent Right basis.
C4T and Roche shall make all reasonable efforts to obtain separate Collaboration Patent Rights covering Products and/or Degronimids, Target Binding Moieties not part of a Degronimid or Product, as well as covering Linker, E3 Ligase Binding Moiety
and/or a Linker bound to an E3 Ligase Binding Moiety that each are not part of a Degronimid or Product. If the parties are unable to agree upon whether such Collaboration Patent Rights cannot be reasonably separated without a negative effect, the
parties will choose an independent, mutually agreed upon Third Party patent attorney to make the determination. Costs of such determination will be shared equally. 

C4T and Roche each shall require all of its employees to assign all inventions related to Products made by them to Roche and C4T, as the case may be. 

  
 - 52 - 

 The determination of inventorship for Inventions shall be in accordance with US inventorship laws as if such
Inventions were made in the US. 
 If Roche does not exercise a Roche Option Right in a timely manner with respect to a Target, then C4T shall cease using
the Roche Compound or portion thereof (such as found in a Degronimid) and C4T shall discontinue prosecution/maintenance of any claim Covering such Roche Compound or portion thereof, if possible by cancellation or disclaimer of the claim when
requested to do so by Roche in writing, or by written agreement that C4T will not enforce such claim against Roche and its Affiliates. With respect to any remaining Patent Rights to which Roche does not exercise a Roche Option Right, C4T can Handle
such Patent Rights at its discretion. 
 Except as specifically set forth herein, this Agreement shall not be construed as (i) giving any of the
Parties any license, right, title, interest in or ownership to the Confidential Information; (ii) granting any license or right under any intellectual property rights; or (iii) representing any commitment by either Party to enter into any
additional agreement, by implication or otherwise. 
 Notwithstanding anything in this Agreement to the contrary, regardless of whether C4T assigns its
rights in Collaboration Patent Rights to Roche, Roche hereby grants to C4T an exclusive (even as to Roche except to the extent set forth in Section 2.1.3), worldwide, royalty-free, irrevocable, sublicensable (including the right to
sublicense through multiple tiers), license under Roche’s interest in the Collaboration Patent Rights to (a) practice the C4T Technology outside the scope of this Agreement (but subject to the terms and conditions of this Agreement) and
(b) Exploit degronimids and products containing degronimids for use with targets that are not Targets, and excluding Degronimids or Products for which Roche has exercised the Roche Option Right or that are still subject to a Roche Option Right.

 Notwithstanding anything in this Agreement to the contrary, regardless of whether Roche assigns its rights in Collaboration Patent Rights to C4T, C4T
hereby grants to Roche an exclusive, worldwide, royalty-free, irrevocable, sublicensable (including the right to sublicense through multiple tiers), license under C4T’s interest in the Collaboration Patent Rights to Exploit Target Binding
Moieties. 
  

	 	16.2	 German Statute on Employee’s Inventions 

In accordance with the German Statute on Employees’ Inventions, each Party agrees to claim the unlimited use of any Invention conceived, reduced to
practice, developed, made or created in the performance of, or as a result of, any Research Program, Phase I Plan or Development Plan by employees of any German Affiliates or any other persons acting on behalf of such German Affiliates. For the
avoidance of doubt, each Party is responsible for fulfilling the obligations towards their employees under the German Statute of Employee’s Inventions. 
  

	 	16.3	 Trademarks and Labeling 

Roche shall own all trademarks used on or in connection with Licensed Products and shall, at its sole cost, be responsible for procurement, maintenance,
enforcement and defense of all trademarks used on or in connection with Licensed Products. Neither Party shall use any trademark of the other Party outside the scope of this Agreement, or knowingly take any action that would materially adversely
affect the value of any such trademark. Each Party shall retain the right to monitor the quality of the goods on or with which its trademark is used to the extent necessary to maintain its trademark rights. 

  
 - 53 - 

 Roche shall have the right to obtain the International
Non-proprietary Name (INN) from the World Health Organization and the US Adopted Name (USAN) from the US adopted Names Council (USANC) as the generic name(s) for the Products. 

 

	 	16.4	 Prosecution of Patent Rights 

Each Party shall (i) consult with the other Party as to the Handling of Collaboration Patent Rights and, with respect to C4T, any other C4T Patent Rights
that cover a Product or a Degronimid; and (ii) furnish to the other Party copies of all documents relevant to any such Handling in sufficient time before any action is due to allow the other Party to provide comments thereon, which comments
shall be considered. The Party not Handling the Patent Rights shall cooperate, in all reasonable ways with the Handling of the Patent Rights. 
  

	 	16.5	 Patent Coordination Team 

Where the Parties need to consult with each other on the Handling of C4T Patent Rights, the Parties shall establish a patent coordination team and shall adopt
procedures for interacting on patent matters. 
  

	 	16.6	 Unified Patent Court (Europe) 

At any time prior to the end of the “transitional period” as such term is used in Article 83 of the Agreement on a Unified Patent Court between
the participating Member States of the European Union, for a given relevant EU Patent Right, Roche may request in writing thatC4T either (i) opt out from the exclusive competence of the Unified Patent Court or (ii) if applicable, withdraw
a previously-registered opt-out, and C4T shall notify the Registry, pay any such registry fee and take such other action as may be necessary to effect the opt-out or opt-out withdrawal (“Register”). Roche will bear the expenses directly in context with the opt-out or withdrawal of a previously-registered opt-out (like official fees and attorney fees for initiating the opt-out or withdrawal). All other patent fees related to prosecution will be born as described in Para 16.1.
C4T shall use reasonable efforts to Register within [***] of receipt of Roche’s written request, or such other time parameters reasonably specified by Roche. 
  

	 	16.7	 CREATE Act 

It is the intention of the Parties that this Agreement is a “joint research agreement” as that phrase is defined in 35 USC §103(c)(3). 

 

	 	16.8	 Infringement 

Each Party shall promptly provide written notice to the other Party during the Agreement Term of any (i) known infringement or suspected infringement by a
Third Party of any Patent Rights, it is Handling hereunder to the extent that such Patent Rights cover a Degronimid or Product, or (ii) known or suspected unauthorized use or misappropriation by a Third Party of any C4T Know-How, Roche Know-How or Joint Know-How pertaining to a Degronimid or Product, and shall provide the other Party with all evidence
in its possession supporting such infringement or unauthorized use or misappropriation. 
 Within [***] after Roche provides or receives such written
notice (“Decision Period”), Roche, in its sole discretion, shall decide whether or not to initiate a suit or action in the Territory regarding such infringement or unauthorized use or misappropriation and shall notify C4T in writing
of its decision in writing (“Suit Notice”). 
 If Roche decides to bring a suit or take action, once Roche provides Suit Notice, Roche may
immediately commence such suit or take such action. 

  
 - 54 - 

 Roche shall keep C4T informed of the status of any such suit or action and shall provide C4T with copies, to
the extent Roche is lawfully permitted to do so, of all substantive documents or communications filed in such suit or action. Roche shall have the sole and exclusive right to select counsel for any such suit or action. 

Roche shall, except as provided below, pay all expenses of the suit or action, including Roche’s attorneys’ fees and court costs. Any damages,
settlement fees or other consideration received as a result of such suit or action shall be allocated as follows: 
  

	(a)	 First, to reimburse Roche for its costs and, if any remains, to C4T for any advisory counsel fees and costs;
and 

  

	(b)	 Second, the balance, if any, shall be allocated [***] to Roche, and [***] to C4T.

 If Roche believes it is reasonably necessary or desirable to obtain an effective remedy, upon written request C4T agrees to be joined
as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to the suit or action. At Roche’s written request, C4T shall
offer reasonable assistance to Roche in connection therewith at no charge to Roche except for reimbursement of reasonable out-of-pocket expenses incurred by C4T in
rendering such assistance. C4T shall have the right to participate and be represented in any such suit or action by its own counsel at its own expense. 

Roche may settle, consent judgment or otherwise voluntarily dispose of the suit or action (“Settlement”) without the written consent of C4T
but only if such Settlement can be achieved without adversely affecting C4T (including any of its Patent Rights and including by resulting in a reduction in royalties or milestones payable hereunder). If a Settlement could adversely affectC4T, then
the written consent of C4T would be required, which consent shall not be unreasonably withheld. 
 In the event that Roche (i) does not in writing
advise C4T within the Decision Period that Roche will commence suit or take action, or (ii) fails to commence suit or take action within a reasonable time after providing Suit Notice, Roche shall assign such Patent Right to C4T and C4T shall
thereafter have the right to commence suit or take action in the Territory with respect to such infringement or suspected infringement. In such situation and, notwithstanding anything in this Agreement to the contrary, C4T shall have full discretion
as to how it wishes to handle such suit and may reach settlement and retain all damages, settlement fees or other consideration under any terms and conditions it desires. If C4T believes it is reasonably necessary or desirable to obtain an effective
remedy, upon written request, Roche agrees to be joined as a party to the suit or action but shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to the suit or
action. 
 For any Roche Patent Right that Covers a Roche Compound, Roche, in its sole discretion, shall decide whether or not to initiate such suit or
action in the Territory. Roche shall have full discretion as to how it wishes to handle such suit and may reach Settlement and retain all damages, settlement fees or other consideration under any terms and conditions it desires. However, if a
Settlement could adversely affect C4T by resulting in a reduction in royalties or milestones payable hereunder or adversely affect a C4T Patent Right or Collaboration Patent Right, then the written consent of C4T shall be required, for such
settlement. 

  
 - 55 - 

	 	16.9	 Defense 

If an action for infringement is commenced against either Party, its licensees or its Sublicensees related to C4T’s conduct of the Research Program within
the scope of the Research Plan, the Phase I Plan, the Development Plan, or the discovery, development, manufacture, use or sale of a Product, then Roche shall have the right (but not the obligation) to defend such action at its own expense, and C4T
shall assist and cooperate with Roche, at Roche’s expense, to the extent necessary in the defense of such suit. Roche shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion, so long as such
settlement or adverse judgment does not adversely affect the rights of C4T and its Affiliates (including any patent rights Controlled by any of them and including by resulting in a reduction in royalties or milestones payable hereunder). Roche shall
assume full responsibility for the payment of any award for damages, or any amount due pursuant to any settlement entered into by it with such Third Party. 

If the manufacture, use, importation, offer for sale or sale of any Product pursuant to this Agreement results in any claim, suit or proceeding alleging
patent infringement or trade secret misappropriation against C4T or a member of the Roche Group, then such Party shall promptly notify the other Party hereto. The Parties shall cooperate with each other in connection with any such claim, suit or
proceeding and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding. 
 If a Third
Party asserts that Patent Rights owned by or licensed to it are infringed by the development, manufacture, use, importation, offer for sale or sale of Products by a member of the Roche Group, or that its trade secrets were misappropriated in
connection with such activity, then Roche shall have the exclusive right and responsibility to resolve any such claim, whether by obtaining a license from such Third Party, by defending against such Third Party’s claims or otherwise, and shall
be solely responsible for the defense of any such action, any and all costs incurred in connection with such action (including, without limitation, attorneys’ and expert fees) and all liabilities incurred in connection therewith, with the
understanding that Roche may not defend or settle such dispute in a manner that adversely affects C4T Patent Rights or Collaboration Patent Rights without the written consent of C4T, which may not be unreasonably withheld. 

 

	 	16.10	 Common Interest Disclosures 

With regard to any information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or technology
owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to what extent, Third Party intellectual property rights may affect the conduct of the Research Program, Phase I Plan, Development Plan
and/or Degronimids and/or Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on allegations of misuse or infringement of intellectual property rights relating to the conduct of
the Research Program, Phase I Plan, Development Plan and/or Degronimids and/or Products. Accordingly, the Parties agree that all such information and materials obtained by C4T and Roche from each other will be used solely for purposes of the
Parties’ common legal interests with respect to the conduct of the Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product privilege, and any other privilege or immunity that may
otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials. Neither Party shall have the authority to waive any
privilege or immunity on behalf of the other Party without such other Party’s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be deemed to apply against any other Party. 

  
 - 56 - 

	 	16.11	 Hatch-Waxman 

Notwithstanding anything herein to the contrary, should a Party receive a certification for a Product pursuant to the Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417, known as the Hatch-Waxman Act), as amended, or its equivalent in a country other than the US, then such Party shall immediately provide the other Party with a copy
of such certification. Roche shall have [***] from date on which it receives or provides a copy of such certification to provide written notice to C4T (“H-W Suit Notice”) whether Roche
will bring suit, at its expense, within a [***] period from the date of such certification. Should such [***] period expire without Roche bringing suit or providing such H-W Suit Notice, then C4T
shall be free to immediately bring suit in its name. 
  

	 	16.12	 Patent Term Extensions 

The Parties shall use Commercially Reasonable Efforts to obtain all available patent term extensions, adjustments or restorations, or supplementary protection
certificates (“SPCs”, and together with patent term extensions, adjustments and restorations, “Patent Term Extensions”) Covering a Product. C4T shall execute such authorizations and other documents and take such
other actions as may be reasonably requested by Roche to obtain such Patent Term Extensions, including designating Roche as its agent for such purpose as provided in 35 USC § 156. All filings for such Patent Term Extensions shall be made
by Roche; provided, that in the event that Roche elects not to file for a Patent Term Extension, Roche shall (a) promptly inform C4T of its intention not to file and (b) grant C4T the right to file for such Patent Term Extension. Each
Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such extensions. The Parties shall cooperate with each other in gaining patent term restorations,
extensions and/or SPCs wherever applicable to C4T Patent Rights Covering a Product. 
 17. C4T Representations, Warranties and Covenants 

 

	 	17.1	 Safety Data 

C4T has disclosed to Roche and will immediately continue to disclose to Roche (i) the results of all preclinical testing and human clinical testing of
Product in its possession or control and (ii) all information in its possession or control concerning side effects, injury, toxicity or sensitivity reaction and incidents or severity thereof with respect to Product. 

 

	 	17.2	 Third Party Patent Rights 

C4T has no knowledge of the existence of any patent or patent application owned by or licensed to any Third Party that could prevent Roche from making, having
made, using, offering for sale, selling or importing Product in the Territory. 
  

	 	17.3	 Ownership of Patent Rights 

C4T is the exclusive owner of all right, title and interest in, or is the exclusive licensee of, the C4T Base Patent Rights. Appendix 1.5 contains a
complete and accurate list of all patents and patent applications included in the C4T Base Patent Rights. 

  
 - 57 - 

	 	17.4	 Inventors 

C4T has obtained the assignment of, or an exclusive license under, all interest and all rights or licenses thereunder with respect to the C4T Patent Rights
necessary to grant the licenses granted hereunder. All of C4T’s employees, officers and consultants have executed agreements requiring assignment to C4T of all Inventions made by such individuals during the course of and as a result of their
association with C4T. C4T covenants that in the future all of C4T’s employees, officers and consultants will have executed agreements requiring assignment to C4T of all Inventions made by such individuals during the course of and as a result of
their association with C4T. 
  

	 	17.5	 Grants 

To the best of C4T’s knowledge and belief, C4T has the lawful right to grant Roche and its Affiliates the rights and licenses described in this Agreement.

  

	 	17.6	 Authorization 

The execution, delivery and performance of this Agreement by C4T and all instruments and documents to be delivered by C4T hereunder: (i) are within the
corporate power of C4T; (ii) have been duly authorized by all necessary or proper corporate action; (iii) are not in contravention of any provision of the certificate of formation or limited liability company agreement of C4T; (iv) to
the knowledge of C4T, will not violate any law or regulation or any order or decree of any court of governmental instrumentality; (v) will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to
which C4T is a party or by which C4T or any of its property is bound, which violation would have an adverse effect on the financial condition of C4T or on the ability of C4T to perform its obligations hereunder; and (vi) do not require any
filing or registration with, or the consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than approvals required under the HSR Act, Regulatory Approvals required
for the sale of Products and filings with Regulatory Authorities required in connection with Products). 
  

	 	17.7	 Validity of Patent Rights 

C4T is not in possession of any information that would, in its reasonable opinion, render invalid and/or unenforceable any claims in any issued patent licensed
pursuant to this Agreement. C4T has no knowledge of any inventorship disputes concerning any C4T Patent Rights. 
  

	 	17.8	 Ownership and Validity of Know-How 

C4T Know-How is legitimately in the possession of C4T and has not been misappropriated from any Third Party. C4T has
taken and will continue to take reasonable measures to protect the confidentiality of its Know-How. 
  

	 	17.9	 No Claims 

There are no claims or investigations pending or threatened against C4T or any of its Affiliates, at law or in equity, or before or by any governmental
authority relating to the matters contemplated under this Agreement or that would materially adversely affect C4T’s ability to perform its obligations hereunder. 
  

	 	17.10	 No Conflict 

Neither C4T nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of this
Agreement or that would impede the fulfillment of C4T’s obligations hereunder. 

  
 - 58 - 

	 	17.11	 Protection of Know-How 

C4T shall at all times exercise Commercially Reasonable Efforts to safeguard the confidentiality of C4T Know-How and
Roche Know-How to protect its value. With respect to Know-How licensed from DFCI (including Know-How related to assays), such
obligation shall be to the extent permissible and for the maximum time permissible under C4T’s existing obligations to DFCI. 
  

	 	17.12	 No Other Representations 

EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS
OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF PRODUCTS. 
 18. Indemnification 

 

	 	18.1	 Indemnification by Roche 

Roche shall indemnify, hold harmless and defend C4T and its directors, officers, employees and agents from and against any and all losses, expenses, cost of
defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts C4T becomes legally obligated to pay because of breach of contract by Roche or any claim or claims
against it to the extent that such claim or claims arise out of [***], except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of C4T. 

 

	 	18.2	 Indemnification by C4T 

C4T shall indemnify, hold harmless and defend Roche and its directors, officers, employees and agents from and against any and all losses, expenses, cost of
defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Roche becomes legally obligated to pay because of any claim or claims against it to the extent that
such claim or claims arise out of [***], except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of Roche. 

 

	 	18.3	 Procedure 

In the event of a claim by a Third Party against a Party entitled to indemnification under this Agreement (“Indemnified Party”), the
Indemnified Party shall promptly notify the other Party (“Indemnifying Party”) in writing of the claim and the Indemnifying Party shall undertake and solely manage and control, at its sole expense, the defense of the claim and its
settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in any such action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation
costs or expenses incurred by the Indemnified Party without the Indemnifying Party’s written consent. The Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from
all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. 

  
 - 59 - 

 19. Liability 
  

	 	19.1	 Limitation of Liability 

Subject to Article 5, neither Party shall be liable to the other Party as a result of failure or delay to develop and/or commercialize the Degronimid or the
Product, as applicable, including but not limited to, a) a delay in timelines, or b) delay or failure to recruit patients, or c) a change in its respective study protocols, or d) failure of a Party to obtain Regulatory Approval
for the Degronimid or the Product, as applicable. 
  

	 	19.2	 Disclaimer 

EXCEPT FOR INDEMNIFICATION UNDER ARTICLE 18 AND BREACH OF CONFIDENTIALITY AND NON-USE UNDER ARTICLE 20, NEITHER PARTY
SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER. 

20. Obligation Not to Disclose Confidential Information 
  

	 	20.1	 Communication and Information Exchange 

Roche may conduct in the future or may presently be conducting research that may involve Roche Compounds, Targets or the treatment of Indications. Accordingly,
Roche shall have the right to limit what Confidential Information it receives from C4T and how such Information is to be provided to Roche. The Roche and C4T Alliance Directors shall meet to implement procedures for the exchange of Confidential
Information designed to safeguard each Party’s Information and to prevent contamination of Roche research by C4T Confidential Information. Until such procedures are implemented, the Alliance Directors shall be the sole conduits for exchanging
Information between the Parties. 
  

	 	20.2	 Non-Use and Non-Disclosure

 During the Agreement Term and for [***] thereafter, a Receiving Party shall (i) treat Confidential Information provided
by Disclosing Party as it would treat its own information of a similar nature, (ii) take all reasonable precautions not to disclose such Confidential Information to Third Parties, without the Disclosing Party’s prior written consent, and
(iii) not use such Confidential Information other than for fulfilling its obligations under this Agreement or in connection with a license granted hereunder. 
  

	 	20.3	 Permitted Disclosure 

Notwithstanding the obligation of non-use and non-disclosure set forth in
Section 20.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial considerations. 

 

	 	20.4	 Press Releases 

Roche shall issue press releases in accordance with its internal policy that typically does not issue a second press release until proof of concept has been
achieved for a Product. Roche shall provide C4T with a copy of any draft press release related to the activities contemplated by this Agreement at least [***] prior to its intended publication for C4T’s review. C4T may provide Roche with
suggested modification to the draft press release. Roche shall consider C4T’s suggestions in issuing its press release. 

  
 - 60 - 

 C4T shall only issue press releases related to the activities contemplated by this Agreement that have
either (i) been approved by Roche or (ii) are required to be issued by C4T as a matter of law and C4T has a competent legal opinion to that effect. In all circumstances, C4T shall provide Roche with a draft press release at least
[***] prior to its intended publication for Roche’s review. During such period, Roche shall (i) approve the draft press release and permit C4T to issue the press release, (ii) contact C4T to discuss modification to the draft
press release, or (iii) contact C4T and disapprove the press release. If Roche asks for modification, then C4T shall either make such modification or work with Roche to arrive at a press release that Roche approves. If C4T issues a press
release without Roche’s approval, then C4T must obtain a competent legal opinion that the release was required to be issued by C4T as a matter of law. 

To ensure communication alignment, responses (if any) to inquiries by media or other Third Parties after issuance of a permitted press release by C4T (solely
or jointly with Roche) shall consist solely of the press release language or shall follow the response guidelines that may be mutually developed by the Parties. 
  

	 	20.5	 Publications 

During the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of Confidential Information relating to the Product
in any publication or presentation: 
  

	a)	 Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and
published in accordance with their internal guidelines. Roche, in accordance with its internal policies and procedures, shall have the right to publish all studies, clinical trials and results thereof on the clinical trial registries that are
maintained by or on behalf of Roche. C4T shall not publish any studies, clinical trials or results thereof on its clinical trial registry, provided however, that Roche’s clinical trial registry can be accessed via a link from C4T’s
clinical trial registry. 

  

	b)	 A Party (“Publishing Party”) shall provide the other Party with a copy of any proposed
publication or presentation at least [***] prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential
Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies
(“Publishing Notice”) the Publishing Party in writing, within [***] after receipt of the copy of the proposed publication or presentation that such publication or presentation in its reasonable judgment (i) contains an
invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other Party reasonably desires to obtain patent protection or (ii) could be expected to have a material adverse effect on the commercial value
of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be
for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event less than [***] from the date of the Publishing Notice. 

 

	 	20.6	 Commercial Considerations 

Nothing in this Agreement shall prevent a Party or its Affiliates from disclosing Confidential Information of the other Party or its Affiliates to
(i) governmental agencies to the extent required or desirable to secure government approval for the development, manufacture or sale of 

  
 - 61 - 

 
Product in the Territory, (ii) Third Parties acting on behalf of Roche, to the extent reasonably necessary for the development, manufacture or sale of Product in the Territory,
(iii) Third Parties requesting clinical trial data information (in accordance with Roche’s then-current data sharing policy) or (iv) Third Parties to the extent reasonably necessary to market the Product in the Territory. The
Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information is required to be disclosed by the Receiving Party to comply with Applicable Law, to defend or prosecute litigation or to
comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, takes reasonable and lawful actions to minimize the degree of such
disclosure. In addition, C4T may provide a copy of this Agreement to DFCI and may disclose the existence and terms of this Agreement to potential financing sources, provided that such disclosure is under a confidentiality agreement having terms and
conditions at least as stringent as those contained in this Agreement. 
 21. Term and Termination 

 

	 	21.1	 Commencement and Term 

This Agreement shall commence upon the Effective Date and continue for the Agreement Term. 

 

	 	21.2	 Termination and Change of Control 

 

	 	21.2.1	 Termination for Breach 

A Party (“Non-Breaching Party”) shall have the right to terminate this Agreement in its entirety or on
a Target-by-Target, Product-by-Product or country-by-country (in the case of termination by C4T) basis in the event the other Party (“Breaching Party”) is in breach of any of its material obligations under this Agreement. The non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach and the countries in which the Non-Breaching Party intends to
have this Agreement terminate. The Breaching Party shall have a period of [***] after such written notice is provided (“Peremptory Notice Period”) to cure such breach. If the Breaching Party has a bona fide dispute as
to whether such breach occurred or has been cured, it will so notify the Non-Breaching Party, and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to
Section 23.6. Upon a determination of breach or failure to cure, the Breaching Party may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent
withdrawal of the Non-Breaching Party’s request for termination, this Agreement shall terminate in its entirety or such identified countries effective as of the expiration of the Peremptory Notice Period.

  

	 	21.2.2	 Insolvency 

A Party shall have the right to terminate this Agreement, if the other Party incurs an Insolvency Event; provided, however, in the case of any involuntary
bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof. 

 

	 	21.2.3	 Change of Control 

If there is a Change of Control of C4T whereby C4T is controlled (as such term is used in the Affiliate definition in Section 1.1), then Roche shall, in
its sole discretion, have the right to implement the procedures set forth in Section 21.3.3 by providing notice to C4T within [***] of becoming aware of the Change of Control. If there is a Change of Control of C4T, then C4T shall
immediately notify Roche of such Change of Control. 

  
 - 62 - 

	 	21.2.4	 Termination by Roche without a Cause 

Roche shall have the right to terminate this Agreement at any time as a whole or on a
Product-by-Product, Target-by-Target (and as a consequence, all Products to such Target),
or country-by-country basis upon (a) [***] prior written notice in the case of
Product-by-Product or Target-by-Target termination, (b) [***] prior written notice
in the case of termination as a whole or country-by-country termination before First Commercial Sale of the Product, or (c) upon [***] prior written notice
in the case of termination as a whole or country-by-country termination after the First Commercial Sale of the Product. The effective date of termination under this
Section 21.2.4 shall be the date [***], [***] or [***], as the case may be, after Roche provides such written notice to C4T. 
  

	 	21.3	 Consequences of Termination and Change of Control 

 

	 	21.3.1	 Termination by C4T for Breach by Roche, Roche Insolvency, by Roche without Cause 

Upon any termination by C4T for breach by Roche under Section 21.2.1 or for an Insolvency Event of Roche pursuant to 21.2.2 or by Roche without cause
pursuant to Section 21.2.4, on the effective date of termination, (a), the rights and licenses granted by C4T to Roche under this Agreement shall terminate in their entirety or on a Product-by-Product, Target-by-Target or
country-by-country basis, as applicable, (b) except as set forth in this Section 21.3.1 or as otherwise explicitly set forth in this Agreement, the rights and
obligations of the Parties hereunder will terminate with respect to the Target, Product, or country and any applicable Target shall become a “Terminated Target”, and (c) Roche will execute all documents and take all such
further actions as may be reasonably requested by C4T in order to give effect to the foregoing clauses. 
 If C4T desires to continue to research, develop,
manufacture, commercialize and otherwise exploit such Roche Product(s) or CT Co-Dev Products (or any derivatives, improvements, modifications or enhancements against the applicable Target thereof)
(collectively, the “Reversion Products”) in the Field after such termination, then C4T shall give a Continuation Election Notice to Roche within [***] of the effective date of termination and pay to Roche a transitional fee
of [***]. If Roche receives such a timely Continuation Election Notice and such transitional fee, and to the extent reasonably requested by C4T: 
  

	(a)	 As promptly as practicable after the effective date of termination, Roche shall, to the extent Roche has the
right to do so under Applicable Law, assign and transfer to C4T or C4T’s designee possession and ownership of all governmental or regulatory filings, regulatory materials, pricing approvals and Regulatory Approvals, all copies of material
correspondence and conversation logs with Regulatory Authorities relating to the research, development, manufacture, commercialization and exploitation of the Reversion Products, all final pre-clinical and
clinical study reports and clinical study protocols, global trademarks, and all data, including non-clinical and clinical data and other material sales and marketing related information in Roche’s
possession and control related solely to Reversion Product(s) or the corresponding Target(s) to the extent necessary or reasonably useful for C4T to continue to research, develop, manufacture, commercialize and otherwise exploit the Reversion
Product(s) in the Field. All data and other information shall be transferred in the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if required by Applicable Law. Roche shall not be required to
prepare or finalize any new data, reports or information solely for purposes of transfer to C4T. 

  
 - 63 - 

	(b)	 Roche shall appoint C4T as Roche’s or Roche’s Affiliates’ (and to the extent permitted by the
applicable sublicense, its Sublicensees’) agent for all Reversion Product-related matters involving Regulatory Authorities in the country, or Territory, as applicable, until all Regulatory Approvals, regulatory materials, pricing approvals and
other governmental or regulatory filings required to be assigned to C4T hereunder have, in fact, been assigned to C4T or its designee, but in no event longer than the [***] anniversary of the effective date of termination. In the event of
failure to obtain assignment of any of the items required to be assigned under this Section 21.3.1, Roche hereby consents and grants to C4T or its designee the right to access and reference (without any further action required on the part of
Roche, whose authorization to file this consent with any Regulatory Authority is hereby granted) any such item with respect to all Reversion Products. 

  

	(c)	 If the effective date of termination is after First Commercial Sale of a Reversion Product, then, to the extent
permitted by Applicable Law, Roche or its Affiliates (or to the extent permitted by the applicable sublicense, its Sublicensees) will appoint C4T or its designee as its exclusive distributor of such Reversion Products in the relevant country, Roche
Territory or Territory, and grant C4T or its designee the right to appoint sub-distributors, until such time as all Regulatory Approvals in the relevant country, Roche Territory or Territory have been
transferred to C4T or its designee, but in no event longer than the [***] anniversary of the effective date of termination. 

  

	(d)	 Roche shall assign and transfer all Clinical Study agreements, to the extent such agreements have not been
cancelled and are assignable without Roche paying any material consideration or commencing litigation in order to effect an assignment of any such agreement. 

  

	(e)	 C4T shall, upon transfer from Roche pursuant to this Section 21.3.1, have the right to disclose such
filings, approvals and data to (i) governmental agencies of the country to the extent required or desirable to secure government approval for the development, manufacturing or sale of Reversion Product(s) in the country, (ii) Third Parties
acting on behalf of C4T, its Affiliates or licensees, to the extent reasonably necessary for the research, development, manufacture, commercialization and exploitation of Reversion Product(s) in the country, and (iii) Third Parties to the
extent reasonably necessary to research, develop, manufacture, commercialize or otherwise exploit Reversion Product(s) in the country. 

  

	(f)	 Roche shall grant (without any further action required on the part of C4T) to C4T (a) an exclusive (even
as to Roche), perpetual, irrevocable (except as set forth below), license, with the right to grant sublicenses through multiple tiers, under the (i) Roche Know How and (ii) Patent Rights Controlled by Roche that are necessary for the
research, development, manufacture or commercialization of Reversion Products, such Roche Know-How and Patent Rights shall be limited to Roche Know-How and Patent Rights
made after the Effective Date and in accordance with a Research Plan, Phase I Plan or Development Plan) and Roche’s interest in the Joint Patent Rights, solely to the extent necessary to allow C4T, its Affiliates or licensees to research,
develop, manufacture, commercialize or otherwise exploit the Reversion Product(s) in the Field in the terminated country(ies), and (b) a non-exclusive, worldwide, perpetual, irrevocable (except as set
forth below) license, with the right to grant sublicenses through multiple 

  
 - 64 - 

	 	
tiers, under the (i) Roche Know How and (ii) Patent Rights Controlled by Roche that are necessary for the research, development, manufacture or commercialization of Reversion Products,[
such Roche Know-How and Patent Rights shall be limited to Roche Know-How and Patent Rights made after the Effective Date and in accordance with a Research Plan, Phase I
Plan or Development Plan)] and Roche’s interest in the Joint Patent Rights and Joint Know-How, solely to the extent necessary to allow C4T, its Affiliates or licensees to research, have researched,
develop, have developed, use, have used, make, have made, import, have imported, export and have exported Reversion Product(s) in the Field anywhere in the world in order to market, have marketed, distribute, have distributed, sell, have sold and
offer for sale and have offered for sale (including all research, development, manufacture and commercialization activities) such Reversion Product(s) in the Field in the terminated country(ies) (collectively, the “Reversion
License”). For clarity, the Reversion License is in addition to any licenses granted to C4T in Section 3.1.5; provided that, to the extent the Reversion License covers any subject matter for which C4T grants a license to Roche pursuant
to Section 3.1.5, such license in Section 3.1.5 shall be limited to not include any such subject matter that overlaps with the Reversion License. 

  

	(g)	 Royalties would be payable by C4T to Roche on the Calendar Year worldwide C4T Net Sales of the applicable
Reversion Product, and the tiered royalty rates table below would apply to such C4T Net Sales depending on (i) the origin of such Reversion Product and (ii) the stage of development at the effective date of
termination.

 Royalty Rates for Calendar Year C4T Net Sales of a Reversion Product 

 

					
	 Type of Target / Origin

of Reversion Product
	  	Termination after [***]
(Percent (%) of such
C4T Net Sales)	 	Termination after [***]
(Percent (%) of such
C4T Net Sales)
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

 Payments would be made by C4T to Roche in a manner analogous to that set forth in Section 12.12, including
adjustments in a manner analogous to those set forth in Sections 12.12.2.1 - 12.12.2.3. Notwithstanding anything to the contrary in this Section 21.3.1(g), Roche will have the right to terminate the licenses granted to C4T in this
Section 21.3.1(g) with respect to a Reversion Product in full upon [***] prior written notice to C4T in the event of any material breach by C4T of its payment obligations under this Section 21.3.1(g). Notwithstanding the foregoing,
any such termination under this Section 21.3.1(g) will not be effective if such breach has been cured within [***] after written notice thereof is given by Roche to C4T specifying the nature of the alleged breach. 

For clarity, with respect to any Roche IP that is in-licensed by the Roche Group, C4T will be
responsible for any payments due to a Third Party with respect thereto and C4T’s rights will be subject to the terms of the applicable Third Party agreement. At C4T’s written request, the Parties will enter into commercially reasonable
prosecution and enforcement and defense terms for the Roche IP with respect to the Reversion Products, and C4T will bear the costs of such prosecution, enforcement and defense activities to the extent related to such Reversion Products. 

  
 - 65 - 

	(h)	 Roche will promptly transfer and assign to C4T all of Roche’s and its Affiliates’ (or, if applicable,
will cause its or their licensees or sublicensees to transfer and assign) rights, title and interests in and to Roche’s (and such Affiliates’ and licensees’ and sublicensees’) global trademark(s) solely used to identify the
Reversion Products (but not any house marks, or logos or any trademark of Roche or its Affiliates, containing the word “Roche” or any such Affiliate) in the Field. 

 

	(i)	 If C4T so requests, and to the extent permitted under Roche’s obligations to Third Parties on the
effective date of termination, Roche will transfer to C4T any Third Party agreements relating solely to the research, development, manufacture, commercialization and exploitation of the Reversion Products to which Roche is a party, subject to any
required consents of such Third Party, which Roche will use Commercially Reasonable Efforts to obtain promptly. 

  

	(j)	 Roche will execute all documents and take all such further actions as may be reasonably requested by C4T in
order to give effect to the foregoing clauses. 

  

	 	21.3.2	 Termination by Roche for Breach by C4T or C4T Insolvency 

Upon breach by C4T or C4T’s Insolvency, Roche shall have the right to terminate this Agreement in accordance with Section 21.2.1 or
Section 21.2.2, as applicable. In such event, the rights and licenses granted by Roche to C4T and by C4T to Roche under this Agreement shall terminate in their entirety or on a
Product-by-Product or Target-by-Target basis, as applicable, on the effective date of
termination. 
  

	 	21.3.3	 Effects of Change of Control 

If there is a Change of Control as set forth in Section 21.2.3 where the Change of Control Party is a company that develops or commercializes
pharmaceutical products (for clarity, generally for itself and not typically on a contract basis for other companies), then Roche shall have the right to mandate that C4T set up procedures to prevent the disclosure of sensitive business and
Confidential Information (including any data, results, structures and synthesis protocols of Degronimids under the Research Plans) to the Change of Control Group [***]. 

 

	 	21.3.4	 Direct License 

Irrespective of anything to the contrary in this Agreement, any Compulsory Sublicense shall remain in full force and effect as may be required by Applicable
Law, any existing, permitted sublicense granted by Roche under Section 2.1.2 of this Agreement (and any further sublicenses thereunder) shall, upon the written request of Roche, remain in full force and effect, provided that (i) such
Sublicensee is not then in breach of its sublicense agreement (and, in the case of termination by C4T for breach by Roche, that such Sublicensee and any further sublicensees did not cause the breach that gave rise to the termination by C4T); and
(ii) such Sublicensee agrees to be bound to C4T under the terms and conditions of such sublicense agreement, provided that (1) such Sublicensee is obligated to pay C4T no less than C4T would have received from Roche under this Agreement,
and (2) C4T would not have any more obligations, or fewer rights, with respect to such Sublicensee as compared to Roche under this Agreement. C4T shall thereafter enter into a direct license with such Sublicensee on terms consistent with this
Agreement. 

  
 - 66 - 

	 	21.3.5	 Royalty and Payment Obligations 

Termination of this Agreement by a Party, for any reason, shall not release Roche from any obligation to pay royalties or make any payments to C4T that are
payable prior to the effective date of termination. Termination of this Agreement by a Party, for any reason, will release Roche from any obligation to pay royalties or make any payments to C4T that would otherwise become payable on or after the
effective date of termination. 
  

	 	21.3.6	 Other Obligations. 

21.3.6.1 Obligations related to Ongoing Activities. 
 If C4T does
not provide timely Continuation Election Notice, then Roche (a) shall have the right to cancel all ongoing obligations and (b) shall complete all non-cancellable obligations at its own expense. 

If C4T provides such timely Continuation Election Notice and pays the applicable transitional fee, then from the date of notice of termination until the
effective date of termination, Roche shall continue all activities contemplated by this Agreement, including preparatory activities, ongoing as of the date of notice of termination. However, Roche shall not be obliged to initiate any new activities
not ongoing at the date of notice of termination. 
 After the effective date of termination, neither Roche nor C4T shall have any obligation to perform
and/or complete any activities, except as expressly stated herein. 
 Notwithstanding the foregoing, in case of termination by C4T under Section 21.2.1
or 21.2.2, or by Roche under Section 21.2.4, upon the request of C4T, Roche shall, at C4T’s election and at C4T’s sole cost after the effective date of termination, either (i) complete any Clinical Studies related to the
Product(s) that are being conducted under its IND for the Product(s) and are ongoing as of the effective date of termination or (ii) continue such Clinical Studies until they can be transferred to C4T; provided, however, that: 

 

	 	(a)	 both C4T and Roche in their reasonable judgment have concluded that completing any such Clinical Studies does
not present an unreasonable risk to patient safety; 

  

	 	(b)	 Roche shall have no obligation to recruit or enroll any additional patients after the date of termination;

  

	 	(c)	 Roche shall transfer all ongoing Clinical Studies for C4T Co-Dev
Products to C4T as soon as practicable, (unless such Clinical Studies need to be wound down for lack of safety or efficacy). Roche shall bear its share of the Development Costs of such Clinical Studies for such C4T
Co-Dev Products until the effective date of termination and thereafter all costs shall be solely borne by C4T; and 

  

	 	(d)	 Roche shall transfer all ongoing Clinical Studies for Roche Products to C4T as soon as practicable, (unless
such Clinical Studies need to be wound down for lack of safety or efficacy). 

  
 - 67 - 

 In the event that C4T does not elect to have Roche complete any Clinical Studies related to the Product(s)
that are being conducted under Roche’s IND(s) for the Product(s) and are ongoing as of the effective date of termination, then Roche will wind down such ongoing Clinical Studies, subject to the Parties’ sharing any Development Costs for
such Clinical Studies incurred during the wind down period. 
 21.3.6.2 Obligations Related to Manufacturing 

 

	 	(a)	 Clinical Supplies 

In the case of termination by C4T under Section 21.2.1 for uncured breach by Roche, or 21.2.2 for Roche insolvency, or by Roche under
Section 21.2.4, if C4T elects to develop the Reversion Product(s), Roche shall, upon C4T’s request, transfer all existing and available clinical material to C4T at FBMC. After such transfer is effectuated, Roche shall have no obligation to
perform any additional activities concerning the clinical supplies (e.g. retesting, analyses). C4T shall assume all liability for the use of such material. At C4T’s request, Roche shall transfer the technology necessary to manufacture the
clinical material to C4T or its designee as soon as practicable, at Roche’s expense, and Roche will reasonably assist C4T through its relationships with CROs to help enable C4T to assume responsibility for manufacturing. 

 

	 	(b)	 Commercial Supplies 

In the case of termination by C4T under Section 21.2.1 for uncured breach byu Roche, or 21.2.2 for Roche insolvency, or by Roche under
Section 21.2.4, if a Reversion Product is marketed in any country of Territory on the date of the notice of termination of this Agreement, upon the request of C4T, Roche shall manufacture and supply such Reversion Product to C4T under a
manufacturing transfer and transition plan for a period that shall not exceed [***] from the effective date of the termination of this Agreement at FBMC [***]. C4T shall use Commercially Reasonable Efforts to take over the
manufacturing as soon as reasonably possible after the effective date of termination. 
  

	 	21.3.7	 Termination in General 

In the event of any termination by Roche, C4T shall use Commercially Reasonable Efforts to minimize any cancellable expenses after the notice of termination
and to wind down activities in an expeditious manner. Roche shall have no obligation to provide to C4T any rights or access to Combination Products, patient data, patient samples, or intellectual property or materials to which Roche does not have
Control. Unless otherwise agreed by the Parties, the termination of this Agreement shall cause the automatic termination of all ancillary agreements related hereto, if any. 
  

	 	21.4	 Survival 

Article 1 (Definitions – to the extent necessary to interpret the Agreement), Article 15 (Auditing); Section 16.1 (Ownership of Inventions),
Article 18 (Indemnification), Article 19 (Liability), Article 20 (Obligation Not to Disclose Confidential Information), Section 2.1.3 (Commercial License Following Research Program Initiation), Section 2.1.4 (Freedom of
Operation), Section 21.3 (Consequences of Termination and Change of Control), Section 21.4 (Survival), Section 23.5 (Governing Law), and Section 23.7 (Arbitration) and any other sections that by their nature are intended to
survive any expiration or termination of this Agreement shall survive any expiration or termination of this Agreement for any reason. Notwithstanding anything to the contrary in this Article 21, the grant-back licenses of assigned Collaboration
Patent Rights set forth in Section 16.1 shall survive any expiration or termination of this Agreement. 

  
 - 68 - 

 22. Bankruptcy 

All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by C4T to Roche are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under Section 101(60) of the Bankruptcy Code. Unless Roche elects to terminate
this Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, subject to the continued performance of
its obligations under this Agreement. 
 23. Miscellaneous 
  

	 	23.1	 US Manufacture 

Roche shall manufacture Products leased, used or Sold in the US under C4T IP substantially in the United States as required by 35 U.S.C. 204 and 37 C.F.R. 401
et seq., as amended, provided that, if necessary, C4T will assist Roche or its designated Affiliate(s) in any attempt to secure a waiver of the United States manufacturing requirement contained in 35 U.S.C. Section 204. 

 

	 	23.2	 Other Government Laws 

Roche shall comply with, and require that its Affiliates and Sublicensees to comply with, all government statutes and regulations applicable to Products. These
include but are not limited to FDA statutes and regulations, the Export Administration Act of 1979, as amended, codified in 50 App. U.S.C. 2041 et seq. and the regulations promulgated thereunder or other applicable export statutes or regulations.

  

	 	23.3	 Patent Marking 

Roche shall mark, and shall require its Sublicensees and Affiliates to mark, directly or via a mechanism such as the Orange Book, all Licensed Products sold in
the US in a manner designed to allow enforcement of the C4T Patent Rights Covering such Licensed Products. 
  

	 	23.4	 Publicity – Use of Name 

Each Party, its Affiliates and Sublicensees shall not use the names of DFCI, its related entities or its employees, or any adaptations thereof, in any
advertising, promotional or sales literature, or in any securities report required by the Securities and Exchange Commission (except as required by law), without the prior written consent of DFCI in each case. However, each Party may (a) refer
to publications in the scientific literature by employees of DFCI or (b) state that a sub-license from DFCI has been granted as provided in this Agreement. 

 

	 	23.5	 Governing Law 

This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference to its conflict of laws principles,
and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 
 Notwithstanding
anything to the contrary in this Agreement, issues regarding the scope, construction, validity and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions have
issued the Patent Rights in question. 

  
 - 69 - 

	 	23.6	 Disputes 

Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred to the respective
executive officers of the Parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows: 

For C4T:         CEO 

For Roche:     Head of Roche Partnering 
  

	 	23.7	 Arbitration 

Should the Parties fail to agree within [***] after such dispute has first arisen, it shall be finally settled by arbitration in accordance with the
Rules of American Arbitration Association (AAA) as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. The place of arbitration shall be New York, New York. The language to be used shall be English.

  

	 	23.7.1	 Arbitrators 

Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the request for arbitration within [***] of being
requested to do so, or if the respondent should fail to appoint an arbitrator in its answer to the request for arbitration within [***] of being requested to do so, the other Party shall request the AAA to make such appointment. 

The arbitrators nominated by the Parties shall, within [***] from the appointment of the arbitrator nominated in the answer to the request for
arbitration, and after consultation with the Parties, agree and appoint a third arbitrator, who will act as a chairman of the three arbitrator committee (the “Arbitral Tribunal”). Should such procedure not result in an appointment within
the [***] time limit, either Party shall be free to request the AAA to appoint the third arbitrator. 
 Where there is more than one claimant and/or
more than one respondent, the multiple claimants or respondents shall jointly appoint one arbitrator. 
 If any Party-appointed arbitrator or the third
arbitrator resigns or ceases to be able to act, a replacement shall be appointed in accordance with the arrangements provided for in this clause. 
 The
language of the arbitration shall be English. Documents submitted in the arbitration (the originals of which are not in English) shall be submitted together with an English translation. 

 

	 	23.7.2	 Decisions; Timing of Decisions 

The arbitrators shall render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later than
[***] from the date on which the arbitrators were appointed to the dispute. A transcript of the evidence adduced at the arbitration hearing shall be made and, upon request, shall be made available to each Party. 

  
 - 70 - 

 Notwithstanding the above, in the case of JRC, JDC or JCC disputes that are not finally resolved pursuant to
Section 11.5.3, the arbitrators shall render a written opinion setting forth findings of fact and conclusions of law with the reason therefor stated, within no later than [***] from the date on which the arbitrators were appointed to the
dispute. 
 The time periods set forth in the AAA Arbitration Rules shall be followed; provided however that the arbitrators may modify such time periods as
reasonably necessary to render a written opinion in accordance with this Section 23.7.2. 
 The arbitrator is empowered to award any remedy allowed by
law, including money damages, prejudgment interest and attorneys’ fees, and to grant final, complete, interim, or interlocutory relief, including injunctive relief. 

This arbitration agreement does not preclude either Party seeking conservatory or interim measures from any court of competent jurisdiction including, without
limitation, the courts having jurisdiction by reason of either Party’s domicile. Conservatory or interim measures sought by either Party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim
measures. Conservatory or interim measures sought by either Party before the Arbitral Tribunal shall not preclude any court of competent jurisdiction granting conservatory or interim measures. 

In the event that any issue shall arise which is not clearly provided for in this Section 23.7, the matter shall be resolved in accordance with the AAA
Arbitration Rules. 
 Any arbitration proceeding hereunder shall be confidential and the arbitrators shall issue appropriate protective orders to safeguard
each Party’s Confidential Information. Except as required by law, neither Party shall make (or instruct the arbitrators to make) any public announcement with respect to the proceedings or decision of the arbitrators without prior written
consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrators, except as required in connection with the enforcement of such award or as otherwise
required by Applicable Law. 
 Notwithstanding anything to the contrary in this Agreement, any and all issues regarding the scope, construction, validity
and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent Rights in question. 

Notwithstanding anything to the contrary in this Agreement, any and all issues regarding a breach or alleged breach of a Party’s obligations under
Article 20 (Obligation Not to Disclose Confidential Information) shall be determined in a court of competent jurisdiction under the laws of the State of New York, with express exclusion of its conflict of laws principles and any and all issues
regarding the scope, construction, validity and/or enforceability of any Patent Rights shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patent Rights in question. 

 

	 	23.8	 Assignment 

Neither Party may assign its rights or obligations under this Agreement absent the prior written consent of the other Party, except to any of its Affiliates or
in the context of a merger, acquisition, sale or other transaction involving all or substantially all of the assets relating to the Agreement relates of the Party seeking to assign, in which case such Party in its sole discretion may assign its
rights and obligations under this Agreement. Any permitted assignment shall be binding on the successors of the assigning Party. 

  
 - 71 - 

	 	23.9	 Debarment 

Each Party represents and warrants that it has never been debarred under 21 U.S.C. §335a, disqualified under 21 C.F.R. §312.70 or §812.119,
sanctioned by a Federal Health Care Program (as defined in 42 U.S.C §1320 a-7b(f)), including without limitation the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or
otherwise declared ineligible from any other similar Federal or state agency or program. In the event a Party receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the above-referenced statutes, such
Party shall immediately notify the other Party in writing and the notified Party shall have the right, but not the obligation, to terminate this Agreement, effective, at such Party’s option, immediately or at a specified future date. 

 

	 	23.10	 Independent Contractor 

No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner
whatsoever or to create or impose any contractual or other liability on the other Party without said Party’s prior written approval. For all purposes, and not- withstanding any other provision of this
Agreement to the contrary, C4T legal relationship to Roche under this Agreement shall be that of independent contractor, and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment,
franchise, agency or fiduciary relationship between the Parties. 
  

	 	23.11	 Unenforceable Provisions and Severability 

If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and
enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However, the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not
affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 
  

	 	23.12	 Waiver 

The failure by either Party to require strict performance and/or observance of any obligation, term, provision or condition under this Agreement will neither
constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute
a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
  

	 	23.13	 Appendices 

All Appendices to this Agreement shall form an integral part to this Agreement. 
  

	 	23.14	 Entire Understanding 

This Agreement contains the entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all prior
agreements, understandings and arrangements, whether written or oral. Amendments 
 No amendments of the terms and conditions of this Agreement shall be
binding upon either Party hereto unless in writing and signed by both Parties. 

  
 - 72 - 

	 	23.15	 Invoices 

All invoices that are required or permitted hereunder shall be in writing and sent by C4T to Roche at the following address or such other address as Roche may
later provide: 
 F. Hoffmann-La Roche Ltd 

Kreditorenbuchhaltung 

Grenzacherstrasse 124 
 4070 Basel

 Switzerland 
  

	 	23.16	 Notice 

All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by
personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 

 

			
	if to C4T, to:	  	 C4 Therapeutics, Inc.
 490 Arsenal Street

Watertown, MA 02472
 U.S.A.

Attn: Chief Executive Officer
 Facsimile No.:
___________________

		
	and:	  	 Goodwin Procter LLP
 100 Northern
Avenue
 Boston, Massachusetts 02210
 U.S.A.

Facsimile No.: +1 617 523-1231

Attn: Lawrence S. Wittenberg

lwittenberg@goodwinprocter.com

		
	if to Roche, to:	  	 F. Hoffmann-La Roche Ltd

Grenzacherstrasse 124
 4070 Basel

Switzerland
 Attn: Legal Department

Facsimile No.: +41 61 688 13 96

		
	and:	  	 Hoffmann-La Roche Inc.

150 Clove Road
 Suite 8

Little Falls, New Jersey 07424
 U.S.A.

Attn. Corporate Secretary
 Facsimile No.: +1 973 890-8433

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 
 [Signature Page Follows] 

  
 - 73 - 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 

 

	
	C4 Therapeutics, Inc.
	
	/s/ Andrew Phillips
	Name: Andrew Phillips
	Title: President and CEO

  

									
	F. Hoffmann-La Roche Ltd	 		 	
			
	/s/ James Sabry	 	  
	 	/s/ Stefan Arnold
	Name: James Sabry, M.D., Ph.D.	 		 	Name: Stefan Arnold
	Title: Global Head Pharma Partnering	 		 	Title: Head Legal Pharma

  

	
	Hoffmann-La Roche Inc.
	
	/s/ John P. Parise
	Name: John P. Parise
	Title: Authorized Signatory

  
 - 74 - 

 Appendix 1.5 

C4T Base Patent Rights 

[***] 

 Appendix 1.15 

C4T Patent Rights 

[***] 

 Appendix 1.22 

CCS Criteria 
 [***]

 Appendix 1.28 

Collaboration Patent Rights 

[***] 

 Appendix 1.82 

Phase I Data Package 

[***] 

 Appendix 1.94 

Research plan 
 [***]

 Appendix 1.103 

Report Criteria 
 [***]

 Appendix 1.105(a) 

Excluded Patent Rights 

[***] 

 Appendix 1.105(b) 

Roche Patent Rights as of the Restatement Date 

[***] 

 Appendix 1.113 

Targets 
 [***] 

 Appendix 4.1.8 

CROs 
 [***] 

 Appendix 7.1 

CMOs 
 [***] 

 Appendix 8.2.1 

Co-Detail Term Sheet 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]